<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T10:41:46Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:6903447" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:6903447</identifier>
        <datestamp>2019-12-19</datestamp>
        <setSpec>cachex</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" article-type="research-article">
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">J Cachexia Sarcopenia Muscle</journal-id>
              <journal-id journal-id-type="iso-abbrev">J Cachexia Sarcopenia Muscle</journal-id>
              <journal-id journal-id-type="doi">10.1007/13539.2190-6009</journal-id>
              <journal-id journal-id-type="publisher-id">JCSM</journal-id>
              <journal-title-group>
                <journal-title>Journal of Cachexia, Sarcopenia and Muscle</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">2190-5991</issn>
              <issn pub-type="epub">2190-6009</issn>
              <publisher>
                <publisher-name>John Wiley and Sons Inc.</publisher-name>
                <publisher-loc>Hoboken</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC6903447</article-id>
              <article-id pub-id-type="pmcid">PMC6903447</article-id>
              <article-id pub-id-type="pmc-uid">6903447</article-id>
              <article-id pub-id-type="pmid">31568675</article-id>
              <article-id pub-id-type="doi">10.1002/jcsm.12472</article-id>
              <article-id pub-id-type="publisher-id">JCSM12472</article-id>
              <article-id pub-id-type="other">JCSM-D-19-00022</article-id>
              <article-categories>
                <subj-group subj-group-type="overline">
                  <subject>Original Article</subject>
                </subj-group>
                <subj-group subj-group-type="heading">
                  <subject>Original Articles</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Testosterone therapy induces molecular programming augmenting physiological adaptations to resistance exercise in older men</article-title>
                <alt-title alt-title-type="right-running-head">Testosterone augments muscle adaptations to resistance exercise</alt-title>
                <alt-title alt-title-type="left-running-head">N. Gharahdaghi <italic>et al</italic>.</alt-title>
              </title-group>
              <contrib-group>
                <contrib id="jcsm12472-cr-0001" contrib-type="author">
                  <name>
                    <surname>Gharahdaghi</surname>
                    <given-names>Nima</given-names>
                  </name>
                  <xref ref-type="aff" rid="jcsm12472-aff-0001">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib id="jcsm12472-cr-0002" contrib-type="author">
                  <name>
                    <surname>Rudrappa</surname>
                    <given-names>Supreeth</given-names>
                  </name>
                  <xref ref-type="aff" rid="jcsm12472-aff-0001">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib id="jcsm12472-cr-0003" contrib-type="author">
                  <name>
                    <surname>Brook</surname>
                    <given-names>Matthew S.</given-names>
                  </name>
                  <xref ref-type="aff" rid="jcsm12472-aff-0001">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib id="jcsm12472-cr-0004" contrib-type="author">
                  <name>
                    <surname>Idris</surname>
                    <given-names>Iskandar</given-names>
                  </name>
                  <xref ref-type="aff" rid="jcsm12472-aff-0001">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib id="jcsm12472-cr-0005" contrib-type="author">
                  <name>
                    <surname>Crossland</surname>
                    <given-names>Hannah</given-names>
                  </name>
                  <xref ref-type="aff" rid="jcsm12472-aff-0001">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib id="jcsm12472-cr-0006" contrib-type="author">
                  <name>
                    <surname>Hamrock</surname>
                    <given-names>Claire</given-names>
                  </name>
                  <xref ref-type="aff" rid="jcsm12472-aff-0002">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib id="jcsm12472-cr-0007" contrib-type="author">
                  <name>
                    <surname>Abdul Aziz</surname>
                    <given-names>Muhammad Hariz</given-names>
                  </name>
                  <xref ref-type="aff" rid="jcsm12472-aff-0001">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib id="jcsm12472-cr-0008" contrib-type="author">
                  <name>
                    <surname>Kadi</surname>
                    <given-names>Fawzi</given-names>
                  </name>
                  <xref ref-type="aff" rid="jcsm12472-aff-0003">
                    <sup>3</sup>
                  </xref>
                </contrib>
                <contrib id="jcsm12472-cr-0009" contrib-type="author">
                  <name>
                    <surname>Tarum</surname>
                    <given-names>Janelle</given-names>
                  </name>
                  <xref ref-type="aff" rid="jcsm12472-aff-0003">
                    <sup>3</sup>
                  </xref>
                </contrib>
                <contrib id="jcsm12472-cr-0010" contrib-type="author">
                  <name>
                    <surname>Greenhaff</surname>
                    <given-names>Paul L.</given-names>
                  </name>
                  <xref ref-type="aff" rid="jcsm12472-aff-0004">
                    <sup>4</sup>
                  </xref>
                </contrib>
                <contrib id="jcsm12472-cr-0011" contrib-type="author">
                  <name>
                    <surname>Constantin‐Teodosiu</surname>
                    <given-names>Dumitru</given-names>
                  </name>
                  <xref ref-type="aff" rid="jcsm12472-aff-0004">
                    <sup>4</sup>
                  </xref>
                </contrib>
                <contrib id="jcsm12472-cr-0012" contrib-type="author">
                  <name>
                    <surname>Cegielski</surname>
                    <given-names>Jessica</given-names>
                  </name>
                  <xref ref-type="aff" rid="jcsm12472-aff-0001">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib id="jcsm12472-cr-0013" contrib-type="author">
                  <name>
                    <surname>Phillips</surname>
                    <given-names>Bethan E.</given-names>
                  </name>
                  <xref ref-type="aff" rid="jcsm12472-aff-0001">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib id="jcsm12472-cr-0014" contrib-type="author">
                  <name>
                    <surname>Wilkinson</surname>
                    <given-names>Daniel J.</given-names>
                  </name>
                  <xref ref-type="aff" rid="jcsm12472-aff-0001">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib id="jcsm12472-cr-0015" contrib-type="author">
                  <name>
                    <surname>Szewczyk</surname>
                    <given-names>Nathaniel J.</given-names>
                  </name>
                  <xref ref-type="aff" rid="jcsm12472-aff-0001">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib id="jcsm12472-cr-0016" contrib-type="author">
                  <name>
                    <surname>Smith</surname>
                    <given-names>Kenneth</given-names>
                  </name>
                  <xref ref-type="aff" rid="jcsm12472-aff-0001">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib id="jcsm12472-cr-0017" contrib-type="author" corresp="yes">
                  <name>
                    <surname>Atherton</surname>
                    <given-names>Philip J.</given-names>
                  </name>
                  <xref ref-type="aff" rid="jcsm12472-aff-0001">
                    <sup>1</sup>
                  </xref>
                  <address>
                    <email>philip.atherton@nottingham.ac.uk</email>
                  </address>
                </contrib>
              </contrib-group>
              <aff id="jcsm12472-aff-0001">
                <label>
                  <sup>1</sup>
                </label>
                <named-content content-type="organisation-division">MRC‐ARUK Centre for Musculoskeletal Ageing Research and Nottingham NIHR BRC, School of Medicine</named-content>
                <institution>University of Nottingham, Derby</institution>
                <country country="GB">UK</country>
              </aff>
              <aff id="jcsm12472-aff-0002">
                <label>
                  <sup>2</sup>
                </label>
                <named-content content-type="organisation-division">Institute of Food and Health</named-content>
                <institution>University College Dublin, Belfield</institution>
                <city>Dublin</city>
                <country country="IE">Ireland</country>
              </aff>
              <aff id="jcsm12472-aff-0003">
                <label>
                  <sup>3</sup>
                </label>
                <named-content content-type="organisation-division">Division of Sports Sciences, School of Health and Medical Sciences</named-content>
                <institution>Örebro University</institution>
                <city>Örebro</city>
                <country country="SE">Sweden</country>
              </aff>
              <aff id="jcsm12472-aff-0004">
                <label>
                  <sup>4</sup>
                </label>
                <named-content content-type="organisation-division">MRC‐ARUK Centre for Musculoskeletal Ageing Research, School of Life Sciences</named-content>
                <institution>University of Nottingham, Nottingham</institution>
                <city>Nottingham</city>
                <country country="GB">UK</country>
              </aff>
              <author-notes>
                <corresp id="correspondenceTo"><label>*</label>Correspondence to: Professor Philip J. Atherton, MRC‐ARUK Centre for Musculoskeletal Ageing Research, Division of Medical Sciences and Graduate Entry Medicine, University of Nottingham, Derby, Royal Derby Hospital Centre, Uttoxeter Road, DE22 3DT Derby, UK. Email: <email>philip.atherton@nottingham.ac.uk</email></corresp>
              </author-notes>
              <pub-date pub-type="epub">
                <day>30</day>
                <month>9</month>
                <year>2019</year>
              </pub-date>
              <pub-date pub-type="ppub">
                <month>12</month>
                <year>2019</year>
              </pub-date>
              <volume>10</volume>
              <issue>6</issue>
              <issue-id pub-id-type="doi">10.1002/jcsm.v10.6</issue-id>
              <fpage>1276</fpage>
              <lpage>1294</lpage>
              <history>
                <date date-type="received">
                  <day>22</day>
                  <month>1</month>
                  <year>2019</year>
                </date>
                <date date-type="rev-recd">
                  <day>14</day>
                  <month>5</month>
                  <year>2019</year>
                </date>
                <date date-type="accepted">
                  <day>12</day>
                  <month>6</month>
                  <year>2019</year>
                </date>
              </history>
              <permissions>
                <!--<copyright-statement content-type="issue-copyright"> &#x000a9; 2019 The Authors. Published by John Wiley & Sons Ltd. on behalf of the Society on Sarcopenia, Cachexia and Wasting Disorders. <copyright-statement>-->
                <copyright-statement content-type="article-copyright">© 2019 The Authors. Journal of Cachexia, Sarcopenia and Muscle published by John Wiley &amp; Sons Ltd on behalf of the Society on Sarcopenia, Cachexia and Wasting Disorders</copyright-statement>
                <license license-type="creativeCommonsBy">
                  <license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p>
                </license>
              </permissions>
              <self-uri content-type="pdf" xlink:href="file:JCSM-10-1276.pdf"/>
              <abstract>
                <title>Abstract</title>
                <sec id="jcsm12472-sec-0001">
                  <title>Background</title>
                  <p>The andropause is associated with declines in serum testosterone (T), loss of muscle mass (sarcopenia), and frailty. Two major interventions purported to offset sarcopenia are anabolic steroid therapies and resistance exercise training (RET). Nonetheless, the efficacy and physiological and molecular impacts of T therapy adjuvant to short‐term RET remain poorly defined.</p>
                </sec>
                <sec id="jcsm12472-sec-0002">
                  <title>Methods</title>
                  <p>Eighteen non‐hypogonadal healthy older men, 65–75 years, were assigned in a random double‐blinded fashion to receive, biweekly, either placebo (P, saline, <italic>n</italic> = 9) or T (Sustanon 250 mg, <italic>n</italic> = 9) injections over 6 week whole‐body RET (three sets of 8–10 repetitions at 80% one‐repetition maximum). Subjects underwent dual‐energy X‐ray absorptiometry, ultrasound of vastus lateralis (VL) muscle architecture, and knee extensor isometric muscle force tests; VL muscle biopsies were taken to quantify myogenic/anabolic gene expression, anabolic signalling, muscle protein synthesis (D<sub>2</sub>O), and breakdown (extrapolated).</p>
                </sec>
                <sec id="jcsm12472-sec-0003">
                  <title>Results</title>
                  <p>Testosterone adjuvant to RET augmented total fat‐free mass (<italic>P=</italic>0.007), legs fat‐free mass (<italic>P=</italic>0.02), and appendicular fat‐free mass (<italic>P=</italic>0.001) gains while decreasing total fat mass (<italic>P=</italic>0.02). Augmentations in VL muscle thickness, fascicle length, and quadriceps cross‐section area with RET occured to a greater extent in T (<italic>P</italic> &lt; 0.05). Sum strength (<italic>P=</italic>0.0009) and maximal voluntary contract (e.g. knee extension at 70°) (<italic>P=</italic>0.002) increased significantly more in the T group. Mechanistically, both muscle protein synthesis rates (T: 2.13 ± 0.21%·day<sup>−1</sup> vs. P: 1.34 ± 0.13%·day<sup>−1</sup>, <italic>P=</italic>0.0009) and absolute breakdown rates (T: 140.2 ± 15.8 g·day<sup>−1</sup> vs. P: 90.2 ± 11.7 g·day<sup>−1</sup>, <italic>P=</italic>0.02) were elevated with T therapy, which led to higher net turnover and protein accretion in the T group (T: 8.3 ± 1.4 g·day<sup>−1</sup> vs. P: 1.9 ± 1.2 g·day<sup>−1</sup>, <italic>P=</italic>0.004). Increases in ribosomal biogenesis (RNA:DNA ratio); mRNA expression relating to T metabolism (androgen receptor: 1.4‐fold; <italic>Srd5a1</italic>: 1.6‐fold; <italic>AKR1C3</italic>: 2.1‐fold; and <italic>HSD17β3</italic>: two‐fold); insulin‐like growth factor (IGF)‐1 signalling [<italic>IGF‐1Ea</italic> (3.5‐fold) and <italic>IGF‐1Ec</italic> (three‐fold)] and myogenic regulatory factors; and the activity of anabolic signalling (e.g. mTOR, AKT, and RPS6; <italic>P</italic> &lt; 0.05) were all up‐regulated with T therapy. Only T up‐regulated mitochondrial citrate synthase activity (<italic>P=</italic>0.03) and transcription factor A (1.41 ± 0.2‐fold, <italic>P=</italic>0.0002), in addition to peroxisome proliferator‐activated receptor‐γ co‐activator 1‐α mRNA (1.19 ± 0.21‐fold, <italic>P=</italic>0.037).</p>
                </sec>
                <sec id="jcsm12472-sec-0004">
                  <title>Conclusions</title>
                  <p>Administration of T adjuvant to RET enhanced skeletal muscle mass and performance, while up‐regulating myogenic gene programming, myocellular translational efficiency and capacity, collectively resulting in higher protein turnover, and net protein accretion. T coupled with RET is an effective short‐term intervention to improve muscle mass/function in older non‐hypogonadal men.</p>
                </sec>
              </abstract>
              <kwd-group kwd-group-type="author-generated">
                <kwd id="jcsm12472-kwd-0001">Skeletal muscle</kwd>
                <kwd id="jcsm12472-kwd-0002">Protein turnover</kwd>
                <kwd id="jcsm12472-kwd-0003">Testosterone</kwd>
                <kwd id="jcsm12472-kwd-0004">Resistance exercise</kwd>
                <kwd id="jcsm12472-kwd-0005">Ageing</kwd>
              </kwd-group>
              <funding-group>
                <award-group id="funding-0001">
                  <funding-source>
                    <institution-wrap>
                      <institution>Medical Research Council </institution>
                      <institution-id institution-id-type="open-funder-registry">10.13039/501100000265</institution-id>
                    </institution-wrap>
                  </funding-source>
                  <award-id>MR/P021220/1</award-id>
                  <award-id>MR/R502364/1</award-id>
                </award-group>
              </funding-group>
              <counts>
                <fig-count count="10"/>
                <table-count count="3"/>
                <page-count count="19"/>
                <word-count count="8617"/>
              </counts>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>source-schema-version-number</meta-name>
                  <meta-value>2.0</meta-value>
                </custom-meta>
                <custom-meta>
                  <meta-name>cover-date</meta-name>
                  <meta-value>December 2019</meta-value>
                </custom-meta>
                <custom-meta>
                  <meta-name>details-of-publishers-convertor</meta-name>
                  <meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:5.7.2 mode:remove_FC converted:10.12.2019</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
            <notes>
              <p content-type="self-citation">
                <mixed-citation publication-type="journal" id="jcsm12472-cit-0001"><string-name><surname>Gharahdaghi</surname><given-names>N.</given-names></string-name>, <string-name><surname>Rudrappa</surname><given-names>S.</given-names></string-name>, <string-name><surname>Brook</surname><given-names>M. S.</given-names></string-name>, <string-name><surname>Idris</surname><given-names>I.</given-names></string-name>, <string-name><surname>Crossland</surname><given-names>H.</given-names></string-name>, <string-name><surname>Hamrock</surname><given-names>C.</given-names></string-name>, <string-name><surname>Abdul Aziz</surname><given-names>M. H.</given-names></string-name>, <string-name><surname>Kadi</surname><given-names>F.</given-names></string-name>, <string-name><surname>Tarum</surname><given-names>J.</given-names></string-name>, <string-name><surname>Greenhaff</surname><given-names>P. L.</given-names></string-name>, <string-name><surname>Constantin‐Teodosiu</surname><given-names>D.</given-names></string-name>, <string-name><surname>Cegielski</surname><given-names>J.</given-names></string-name>, <string-name><surname>Phillips</surname><given-names>B. E.</given-names></string-name>, <string-name><surname>Wilkinson</surname><given-names>D. J.</given-names></string-name>, <string-name><surname>Szewczyk</surname><given-names>N. J.</given-names></string-name>, <string-name><surname>Smith</surname><given-names>K.</given-names></string-name>, and <string-name><surname>Atherton</surname><given-names>P. J.</given-names></string-name> (<year>2019</year>) <article-title>Testosterone therapy induces molecular programming augmenting physiological adaptations to resistance exercise in older men</article-title>, <source xml:lang="en">Journal of Cachexia, Sarcopenia and Muscle</source>, <volume>10</volume>, <fpage>1276</fpage>–<lpage>1294</lpage>. <pub-id pub-id-type="doi">10.1002/jcsm.12472</pub-id>.</mixed-citation>
              </p>
            </notes>
          </front>
          <body id="jcsm12472-body-0001">
            <sec id="jcsm12472-sec-0005">
              <title>Introduction</title>
              <p>Age‐related declines in muscle mass and strength (sarcopenia)<xref rid="jcsm12472-bib-0001" ref-type="ref">1</xref> are associated with mitochondrial abnormalities,<xref rid="jcsm12472-bib-0002" ref-type="ref">2</xref> fatigue, lack of energy, loss of libido, decreased sexual performance,<xref rid="jcsm12472-bib-0003" ref-type="ref">3</xref> and work capacity.<xref rid="jcsm12472-bib-0004" ref-type="ref">4</xref> Many of these symptoms are accompanied by declines in testosterone (T) bioavailability—the ‘andropause'.<xref rid="jcsm12472-bib-0005" ref-type="ref">5</xref> Moreover, hypogonadal men exhibit a three‐fold increase in mortality and a five‐fold increased risk of cancer‐related deaths.<xref rid="jcsm12472-bib-0006" ref-type="ref">6</xref> Thus, as the ageing populace grows, there remains a need for therapies to counteract the andropause and associated muscle wasting and dysfunction.</p>
              <p>Clinically, older men with a total T of &lt;231 ng·dL<sup>−1</sup> may be offered T therapy<xref rid="jcsm12472-bib-0006" ref-type="ref">6</xref> due to established positive effects on fat‐free mass (FFM),<xref rid="jcsm12472-bib-0007" ref-type="ref">7</xref> fat mass,<xref rid="jcsm12472-bib-0008" ref-type="ref">8</xref> muscle function,<xref rid="jcsm12472-bib-0005" ref-type="ref">5</xref> and mitochondrial biogenesis.<xref rid="jcsm12472-bib-0009" ref-type="ref">9</xref> Intramuscular T injections offer a safer, more efficacious treatment than oral or transdermal T.<xref rid="jcsm12472-bib-0006" ref-type="ref">6</xref> Indeed, dose‐dependent increases in type I and type II fibre areas were found in relation to T injection titrations (25–600 mg·week<sup>−1</sup>) in men &gt;65 years.<xref rid="jcsm12472-bib-0010" ref-type="ref">10</xref> In addition, 6 month T injection (~210 mg biweekly) enhanced net protein balance,<xref rid="jcsm12472-bib-0005" ref-type="ref">5</xref> myofibrillar protein synthesis (MPS),<xref rid="jcsm12472-bib-0011" ref-type="ref">11</xref> FFM,<xref rid="jcsm12472-bib-0005" ref-type="ref">5</xref>, <xref rid="jcsm12472-bib-0011" ref-type="ref">11</xref> and muscular performance<xref rid="jcsm12472-bib-0005" ref-type="ref">5</xref> (albeit through ill‐defined mechanisms). However, the therapeutic efficacy of T injection in older men remains controversial and, likely, non‐beneficial with short‐term physiological dosing (at least in the absence of co‐existing countermeasures). For example, ≤6 week T therapy did not improve MPS, RNA content,<xref rid="jcsm12472-bib-0012" ref-type="ref">12</xref> FFM (transdermal 50 mg·day<sup>−1</sup>),<xref rid="jcsm12472-bib-0013" ref-type="ref">13</xref> or strength (200 mg biweekly for 12 weeks).<xref rid="jcsm12472-bib-0014" ref-type="ref">14</xref>, <xref rid="jcsm12472-bib-0015" ref-type="ref">15</xref> Besides administering longer‐term pharmacological doses of exogenous T, interventions that boost endogenous sex hormones, that is, exercise, might be of greater benefit.<xref rid="jcsm12472-bib-0016" ref-type="ref">16</xref>
</p>
              <p>In relation to strategies to overcome age‐related muscle dysfunction, the effects of resistance exercise training (RET) on skeletal muscle are well defined. RET promotes muscle anabolism (even in old age<xref rid="jcsm12472-bib-0017" ref-type="ref">17</xref>, <xref rid="jcsm12472-bib-0018" ref-type="ref">18</xref>) and stimulates mitochondrial adaptations<xref rid="jcsm12472-bib-0002" ref-type="ref">2</xref>; these effects are also associated with enhanced endogenous T in response to acute bouts of RE.<xref rid="jcsm12472-bib-0019" ref-type="ref">19</xref> Nonetheless, hypertrophic responses to RET are blunted in older age (vs. younger cohorts), so‐called anabolic resistance, suggesting the need for strategies beyond, or adjuvant to RET,<xref rid="jcsm12472-bib-0019" ref-type="ref">19</xref> in order to maximize efficacy. We previously showed that acute RET‐induced systemic induction of endogenous T was related to ensuing muscle hypertrophy in younger men,<xref rid="jcsm12472-bib-0020" ref-type="ref">20</xref> suggesting a link between T and muscle mass gains with RET. Moreover, in keeping with a role for T as an adjuvant therapy to RET in older age, 50–100 mg·day<sup>−1</sup> transdermal T therapy enhanced RET‐induced muscle mass gains over 12 weeks,<xref rid="jcsm12472-bib-0021" ref-type="ref">21</xref> while supra‐physiological doses (600 mg·week<sup>−1</sup>) of T adjuvant to RET for 10 weeks increased FFM and strength (in younger men (19–40 years).<xref rid="jcsm12472-bib-0022" ref-type="ref">22</xref> Such ‘medium‐term' use of T therapy is indicated for minimizing side effects<xref rid="jcsm12472-bib-0023" ref-type="ref">23</xref> of longer‐term T therapy, for example, ≥24 weeks,<xref rid="jcsm12472-bib-0024" ref-type="ref">24</xref> and may be useful for pre‐habilitation/rehabilitation (e.g. from bed‐rest). That said, RET interventions of ~12 weeks still engender a major time burden from the perspective of physiotherapy and engender minimal anthropometrical benefits in the absence of adjuvant therapy, even after 24 weeks in older men.<xref rid="jcsm12472-bib-0021" ref-type="ref">21</xref>
</p>
              <p>We have previously shown that the majority of muscle mass gains with RET occur early into RET,<xref rid="jcsm12472-bib-0020" ref-type="ref">20</xref>, <xref rid="jcsm12472-bib-0025" ref-type="ref">25</xref>, <xref rid="jcsm12472-bib-0026" ref-type="ref">26</xref> albeit that this is blunted in older individuals. Therefore, in an effort to identify a more time‐efficient and clinically efficient strategy of T therapy and to determine the mechanisms of T therapy adjuvant to RET in relation to anabolic resistance, we investigated the efficacy and cellular mechanisms of short‐term RET, coupled to adjuvant T therapy in older men. In a double‐blind investigation into the effects of 6 weeks of RET with or without T therapy, we determined end‐points relating to muscle mass, function, myogenic regulation, anabolic signalling, and protein turnover.</p>
            </sec>
            <sec id="jcsm12472-sec-0006">
              <title>Methods</title>
              <sec id="jcsm12472-sec-0007">
                <title>Study ethics and participants</title>
                <p>This study was approved by the University of Nottingham, Faculty of Medicine and Health Sciences Research Ethics Committee (G11082015 SoMS MSGEM), was conducted according to the Declaration of Helsinki, and was pre‐registered at <ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov">http://clinicaltrials.gov</ext-link> (NCT02152839). Before entry into the study, participants provided written informed consent to participate after all procedures and risks were explained to them. All participants performed activities of daily living and were recreationally active but had not partaken in RET within the previous 12 months. Participants were screened by medical questionnaire, physical examination, routine blood chemistry, and a resting electrocardiogram. Participants who presented with metabolic, respiratory, or cardiovascular disorders or who were prescribed medication (e.g. beta‐adrenergic blocking agents, statins, and anti‐inflammatory drugs) and any other medications that could influence T metabolism were excluded. Of the screened participants, 18 non‐hypogonadal, healthy, normotensive (&lt;140/90) older men with morning serum T concentrations of &gt;230 ng·dL<sup>−1</sup> (suggested threshold of the lower range of normal T to diagnose hypogonadism<xref rid="jcsm12472-bib-0027" ref-type="ref">27</xref>) were assigned in a random double‐blinded fashion to receive biweekly injections of either placebo (P, saline <italic>n</italic> = 9, serum T level) or T (Sustanon 250 mg, <italic>n</italic> = 9) (gold standard dosing<xref rid="jcsm12472-bib-0028" ref-type="ref">28</xref>) over ~6 weeks of whole‐body fully supervised RET. All participants involved in the study were monitored throughout the study for any negative side effects of T injections. No adverse events were reported during or after completion of the study.</p>
              </sec>
              <sec id="jcsm12472-sec-0008">
                <title>Study conduct</title>
                <p>Following baseline measurements of maximal voluntary contraction (MVC) and one‐repetition maximum (1‐RM; on separate days), regardless of group assignment, all participants were further characterized at baseline. This involved collection of fasting blood sampling, muscle ultrasound (Mylab 70; Esaote Biomedica, Italy) of the <italic>m. vastus lateralis</italic> muscle (VL), and a dual‐energy X‐ray absorptiometry (DXA; Lunar Prodigy II, GE Medical Systems, Little Chalfont, UK) scan. Finally, a unilateral muscle biopsy was taken under rested conditions from the VL (<italic>Figure</italic>
<xref rid="jcsm12472-fig-0001" ref-type="fig">1</xref>, baseline i.e. Wk ‐1). Given the moderately short half‐life of T (i.e. 4–5 days<xref rid="jcsm12472-bib-0029" ref-type="ref">29</xref>), it was administered every two‐weeks, and subsequent biopsies were taken at week 0, 1.5, 3, and 6 which were 7, 2, 14, and 7 days after corresponding biweekly T injections, respectively. In order to assess rates of MPS, a basal saliva sample was collected before the muscle biopsy, and the first dose of D<sub>2</sub>O as a bolus of 3 mL·kg<sup>−1</sup> body weight was consumed by participants after the biopsy. The initial priming dose of D<sub>2</sub>O was followed by daily small‐volume ‘top‐ups' of ~20 mL (calculated from measures of each individual's body water pool turnover). Finally, an injection of T or P was administered by an unblinded clinical research technician. The fully supervised RET protocol then commenced and continued for the next 6 weeks. Additional VL biopsies (60 min after bouts of RE to obtain temporal acute effects of RE across training) and other tests/samples took place intermittently during these 6 weeks (<italic>Figure</italic>
<xref rid="jcsm12472-fig-0001" ref-type="fig">1</xref>). All muscle samples were collected under sterile conditions, using the conchotome biopsy technique<xref rid="jcsm12472-bib-0030" ref-type="ref">30</xref> with 1% w/v lidocaine as local anaesthetic. Any fat tissue and connective tissue was rapidly dissected out, and muscle was washed in ice‐cold phosphate‐buffered saline and frozen in liquid nitrogen or liquid nitrogen‐cooled isopentane, before storage at −80 °C. Participants were provided 10 mg (D<sub>3</sub>‐methyl)–3‐methylhistidine (3MH) in 100 mL water on three occasions during the study and returned to the research unit (fasted) after 21 h for blood sampling every 2 h (i.e. at 21, 23, and 25 h after 3MH ingestion). A detailed schematic of the study protocol is depicted in <italic>Figure</italic>
<xref rid="jcsm12472-fig-0001" ref-type="fig">1</xref>.</p>
                <fig fig-type="Figure" xml:lang="en" id="jcsm12472-fig-0001" orientation="portrait" position="float">
                  <label>Figure 1</label>
                  <caption>
                    <p>Schematic diagram of the study protocol. 1‐RM, one‐repetition maximum; 3MH, 3‐methylhistidine; DXA, dual‐energy X‐ray absorptiometry; RET, resistance exercise training.</p>
                  </caption>
                  <graphic id="nlm-graphic-1" xlink:href="JCSM-10-1276-g001"/>
                </fig>
              </sec>
              <sec id="jcsm12472-sec-0009">
                <title>Resistance training procedures and strength assessments</title>
                <p>Participants in both groups performed the same whole‐body RET including leg extension, leg press, leg curl, lat pull‐down, shoulder‐press, and bench press (all three sets of 8–10 repetitions at 80% 1‐RM)<xref rid="jcsm12472-bib-0031" ref-type="ref">31</xref> three times per week non‐consecutively for 6 weeks. Individuals' 1‐RM<xref rid="jcsm12472-bib-0032" ref-type="ref">32</xref> was re‐assessed every 2 weeks before the corresponding training session to maintain intensity with progression. An isokinetic dynamometer (Isocom; Isokinetic Technologies, Eurokinetics, UK) was used to assess isometric knee extensor torque during MVC using two knee joint angles (70 and 80°), with full extension corresponding to 0°. Each individual muscle contraction lasted 4 s, with 30 s rest between contractions and 90 s between knee joint angle assessments. In addition, specific strength (MVC 70°·per LM) was calculated as MVC at 70° divided by leg FFM (LM).</p>
              </sec>
              <sec id="jcsm12472-sec-0010">
                <title>Muscle architecture by ultrasound and dual‐energy X‐ray absorptiometry‐derived muscle mass</title>
                <p>Every 10 days and immediately before corresponding training session, B‐mode ultrasonography (Mylab 70, Esaote Biomedica) with a 100 mm, 10–15 MHz, linear array probe was used for quantification of myo‐architecture. Images were obtained at 50% of the VL length and the mid‐sagittal line while the participant was lying supine on a couch.<xref rid="jcsm12472-bib-0033" ref-type="ref">33</xref> To assess fascicle length (Lf), the transducer was aligned with the fascicles to facilitate optimal image capture of the fascicles. The intersection between fascicles and deep tendon aponeurosis and the perpendicular distance between the superficial and deep tendon aponeurosis were used to assess pennation angle (PA) and muscle thickness (MT).<xref rid="jcsm12472-bib-0034" ref-type="ref">34</xref> Finally, extended field‐of‐view ultrasonography was used to quantify the cross‐sectional area (CSA) of the quadriceps.<xref rid="jcsm12472-bib-0035" ref-type="ref">35</xref> ImageJ software (ImageJ 1.51h) was used to analyse the images.</p>
                <p>Before and after the study, DXA (64752, GE Medical Systems‐Lunar Prodigy, USA) was used to determine total FFM, LM, total fat percentage, total fat mass, FFM index (FFM divided by height squared (FFM·height<sup>−2</sup>)), and appendicular FFM (FFM of arms and legs in kilograms divided by square of height in metres). Participants were asked to attend overnight fasting having not performed any heavy physical activity 24 h prior to scanning. For the DXA scan, participants wore loose comfortable clothing with no metal or plastic zippers, buttons, or snaps. Prior to use on participants, a QA block phantom was used to calibrate the system, to ensure optimal measurement. In addition, spine phantoms were run bimonthly to assess the reproducibility and accuracy of the system over time.</p>
              </sec>
              <sec id="jcsm12472-sec-0011">
                <title>Testosterone enzyme‐linked immunosorbent assay</title>
                <p>Venous blood samples were collected into EDTA‐coated tubes intermittently during the study, that is, before injections and prior to individual resistance exercise sessions in the mornings to measure fluctuations in total T concentrations. Blood samples were immediately cold centrifuged at 1750 <italic>g</italic>, with resulting plasma fractions aliquoted and frozen at –80 °C until further analysis. An enzyme‐linked immunosorbent assay (ab108666, Abcam, UK) competitive technique was used to assess the abundance of total T in the plasma of all participants The intra‐assay coefficient of variation was &lt;5%, and the assay sensitivity was 70 ng·dL<sup>−1</sup>; the detection range was 20–1600 ng·dL<sup>−1</sup>.</p>
              </sec>
              <sec id="jcsm12472-sec-0012">
                <title>Muscle immunohistochemistry</title>
                <p>Serial 5‐μm‐thick VL muscle cross‐sections were cut at −20 °C using a cryostat (Leica, CM 1850, Germany), mounted on glass slides, and air dried at room temperature. Determination of fibre‐type‐specific cross‐sectional area was performed using monoclonal antibodies against slow (BA‐F8) and fast myosin (SC‐71) and laminin (D18) (Developmental Studies Hybridoma Bank). Visualization of the primary antibodies was achieved by incubation with Alexa Fluor 488 and 568 goat anti‐mouse secondary antibodies (Invitrogen A/S) <italic>in situ</italic>. Muscle sections were then mounted with Molecular Probes Prolong Gold antifade reagent (Invitrogen A/S). Three major fibre types (I, IIA, and IIX) were determined as previously described.<xref rid="jcsm12472-bib-0036" ref-type="ref">36</xref> Fibre area was measured using Sigma Scan Pro 5 software.</p>
              </sec>
              <sec id="jcsm12472-sec-0013">
                <title>Body water and protein‐bound alanine muscle protein synthesis</title>
                <p>To determine the exact volume of D<sub>2</sub>O to be consumed for daily ‘top‐ups', each participant provided saliva for the first 3 days after initial D<sub>2</sub>O consumption. These were processed to determine each participant's body water decay rate, and from this, the amount of D<sub>2</sub>O needed to maintain a steady state over the study period could be calculated. Individuals were then provided with stocks of daily D<sub>2</sub>O ‘top‐ups' (~10% initial bolus dose) with thrice weekly saliva collection for rest of the study period. Wilkinson <italic>et al</italic>.<xref rid="jcsm12472-bib-0037" ref-type="ref">37</xref> previously described how body water and muscle protein enrichment were analysed. Briefly, 80–90 μL of saliva was heated in inverted 2 mL autosampler vials for 4 h at 90–100 °C to purify fractions of the body water. The vials were then cooled on ice and before the condensed body water was transferred to a clean autosampler vial for injection. A high‐temperature conversion elemental analyser (Thermo Finnigan, Thermo Scientific, Hemel Hempstead, UK) connected to an isotope ratio mass spectrometer (Delta V advantage, Thermo Scientific) was employed to measure deuterium labelling in saliva (0.1 μL). To assess protein‐bound alanine muscle fraction enrichment, ~40 mg of muscle was homogenized in ice‐cold homogenization buffer to isolate myofibrillar proteins.<xref rid="jcsm12472-bib-0020" ref-type="ref">20</xref> Briefly, 10 min rotary mixing was followed by centrifugation at 11 000 <italic>g</italic> for 15 min at 4 °C, the supernatant (sarcoplasmic fraction) was then collected for immunoblotting, and the pellet was resuspended in 500 μL mitochondrial extraction buffer (MEB) and then homogenized by Dounce and centrifuged at 1000 <italic>g</italic> for 5 min at 4 °C. Insoluble collagen was separated following centrifugation from myofibrillar proteins that were solubilized in 750 μL NaOH and subsequently precipitated using 1 M perchloric acid (PCA) then pelleted by centrifugation. Following overnight hydrolysis at 110 °C in a 0.1 M HCl and Dowex H<sup>+</sup> resin slurry, the amino acids were eluted with 2 M NH<sub>4</sub>OH and dried down. Dried samples were suspended in 60 μL distilled water, 32 μL methanol, and 10 μL pyridine and 8 μL methyl chloroformate with intermittent vortex. The <italic>n</italic>‐methoxycarbonyl methyl esters of the amino acids were then extracted after adding 100 μL chloroform. A molecular sieve was added to remove water for ~20 s before being transferred to vials; incorporation of deuterium into the protein‐bound alanine was determined by gas chromatography–pyrolysis–isotope ratio mass spectrometry (Delta V Advantage, Thermo, Hemel Hempstead, UK).<xref rid="jcsm12472-bib-0020" ref-type="ref">20</xref>
</p>
              </sec>
              <sec id="jcsm12472-sec-0014">
                <title>Calculation of synthetic fractional rate</title>
                <p>MPS was calculated from the deuterium enrichment (APE) in alanine in myofibrillar proteins, using the body water enrichment (APE, corrected for the mean number of deuterium moieties incorporated per alanine, 3.7, and the dilution from the total number of hydrogens in the derivative, i.e. 11) as the precursor labelling between subsequent biopsies. The fractional synthetic rate (FSR) was calculated as follows:
<disp-formula id="jcsm12472-disp-0001"><mml:math id="nlm-math-1"><mml:mi>FSR</mml:mi><mml:mfenced open="(" close=")"><mml:mrow><mml:mo>%</mml:mo><mml:mo>⋅</mml:mo><mml:msup><mml:mi mathvariant="italic">day</mml:mi><mml:mrow><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:mfenced><mml:mo>=</mml:mo><mml:mo>−</mml:mo><mml:mtext mathvariant="italic">In</mml:mtext><mml:mfenced open="[" close="]"><mml:mfrac><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mfenced open="[" close="]"><mml:mfrac><mml:mrow><mml:mo>(</mml:mo><mml:msub><mml:mi mathvariant="italic">APE</mml:mi><mml:mi mathvariant="italic">Ala</mml:mi></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mi mathvariant="italic">APE</mml:mi><mml:mi>P</mml:mi></mml:msub></mml:mrow></mml:mfrac></mml:mfenced></mml:mrow><mml:mi>t</mml:mi></mml:mfrac></mml:mfenced><mml:mo>,</mml:mo></mml:math></disp-formula>where APE<sub>Ala</sub> is deuterium enrichment of protein‐bound alanine, APE<sub>P</sub> is mean precursor enrichment of the body water over the period, and <italic>t</italic> is the time between biopsies. Absolute synthetic rate (ASR) was estimated as follows:
<disp-formula id="jcsm12472-disp-0002"><mml:math id="nlm-math-2"><mml:mi mathvariant="italic">ASR</mml:mi><mml:mfenced open="(" close=")"><mml:mrow><mml:mi>g</mml:mi><mml:mo>⋅</mml:mo><mml:msup><mml:mi mathvariant="italic">day</mml:mi><mml:mrow><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:mfenced><mml:mo>=</mml:mo><mml:mfrac><mml:mi mathvariant="italic">FSR</mml:mi><mml:mn>100</mml:mn></mml:mfrac><mml:mo>×</mml:mo><mml:mtext mathvariant="italic">Total</mml:mtext><mml:mo>⋅</mml:mo><mml:mi>F</mml:mi><mml:mi>F</mml:mi><mml:mi>M</mml:mi><mml:mo>×</mml:mo><mml:mfrac><mml:mn>12.4</mml:mn><mml:mn>100</mml:mn></mml:mfrac><mml:mo>,</mml:mo></mml:math></disp-formula>where alkali‐soluble protein of 12.4% total FFM was assumed.<xref rid="jcsm12472-bib-0038" ref-type="ref">38</xref> Absolute protein breakdown rate (ABR) was estimated as follows:
<disp-formula id="jcsm12472-disp-0003"><mml:math id="nlm-math-3"><mml:mi mathvariant="italic">ABR</mml:mi><mml:mfenced open="(" close=")"><mml:mrow><mml:mi>g</mml:mi><mml:mo>⋅</mml:mo><mml:msup><mml:mi mathvariant="italic">day</mml:mi><mml:mrow><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:mfenced><mml:mo>=</mml:mo><mml:mfrac><mml:mi mathvariant="italic">FBR</mml:mi><mml:mn>100</mml:mn></mml:mfrac><mml:mo>×</mml:mo><mml:mtext mathvariant="italic">Total</mml:mtext><mml:mspace width="0.5em"/><mml:mi mathvariant="italic">FFM</mml:mi><mml:mo>×</mml:mo><mml:mfrac><mml:mn>12.4</mml:mn><mml:mn>100</mml:mn></mml:mfrac><mml:mo>,</mml:mo></mml:math></disp-formula>where fractional breakdown rate (FBR) is calculated as FBR = FSR − FGR, with the fractional growth rate (FGR) assumed to be % FFM gain per day over 7 weeks derived by DXA. In addition, the net protein turnover was calculated as follows: ASR − ABR.</p>
              </sec>
              <sec id="jcsm12472-sec-0015">
                <title>Muscle protein breakdown measures using D<sub>3</sub>–3‐methylhistidine</title>
                <p>Precisely, 100 μL of plasma was aliquoted and deproteinized in 1 mL of ice‐cold acetonitrile:methanol (1:1). Following ~1 h of cooling at −20 °C, samples were centrifuged at 17 000 <italic>g</italic> for 20 min at 4 °C. The resulting supernatant was dried and resuspended in 100 μL acetonitrile: ddH<sub>2</sub>O (1:1). Following centrifugation at 17 000 <italic>g</italic>, samples were transferred to autosampler vials for the determination of D<sub>3</sub>–3MH enrichment by liquid chromatography–mass spectrometry (on a Q Exactive Orbitrap, Thermo Hemel Hempstead, UK). The enrichment decay curves were log transformed to determine the decay constant (<italic>k</italic>), which represents the fractional rate of muscle protein breakdown (MPB).<xref rid="jcsm12472-bib-0039" ref-type="ref">39</xref>
</p>
              </sec>
              <sec id="jcsm12472-sec-0016">
                <title>Muscle RNA, DNA, and protein content</title>
                <p>Approximately 15 mg wet weight muscle was used to determine alkaline‐soluble protein (ASP), RNA, and DNA content. Initially, 0.2 M PCA was used to homogenize tissue, followed by centrifugation at 11 680 <italic>g</italic>. Pellets were re‐solubilized in 0.3 M NaOH, and protein contents were quantified by spectrophotometry (NanoDrop Lite, Thermo Scientific). Thereafter, the resulting supernatant was used for RNA quantification at 260 nm by spectrophotometry; the pellet was then heated at 70 °C for 1 h in 2 M PCA to extract the DNA and centrifuged, and DNA was quantified at 268 nm by spectrophotometry.<xref rid="jcsm12472-bib-0020" ref-type="ref">20</xref>
</p>
              </sec>
              <sec id="jcsm12472-sec-0017">
                <title>Immunoblotting for anabolic/catabolic signalling</title>
                <p>Spectrophotometry was used to determine protein concentrations of sarcoplasmic fractions, and samples were diluted with 3× Laemmli loading buffer to 1 mg·mL<sup>−1</sup>, followed by heating at 95 °C for 5 min. Precisely, 10 μg of sample was loaded onto Criterion XT Bis–Tris–12% SDS‐PAGE gels (Bio‐Rad) for electrophoresis at 185 V for 45 min. After electrophoresis, as previously described,<xref rid="jcsm12472-bib-0040" ref-type="ref">40</xref> samples were transferred onto polyvinylidene difluoride membranes for 45 min at 100 V. Subsequently, 2.5% low‐fat milk, which was diluted in Tris‐buffered saline Tween 20 (TBST), was used to soak and block polyvinylidene difluoride membranes for 1 h at ambient temperature and then incubated in the following primary antibodies overnight at 4 °C (1:2000 dilution in 2.5% bovine serum albumin in TBST): rabbit phospho‐protein kinase B (Akt)<sup>Ser473</sup> (#9271), phospho‐mechanistic target of rapamycin (mTOR)<sup>Ser2448</sup> (#2971), phospho‐mitogen‐activated protein kinase (MEK1/2)<sup>Ser217/221</sup> (#9121), phospho‐MAP kinase‐activated protein kinase 2 (MAPKAPK‐2)<sup>Thr334</sup> (#3007), phospho‐ribosomal protein S6 (RPS6)<sup>ser235/236</sup> (#2211), phospho‐AMP‐activated protein kinase (AMPKα)<sup>Thr172</sup> (#2531), phospho‐regulatory‐associated protein of mTOR (Raptor)<sup>Ser792</sup> (#2083), phospho‐forkhead box O3 (FOXO3a)<sup>Ser253</sup> (#13129) (all from Cell Signaling Technology, Leiden, The Netherlands), muscle‐specific F‐box protein (MAFbx) (#AP2041), muscle RING‐finger protein‐1 (MURF‐1) (#101AP) (both from ECM Biosciences, Versailles, KY, USA), and mouse oxidative phosphorylation (OxPhos) (Abcam, Cambridge, MA, USA). After overnight incubation, membranes were washed 3 × 5 min in TBST and soaked in horseradish peroxidase (HRP)‐conjugated secondary antibody (New England Biolabs; 1:2000 in 2.5% bovine serum albumin in TBST) for 1 h, before 3 × 5 min washes in TBST. In order to quantify band intensity (Chemidoc MP, Bio‐Rad, Hemel Hempstead, UK), membranes were exposed to Chemiluminescent HRP substrate (Millipore Corp., Billerica, MA, USA) for 5 min. Relative arbitrary units were normalized to Coomassie‐stained membranes and to cross gel loading control.</p>
              </sec>
              <sec id="jcsm12472-sec-0018">
                <title>Gene expression analysis of myogenesis, insulin‐like growth factor‐1 related, and testosterone processing</title>
                <p>Approximately 10 mg of muscle was homogenized, with one stainless steel bead (Tissue Lyser II, Qiagen, UK), for 2 min at frequency of 30 s<sup>−1</sup> in 500 μL TRIzol (Life Technologies/Thermo Fisher Scientific) to isolate total RNA according to the manufacturer's instructions. A high‐capacity cDNA reverse transcription kit (Life Technologies) was used to reverse transcribe 500 ng of total RNA for quantitative reverse transcription PCR. Precisely, 1 μL of 1:10 diluted cDNA was added in each well of 384 optical well plates (Life Technologies). Exon–exon boundary specific primers were mixed with SYBR Select Master Mix (Life Technologies), and RNase‐free water and 6 μL of the mixed solution, as well as 1 μL of each cDNA, were added to each well, with samples run in triplicate. The ViiATM 7 Real‐Time PCR System (Life Technologies) was used according to the following thermal cycling conditions: 2 min at 50 °C, 2 min at 95 °C, and 40 cycles of 15 s at 95 °C and 60 s at 60 °C. The ΔΔCt method was used to quantify target mRNA expression with peptidylprolylisomerase A levels measured to correct for variations in RNA input/cDNA synthesis.<xref rid="jcsm12472-bib-0041" ref-type="ref">41</xref> Primer sequences for each of the probed genes are listed in <italic>Table</italic>
<xref rid="jcsm12472-tbl-0001" ref-type="table">1</xref>.</p>
                <table-wrap id="jcsm12472-tbl-0001" xml:lang="en" orientation="portrait" position="float">
                  <label>Table 1</label>
                  <caption>
                    <p>Primer sequences used in PCR</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <thead valign="bottom">
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="center" valign="bottom" rowspan="1" colspan="1"/>
                        <th align="center" valign="bottom" rowspan="1" colspan="1">Forward</th>
                        <th align="center" valign="bottom" rowspan="1" colspan="1">Reverse</th>
                      </tr>
                    </thead>
                    <tbody valign="top">
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">
                          <italic>RPL13A</italic>
                        </td>
                        <td align="left" valign="top" rowspan="1" colspan="1">5′‐TAAACAGGTACTGCTGGGCCG‐3′</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">5′‐CTCGGGAAGGGTTGGTGTTC‐3′</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">
                          <italic>AR</italic>
                        </td>
                        <td align="left" valign="top" rowspan="1" colspan="1">5′‐GGTGAGCAGAGTGCCCTATC‐3′</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">5′‐GCAGTCTCCAAACGCATGTC‐3′</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">
                          <italic>SRD5A1</italic>
                        </td>
                        <td align="left" valign="top" rowspan="1" colspan="1">5′‐TACGGGCATCGGTGCTTAAT‐3′</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">5′‐AATCGCCATTGTACACGCCA‐3′</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">
                          <italic>AKR1C3</italic>
                        </td>
                        <td align="left" valign="top" rowspan="1" colspan="1">5′‐GGAGAAGCAGCAGCAAACATT‐3′</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">5′‐CTTTACTTCTCGGAACCTCTGGA‐3′</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">
                          <italic>HSD17B3</italic>
                        </td>
                        <td align="left" valign="top" rowspan="1" colspan="1">5′‐TGTACTCAGCTTCCAAGGCG‐3′</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">5′‐TATGGGGTCAGCACCTGGAT‐3′</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">
                          <italic>IGF‐1Ea</italic>
                        </td>
                        <td align="left" valign="top" rowspan="1" colspan="1">5′‐TCAAATGTACTTCCTTCTGGGTC‐3′</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">5′‐TAAGGAGGCTGGAGATGTATTGC ‐3′</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">
                          <italic>IGF‐1Ec</italic>
                        </td>
                        <td align="left" valign="top" rowspan="1" colspan="1">5′‐AAATCAGCAGTCTTCCAACCC‐3′</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">5′‐GTGTGCATCTTCACCTTCAAGAAA‐3′</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">
                          <italic>MHC1</italic>
                        </td>
                        <td align="left" valign="top" rowspan="1" colspan="1">5′‐ATCTCTACGCCAGGGTCCTTA‐3′</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">5′‐TTTCGGAGGAAAGGAGCAGC‐3′</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">
                          <italic>MHCIIa</italic>
                        </td>
                        <td align="left" valign="top" rowspan="1" colspan="1">5′‐GCCCTTGGAATGAGGCTGAC‐3′</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">5′‐TGCTGAACTCAGAGGTCCTTGTT‐3′</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">
                          <italic>Myogenin</italic>
                        </td>
                        <td align="left" valign="top" rowspan="1" colspan="1">5′‐CCAGGGGATCATCTGCTCACG‐3′</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">5′‐GGTTTCATCTGGGAAGGCCA‐3′</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">
                          <italic>Myf‐6</italic>
                        </td>
                        <td align="left" valign="top" rowspan="1" colspan="1">5′‐CAAGAAAATCTTGAGGGTGCGG‐3′</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">5′‐TTAGCCGTTATCACGAGCCC‐3′</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">
                          <italic>C‐Myc</italic>
                        </td>
                        <td align="left" valign="top" rowspan="1" colspan="1">5′‐AACCACCACCATCCCTGTTTG‐3′</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">5′‐AAGGCCCCCAGACCCATTTC‐3′</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">
                          <italic>MEOX‐2</italic>
                        </td>
                        <td align="left" valign="top" rowspan="1" colspan="1">5′‐TGAAAGACAGGTGAAAGTCTGG‐3′</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">5′‐ACCAGTTCCTTTTCCCGAGC‐3′</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">
                          <italic>C‐met</italic>
                        </td>
                        <td align="left" valign="top" rowspan="1" colspan="1">5′‐ACAGCTGACTTGCTGAGAGG‐3′</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">5′‐AGGTTTATCTTTCGGTGCCCA‐3′</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">
                          <italic>PAX7</italic>
                        </td>
                        <td align="left" valign="top" rowspan="1" colspan="1">5′‐CGGCCAGACTGCTGTTGATTAT‐3′</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">5′‐GAGTCCCAGCACAGCAGAGT‐3′</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">
                          <italic>PGC1‐α</italic>
                        </td>
                        <td align="left" valign="top" rowspan="1" colspan="1">5′‐GAGTCATACTTGCTCTTGGTG‐3′</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">5′‐GATGATGGAGACAGCTATGGT‐3′</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">
                          <italic>Tfam</italic>
                        </td>
                        <td align="left" valign="top" rowspan="1" colspan="1">5′‐TTCGTCCTCTTTAGCATGCTGA‐3′</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">5′‐CACCGCAGGAAAAGCTGAAG‐3′</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot id="jcsm12472-ntgp-0001">
                    <fn id="jcsm12472-note-0001">
                      <p><italic>AKR1C3</italic>, aldo‐keto reductase family 1 member C3; <italic>AR</italic>, androgen receptor; <italic>C‐met</italic>, met proto‐oncogene, receptor tyrosine kinase; <italic>HSD17B3</italic>, hydroxysteroid 17‐β dehydrogenase 3; <italic>IGF‐1</italic>, insulin‐like growth factor‐1; <italic>MEOX‐2</italic>, mesenchyme homeobox 2; <italic>MHC</italic>, myosin heavy chain; <italic>Myf‐6</italic>, myogenic factor 6; <italic>C‐Myc</italic>, MYC proto‐oncogene, BHLH transcription factor; <italic>PAX7</italic>, paired box 7; <italic>PGC1‐α</italic>, peroxisome proliferator‐activated receptor‐γ co‐activator 1‐α; <italic>RPL13A</italic>, ribosomal protein L13A; <italic>SRD5A1</italic>, steroid 5 α‐reductase 1; <italic>Tfam</italic>, mitochondrial transcription factor A.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
              </sec>
              <sec id="jcsm12472-sec-0019">
                <title>Mitochondrial citrate synthase activity and DNA copy number</title>
                <p>Citrate synthase (CS) activity was measured as described.<xref rid="jcsm12472-bib-0042" ref-type="ref">42</xref> Briefly, after homogenization of 3–5 mg muscle in 1% Triton X‐100 buffer, samples were centrifuged at 22 000 <italic>g</italic> for 3 min, and the supernatant was used for further analysis. Thereafter, 300 μL Master Mix containing 28% 0.05 M Tris buffer (pH 7.6), 1.3% 1 mM 5,5′‐dithiobis‐2‐nitrobenzoic acid, 7% acetyl‐coenzyme A (1.36 mg·mL<sup>−1</sup>), 0.8% oxaloacetate (9.88 mg·mL<sup>−1</sup>), and 63% ddH<sub>2</sub>O was measured at 412 nm as the blank. Finally, 20 μL of separated supernatant was used to measure the maximum rate of reaction (<italic>V</italic>
<sub>max</sub>), compared with whole protein content. To quantify relative mitochondrial DNA (mtDNA) copy number, the extraction of genomic and mtDNA from muscle was performed using a Qiagen QIAamp® DNA Mini Kit, according to the manufacturer's recommendations. Briefly, the procedure involved tissue lysis in a proteinase K buffer, incubation for 3 h at 56 °C to digest myofibrils followed by centrifugation of the lysates through silica membrane‐based nucleic acid purification columns and subsequent elution of the mtDNA and gDNA. The quality and quantity of DNA was assessed by measurement at 260, 280, and 230 nm. The expression level of markers of gDNA and mtDNA used to evaluate their abundance was accomplished by using TaqMan probe real‐time PCR. The TaqMan probe design for the detection of gDNA levels was based on interrogation of the intron sequence spanning between exons 3 and 4 of the genomic hydroxymethylbilane synthase (HMBS) gene to avoid mRNA amplification. The probe design for detection of mtDNA levels was based on interrogation of a stable fragment of the mtDNA loop, namely, the mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 1 (ND1). The 2<sup>−ΔCt</sup> formula, where Δ = Ct<sub>ND1</sub> − Ct<sub>HMBS</sub>, was used to express relative mtDNA copy number.</p>
              </sec>
              <sec id="jcsm12472-sec-0020">
                <title>Statistical analyses</title>
                <p>Data are expressed as mean ± standard error of the mean, while normality of distribution was examined using the Kolmogorov–Smirnov test. In addition, analysis of covariance using baseline values for each outcome as a covariate and repeated measures analysis of variance (time) with one between‐subject factor (group) were used to compare the changes during the RET programme both within and between the two (P vs. T) groups. In addition, independent <italic>t</italic>‐tests were used for comparing fold change between the two groups. Cohen's effect sizes (ES) were also calculated for significant data. ES of 0 to &lt;0.20 were considered ‘trivial', 0.20 to &lt;0.50 were considered ‘small' in magnitude, 0.50 to &lt;0.80 were considered ‘medium', and ≥0.80 were considered ‘large'.<xref rid="jcsm12472-bib-0043" ref-type="ref">43</xref> Where significant differences were found using repeated measures analysis of variance, a Bonferroni <italic>post hoc</italic> test was applied for multiple comparisons. The correlation was assessed using Pearson's product moment correlation coefficient and intraclass correlation coefficient (ICC) was used to test reliability of DXA and ultrasound‐related outputs. The significance level was defined as <italic>P</italic> ≤ 0.05, and all of the statistical analyses were performed using GraphPad Prism 7.01 (La Jolla, CA, USA).</p>
              </sec>
            </sec>
            <sec id="jcsm12472-sec-0021">
              <title>Results</title>
              <p>Physiological characteristics of participants are shown in <italic>Table</italic>
<xref rid="jcsm12472-tbl-0002" ref-type="table">2</xref>. In accordance, only the T study group significantly increased weight (<italic>P=</italic>0.006, 95% confidence interval (CI) = 81–83, ES = 0.19) and body mass index (<italic>P=</italic>0.006, 95% CI = 26–26.6) after 6 weeks of RET, primarily through significant gains in FFM in the T group vs. baseline (see the Body composition section). Further, total plasma T concentrations in the T therapy group were significantly higher than in the P group at all time‐points after baseline (<italic>P</italic> &lt; 0.05), that is, 234.9 ± 7 ng·dL<sup>−1</sup> at baseline, and achieved 973 ± 54 at 0 week and 1149 ± 75 ng·dL<sup>−1</sup> after 5 weeks in T group (95% CI = 1044–1232). Plasma T concentrations during the study are shown in <italic>Figure</italic>
<xref rid="jcsm12472-fig-0002" ref-type="fig">2</xref>.</p>
              <table-wrap id="jcsm12472-tbl-0002" xml:lang="en" orientation="portrait" position="float">
                <label>Table 2</label>
                <caption>
                  <p>Participant characteristics</p>
                </caption>
                <table frame="hsides" rules="groups">
                  <col align="left" span="1"/>
                  <col align="char" char="(" span="1"/>
                  <col align="char" char="(" span="1"/>
                  <col align="char" char="(" span="1"/>
                  <col align="char" char="(" span="1"/>
                  <thead valign="bottom">
                    <tr style="border-bottom:solid 1px #000000">
                      <th rowspan="2" style="border-bottom:solid 1px #000000" align="center" valign="bottom" colspan="1"/>
                      <th colspan="2" align="center" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">T (<italic>n</italic> = 9)</th>
                      <th colspan="2" align="center" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">P (<italic>n</italic> = 9)</th>
                    </tr>
                    <tr style="border-bottom:solid 1px #000000">
                      <th align="center" valign="bottom" rowspan="1" colspan="1">Baseline</th>
                      <th align="center" valign="bottom" rowspan="1" colspan="1">Week 6</th>
                      <th align="center" valign="bottom" rowspan="1" colspan="1">Baseline</th>
                      <th align="center" valign="bottom" rowspan="1" colspan="1">Week 6</th>
                    </tr>
                  </thead>
                  <tbody valign="top">
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">Age (years)</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">69.7 (0.8)</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">––</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">69.5 (1.3)</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">––</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">Height (m)</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">1.75 (0.02)</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">––</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">1.76 (0.02)</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">––</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">Weight (kg)</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">78.6 (3.1)</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">80.4 (3.2)<xref ref-type="fn" rid="jcsm12472-note-0004">a</xref>
</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">81.8 (4.3)</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">82.4 (4.1)</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">BMI (kg·m<sup>−2</sup>)</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">25.7 (1)</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">26.2 (1)<xref ref-type="fn" rid="jcsm12472-note-0004">a</xref>
</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">26.5(1.1)</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">26.7 (1.1)</td>
                    </tr>
                  </tbody>
                </table>
                <table-wrap-foot id="jcsm12472-ntgp-0002">
                  <fn id="jcsm12472-note-0002">
                    <p>P, placebo; T, testosterone.</p>
                  </fn>
                  <fn id="jcsm12472-note-0003">
                    <p>Values are means (standard error of the mean).</p>
                  </fn>
                  <fn id="jcsm12472-note-0004">
                    <label>a</label>
                    <p>Significantly different from baseline, <italic>P</italic> &lt; 0.05.</p>
                  </fn>
                </table-wrap-foot>
              </table-wrap>
              <fig fig-type="Figure" xml:lang="en" id="jcsm12472-fig-0002" orientation="portrait" position="float">
                <label>Figure 2</label>
                <caption>
                  <p>Time course of changes in total testosterone. <sup>a</sup>Significantly different from baseline, <italic>P</italic> &lt; 0.05; <sup>b</sup>significantly different between two groups, <italic>P</italic> &lt; 0.05.</p>
                </caption>
                <graphic id="nlm-graphic-3" xlink:href="JCSM-10-1276-g002"/>
              </fig>
              <sec id="jcsm12472-sec-0022">
                <title>Body composition</title>
                <p>Total FFM (ICC = 0.94) increased significantly following 6 week RET in T (53.0 ± 1.7 to 56.0 ± 5.2 kg, <italic>P=</italic>0.007, 95% CI = 55.5–57.6, ES = 0.45, <italic>Figure</italic>
<xref rid="jcsm12472-fig-0003" ref-type="fig">3</xref>A) but not in P (54.1 ± 6.3 to 54.8 ± 5.8 kg, 95% CI = 53.2–55.4). Likewise, only T augmented LM (17.2 ± 0.7 to 18.1 ± 0.8 kg, 95% CI = 17.8–18.6 vs. 17.4 ± 0.8 to 17.6 ± 0.7 kg, 95% CI = 17.1–17.9, <italic>P=</italic>0.02, ES = 0.30, ICC = 0.96, <italic>Figure</italic>
<xref rid="jcsm12472-fig-0003" ref-type="fig">3</xref>B), appendicular FFM (7.8 ± 0.3 to 8.3 ± 0.3, 95% CI = 8.2–8.5 vs. 7.9 ± 0.3 to 8.0 ± 0.3, 95% CI = 7.7–8.1, <italic>P=</italic>001, ES = 0.54, ICC = 0.94, <italic>Figure</italic>
<xref rid="jcsm12472-fig-0003" ref-type="fig">3</xref>D), and FFM index (17.2 ± 0.4 to 18.2 ± 0.4 kg·m<sup>−2</sup>, 95% CI = 18.1–18.7 vs. 17.5 ± 0.6 to 17.8 ± 0.5 kg·m<sup>−2</sup>, 95% CI = 17.3–18.1, <italic>P=</italic>0.005, ES = 0.42, ICC = 0.92, <italic>Figure</italic>
<xref rid="jcsm12472-fig-0003" ref-type="fig">3</xref>C) after RET. In addition, both total fat percentage (29.7 ± 1.7 to 27.5 ± 1.4%, 95% CI = 27–28.8 vs. 30.6 to 30.2%, 95% CI = 29–30.7, <italic>P=</italic>0.004, ICC = 0.96, ES = 0.43) and total fat mass (22.5 ± 2.0 to 21.3 ± 1.8 kg, 95% CI = 21.6–23.1 vs. 24.7 ± 2.8 to 24.5 ± 2.7 kg, 95% CI = 22.8–24.2, <italic>P=</italic>0.02, ICC = 0.97, ES = 0.29) decreased significantly in T but not in P (<italic>Figure</italic>
<xref rid="jcsm12472-fig-0003" ref-type="fig">3</xref>E and <xref rid="jcsm12472-fig-0003" ref-type="fig">3</xref>F).</p>
                <fig fig-type="Figure" xml:lang="en" id="jcsm12472-fig-0003" orientation="portrait" position="float">
                  <label>Figure 3</label>
                  <caption>
                    <p>Muscle mass and body composition changes. (A–F) Values are means ± standard error of the mean. <sup>a</sup>Significantly different from baseline, <italic>P</italic> &lt; 0.05. FFM, fat‐free mass; TFP, total fat percentage; TFM, total fat mass.</p>
                  </caption>
                  <graphic id="nlm-graphic-5" xlink:href="JCSM-10-1276-g003"/>
                </fig>
              </sec>
              <sec id="jcsm12472-sec-0023">
                <title>Muscle architecture</title>
                <p>Over the RET period, T and P both exhibited increases in MT (2.3 ± 0.07 to 2.6 ± 0.04 cm, 95% CI = 2.5–2.6, <italic>P</italic> &lt; 0.0001, ES = 0.83 vs. 2.3 ± 0.1 to 2.4 ± 0.09 cm, 95% CI = 2.4–2.5, <italic>P</italic> &lt; 0.0001, ICC = 0.81, ES = 0.47), Lf (7.1 ± 0.2 to 7.9 ± 0.2 cm, 95% CI = 7.9–8.2, <italic>P</italic> &lt; 0.0001, ES = 0.84 vs. 7.7 ± 0.1 to 8.1 ± 0.1 cm, 95% CI = 7.7–8, <italic>P</italic> &lt; 0.0001, ES = 0.73), PA (20.0 ± 0.8 to 23.1 ± 0.7°, 95% CI = 21.2–22.6, <italic>P</italic> &lt; 0.0001, ES = 1.2 vs. 17.0 ± 1.2 to 20.3 ± 0.9°, 95% CI = 20.7–22.1, <italic>P</italic> &lt; 0.0001, ES = 0.88), and CSA of the quadriceps (61.4 ± 3.1 to 69.9 ± 2.6 cm<sup>2</sup>, 95% CI = 66.2–70.9, <italic>P</italic> &lt; 0.0001, ES = 0.93 vs. 58.8 ± 4.1 to 64 ± 4.8 cm<sup>2</sup>, 95% CI = 62.9–67.7, <italic>P</italic> &lt; 0.0001, ES = 0.41, ICC = 0.89). The majority of increases were to a greater extent in the T group and with significant differences between groups in MT (<italic>P=</italic>0.01), Lf (<italic>P=</italic>0.001), and CSA (<italic>P=</italic>0.04) (<italic>Figure</italic>
<xref rid="jcsm12472-fig-0004" ref-type="fig">4</xref>A–C).</p>
                <fig fig-type="Figure" xml:lang="en" id="jcsm12472-fig-0004" orientation="portrait" position="float">
                  <label>Figure 4</label>
                  <caption>
                    <p>(A–D) Fold change in muscle architecture. Values are means ± standard error of the mean. <sup>a</sup>Significantly different from baseline, <italic>P</italic> &lt; 0.05; <sup>b</sup>significantly different between two groups, <italic>P</italic> &lt; 0.05. CSA, cross‐section area; Lf, fascicle length; MT, muscle thickness; PA, pennation angle.</p>
                  </caption>
                  <graphic id="nlm-graphic-7" xlink:href="JCSM-10-1276-g004"/>
                </fig>
              </sec>
              <sec id="jcsm12472-sec-0024">
                <title>Fibre‐type cross‐sectional area</title>
                <p>Type I and IIa CSA increased in both the T and P groups after RET (<italic>P</italic> &lt; 0.05), but only T augmented type IIx (3455 ± 187 to 4576 ± 338 μm<sup>2</sup>, 95% CI = 3814–5659 vs. 3751 ± 478 to 3797 ± 767 μm<sup>2</sup>, 95% CI = 2560–4630, <italic>P</italic> = 0.02, ES = 0.64, <italic>Figure</italic>
<xref rid="jcsm12472-fig-0005" ref-type="fig">5</xref>A–C).</p>
                <fig fig-type="Figure" xml:lang="en" id="jcsm12472-fig-0005" orientation="portrait" position="float">
                  <label>Figure 5</label>
                  <caption>
                    <p>(A–C) Time course of changes in fibre‐type cross‐section area (CSA). Values are means ± standard error of the mean. <sup>a</sup>Significantly different from baseline, <italic>P</italic> &lt; 0.05; <sup>b</sup>significantly different between two groups, <italic>P</italic> &lt; 0.05.</p>
                  </caption>
                  <graphic id="nlm-graphic-9" xlink:href="JCSM-10-1276-g005"/>
                </fig>
              </sec>
              <sec id="jcsm12472-sec-0025">
                <title>Muscular performance</title>
                <p>In line with higher levels of T (<italic>P</italic> &lt; 0.0001, <italic>Figure</italic>
<xref rid="jcsm12472-fig-0002" ref-type="fig">2</xref>), only the T group showed a greater increase in static strength after RET, for example, MVC at 70° (169.9 ± 9.6 to 209 ± 11.8 Nm, 95% CI = 11.5–66.6, <italic>P=</italic>0.002, ES = 1.3, <italic>Figure</italic>
<xref rid="jcsm12472-fig-0006" ref-type="fig">6</xref>B) and 80° (169.4 ± 7.3 to 191.7 ± 12.5 Nm, 95% CI = 3.8–40.5, <italic>P=</italic>0.01, ES = 1.01, <italic>Figure</italic>
<xref rid="jcsm12472-fig-0006" ref-type="fig">6</xref>C) vs. baseline. Furthermore, dynamic strength (sum 1‐RM across all six exercises) was augmented into a greater extent in the T group vs. P (60.8 ± 3.6 vs. 43.25 ± 2.4%, 95% CI = T: 54.2–67.7 vs. P: 36.7–49.7, <italic>P=</italic>0.0009, ES = 0.96, <italic>Figure</italic>
<xref rid="jcsm12472-fig-0006" ref-type="fig">6</xref>A). There were similar increases in specific strength (force per unit area) across the groups (95% CI = T: 10.4–12.4; P: 10.1–11.9, ES = T: 0.88; P: 0.65, <italic>P</italic> &lt; 0.05, <italic>Figure</italic>
<xref rid="jcsm12472-fig-0006" ref-type="fig">6</xref>D). Finally, FFM gains were correlated with sum strength gains in the T study group but not in the P group (<italic>Figure</italic>
<xref rid="jcsm12472-fig-0006" ref-type="fig">6</xref>E).</p>
                <fig fig-type="Figure" xml:lang="en" id="jcsm12472-fig-0006" orientation="portrait" position="float">
                  <label>Figure 6</label>
                  <caption>
                    <p>Time course of changes in (A) sum strength and (B–D) muscle strength and (E) correlation between fat‐free mass (FFM) and sum strength. Values are means ± standard error of the mean. <sup>a</sup>Significantly different from baseline, <italic>P</italic> &lt; 0.05; <sup>b</sup>significantly different between two groups, <italic>P</italic> &lt; 0.05. LM, legs fat‐free mass; MVC, maximal voluntary contraction.</p>
                  </caption>
                  <graphic id="nlm-graphic-11" xlink:href="JCSM-10-1276-g006"/>
                </fig>
              </sec>
              <sec id="jcsm12472-sec-0026">
                <title>Muscle protein synthesis and (extrapolated) breakdown</title>
                <p>There was a significant difference in cumulative MPS between T and P during RET (2.13 ± 0.21 vs. 1.34 ± 0.13%·day<sup>−1</sup>, 95% CI = 1.7–2.4 vs. 1.1–1.8, <italic>P=</italic>0.0009, ES = 0.75), in line with findings of elevated FGR in T compared with P (0.12 ± 0.02 vs. 0.03 ± 0.01%·day<sup>−1</sup>, 95% CI = 0.07–0.16 vs. −0.12 to 0.07, <italic>P=</italic>0.005, ES = 0.85) (<italic>Figure</italic>
<xref rid="jcsm12472-fig-0007" ref-type="fig">7</xref>A and <xref rid="jcsm12472-fig-0007" ref-type="fig">7</xref>B). Furthermore, ASR was significantly increased as a result of RET in T (87.8 ± 5.1 to 148.5 ± 15.3 g·day<sup>−1</sup>, 95% CI = 120–176, <italic>P=</italic>0.02, ES = 0.31) but not in P (84.7 ± 4.7 to 92.2 ± 11.3 g·day<sup>−1</sup>, 95% CI = 72–128, <italic>P</italic> &gt; 0.05). In addition, estimated ABR was significantly higher in T than P during RET (140.2 ± 15.8 vs. 90.2 ± 11.7 g·day<sup>−1</sup>, 95% CI = 112–168 vs. 70–126, <italic>P=</italic>0.02, ES = 0.55). Finally, when comparing ASR and ABR, net protein turnover in the T group was higher than in the P group (8.3 ± 1.4 vs. 1.9 ± 1.2 g·day<sup>−1</sup>, 95% CI = 5.4–11.2 vs. −0.9 to 4.8, <italic>P=</italic>0.004, ES = 0.86, <italic>Figure</italic>
<xref rid="jcsm12472-fig-0007" ref-type="fig">7</xref>C–E). Using D<sub>3</sub>–3‐MH, there was no significant difference in MPB between T and P at 6 weeks over the 4 h sampling period (T: 0.043 ± 0.012 vs. P: 0.032 ± 0.004 <italic>k</italic>·h<sup>−1</sup>, <italic>P=</italic>0.5) (<italic>Figure</italic>
<xref rid="jcsm12472-fig-0007" ref-type="fig">7</xref>F).</p>
                <fig fig-type="Figure" xml:lang="en" id="jcsm12472-fig-0007" orientation="portrait" position="float">
                  <label>Figure 7</label>
                  <caption>
                    <p>Muscle protein synthesis, fractional growth rate (FGR), absolute synthetic rate (ASR), absolute breakdown rate (ABR), and protein turnover. Values are means ± standard error of the mean. <sup>a</sup>Significantly different from baseline, <italic>P</italic> &lt; 0.05; <sup>b</sup>significantly different between two groups, <italic>P</italic> &lt; 0.05; <italic>P</italic> &lt; 0.11 Week 6 vs. baseline in testosterone group. FSR, fractional synthetic rate.</p>
                  </caption>
                  <graphic id="nlm-graphic-13" xlink:href="JCSM-10-1276-g007"/>
                </fig>
              </sec>
              <sec id="jcsm12472-sec-0027">
                <title>Muscle alkaline‐soluble protein, DNA, and RNA content</title>
                <p>There were no changes in ASP or DNA concentrations per wet weight muscle (μg·mg<sup>−1</sup>) in T or P with RET; nonetheless, total RNA content (95% CI = T: 2.1–2.5; P: 1.6–2.1, <italic>P=</italic>0.002, ES = 0.78) and RNA:DNA ratio, a reflection of ribosomal capacity for protein synthesis, only increased in the T group (95% CI = T: 1.1–1.2; P: 0.7–1, <italic>P=</italic>0.002, ES = 0.83). Similarly, RNA:ASP ratio, primarily a measure of ribosomal capacity,<xref rid="jcsm12472-bib-0020" ref-type="ref">20</xref> increased in T (95% CI = 17.8–23.5, <italic>P=</italic>0.002, ES = 0.24) but not in P (<italic>P=</italic>0.6, 95% CI = 15.2–20.9) over the RET phase. Finally, the ratio of ASP:DNA, a measure of cell size, did not change in either group (<italic>Table</italic>
<xref rid="jcsm12472-tbl-0003" ref-type="table">3</xref>).</p>
                <table-wrap id="jcsm12472-tbl-0003" xml:lang="en" orientation="portrait" position="float">
                  <label>Table 3</label>
                  <caption>
                    <p>Muscle protein, RNA, DNA, and related ratios</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <col align="left" span="1"/>
                    <col align="char" char="(" span="1"/>
                    <col align="char" char="(" span="1"/>
                    <col align="char" char="(" span="1"/>
                    <col align="char" char="(" span="1"/>
                    <col align="char" char="(" span="1"/>
                    <col align="char" char="(" span="1"/>
                    <col align="char" char="(" span="1"/>
                    <col align="char" char="(" span="1"/>
                    <thead valign="bottom">
                      <tr style="border-bottom:solid 1px #000000">
                        <th rowspan="2" style="border-bottom:solid 1px #000000" align="center" valign="bottom" colspan="1"/>
                        <th colspan="4" align="center" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">Placebo</th>
                        <th colspan="4" align="center" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">Testosterone</th>
                      </tr>
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="center" valign="bottom" rowspan="1" colspan="1">Baseline</th>
                        <th align="center" valign="bottom" rowspan="1" colspan="1">Week 0</th>
                        <th align="center" valign="bottom" rowspan="1" colspan="1">Week 3</th>
                        <th align="center" valign="bottom" rowspan="1" colspan="1">Week 6</th>
                        <th align="center" valign="bottom" rowspan="1" colspan="1">Baseline</th>
                        <th align="center" valign="bottom" rowspan="1" colspan="1">Week 0</th>
                        <th align="center" valign="bottom" rowspan="1" colspan="1">Week 3</th>
                        <th align="center" valign="bottom" rowspan="1" colspan="1">Week 6</th>
                      </tr>
                    </thead>
                    <tbody valign="top">
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">ASP content (μg·mg<sup>−1</sup> ww)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">110.5 (3.9)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">108.5 (2.8)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">107.4 (4.9)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">106.9 (4.5)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">118.2 (3.7)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">115.3 (3.4)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">118.2 (2.7)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">118.5 (4.6)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">RNA content (μg·mg<sup>−1</sup> ww)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">1.6 (0.1)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">1.8 (0.1)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">2.1 (0.1)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">1.9 (0.1)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">1.7 (0.1)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">2.1 (0.1)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">1.8 (0.1)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">2.3 (0.1)<xref ref-type="fn" rid="jcsm12472-note-0007">a</xref>
</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">DNA content (μg·mg<sup>−1</sup> ww)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">2.2 (0.1)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">2.3 (0.1)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">2.2 (0.1)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">2.2 (0.1)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">2.2 (0.1)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">2.2 (0.1)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">2.1 (0.1)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">2.1 (0.1)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">RNA:DNA (ratio)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">0.7 (0.1)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">0.7 (0.1)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">0.9 (0.1)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">0.8 (0.1)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">0.7 (0.1)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">0.9 (0.1)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">0.8 (0.1)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">1.1 (0.1)<xref ref-type="fn" rid="jcsm12472-note-0007">a</xref>
</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">RNA:ASP (ratio)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">15.3 (0.5)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">17.1 (0.8)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">19.9 (1.7)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">18.1 (0.9)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">14.6 (0.9)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">17.8 (1.5)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">15.5 (0.6)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">20.7 (1.5)<xref ref-type="fn" rid="jcsm12472-note-0007">a</xref>
</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">ASP:DNA (ratio)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">50.7 (3.6)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">46.1 (1.7)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">49.2 (3.8)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">47.9 (3.1)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">54.2 (2.4)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">52.6 (2.4)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">56.5 (2.4)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">56.6 (5.2)</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot id="jcsm12472-ntgp-0003">
                    <fn id="jcsm12472-note-0005">
                      <p>ww, wet weight.</p>
                    </fn>
                    <fn id="jcsm12472-note-0006">
                      <p>Values are means (standard error of the mean).</p>
                    </fn>
                    <fn id="jcsm12472-note-0007">
                      <label>a</label>
                      <p>Significantly different from baseline, <italic>P</italic> &lt; 0.05.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
              </sec>
              <sec id="jcsm12472-sec-0028">
                <title>Intramuscular signalling pathways</title>
                <p>Acute exercise‐induced anabolic signalling was quantified 60 min after the first (0 week), ninth (3 weeks), and 18th (6 weeks) resistance exercise sessions. We observed significant increases in the acute phosphorylation of AKT<sup>Ser473</sup> (95% CI = 2–4.2 vs. 0.7–3, <italic>P=</italic>0.0006, ES = 0.66), mTOR<sup>Ser2448</sup> (95% CI = 1.9–5.3 vs. 0.1–3.3, <italic>P=</italic>0.001, ES = 0.0.64), MEK1/2<sup>Ser217/221</sup> (95% CI = 1.1–3.6 vs. −0.1 to 2.5, <italic>P=</italic>0.02, ES = 0.43), MAPKAPK‐2<sup>Thr334</sup> (95% CI = 1.1–2.6 vs. 0.3–1.8, <italic>P=</italic>0.03, ES = 0.32), and RPS6<sup>ser240/244</sup> (95% CI = 4.2–10.2 vs. 0.3–6.3, <italic>P=</italic>0.001, ES = 0.44) in T (6 weeks vs. baseline) but not in P. In contrast to this, the P group increased activation of AMPKα<sup>Thr172</sup> (95% CI = 1.5–3.4 vs. 1.8–3.6, <italic>P=</italic>0.02, ES = 0.25) and Raptor<sup>Ser792</sup> (95% CI = 0.24–1.6 vs. 1.1–2.4, <italic>P=</italic>0.01, ES = 0.84) after 6 weeks RET. Furthermore, FoxO3a<sup>Ser253</sup> phosphorylation (<italic>P=</italic>0.01) was increased only after the first exercise bout in the P group. The relative abundance of MAFbx and MURF‐1 was unchanged throughout the study (<italic>Figure</italic>
<xref rid="jcsm12472-fig-0008" ref-type="fig">8</xref>).</p>
                <fig fig-type="Figure" xml:lang="en" id="jcsm12472-fig-0008" orientation="portrait" position="float">
                  <label>Figure 8</label>
                  <caption>
                    <p>Intramuscular signalling pathways. Values are means ± standard error of the mean. <sup>a</sup>Significantly different from baseline, <italic>P</italic> &lt; 0.05; <sup>b</sup>significantly different between two groups, <italic>P</italic> &lt; 0.05.</p>
                  </caption>
                  <graphic id="nlm-graphic-15" xlink:href="JCSM-10-1276-g008"/>
                </fig>
              </sec>
              <sec id="jcsm12472-sec-0029">
                <title>Muscle gene expression</title>
                <p>The expression of a number of genes involved in T metabolism was augmented in T vs. baseline but not in the P group, that is, androgen receptor (<italic>AR</italic>) (1.4 ± 0.1‐fold change, 95% CI = 1.2–1.5 vs. 0.84–1.2, <italic>P=</italic>0.01, ES = 0.71), <italic>Srd5a1</italic> (1.6 ± 0.2‐fold change, 95% CI = 1.3–1.9 vs. 0.76–1.4, <italic>P=</italic>0.01, ES = 0.7), <italic>HSD17β3</italic> (2 ± 0.4‐fold change, 95% CI = 1.3–2.7 vs. 0.5–1.9, <italic>P=</italic>0.03, ES = 0.33), and <italic>AKRIC3</italic> (2.1 ± 0.8‐fold change, 95% CI = 1.2–3.1 vs. 0.9–2.7, <italic>P=</italic>0.01, ES = 0.14, <italic>Figure</italic>
<xref rid="jcsm12472-fig-0009" ref-type="fig">9</xref>A–D) increased after 6 week RET only in T. In addition, <italic>IGF‐1Ea</italic> (3.5 ± 0.07‐fold change, 95% CI = 2.3–4.7 vs. 0.4–2.8, <italic>P</italic> &lt; 0.0001, ES = 0.63) and <italic>IGF‐1Ec</italic> (3 ± 0.4‐fold change, 95% CI = 2.3–3.7 vs. 0.8–2.2, <italic>P</italic> &lt; 0.0001, ES = 0.83) expression increased only in T after 6 week RET (<italic>Figure</italic>
<xref rid="jcsm12472-fig-0009" ref-type="fig">9</xref>E and <xref rid="jcsm12472-fig-0009" ref-type="fig">9</xref>F). While mRNA expression of <italic>MHCI</italic> decreased in both groups (<italic>P</italic> &lt; 0.05), the expression of <italic>MHCIIa</italic> was augmented only in T (1.72 ± 0.3‐fold change, 95% CI = 1.2–2.2 vs. 0.6–1.7, <italic>P=</italic>0.02, ES = 0.33) (<italic>Figure</italic>
<xref rid="jcsm12472-fig-0009" ref-type="fig">9</xref>G and <xref rid="jcsm12472-fig-0009" ref-type="fig">9</xref>H). T coupled with RET augmented myogenesis‐related gene expression, that is, <italic>Myogenin</italic> (2.6 ± 0.7‐fold change, 95% CI = 1.3–4.1 vs. 0.1–2.7, <italic>P=</italic>0.02, ES = 0.53), <italic>C‐Myc</italic> (7.2 ± 1.1‐fold change, 95% CI = 5.3–9.1 vs. 4.3–8.3, <italic>P=</italic>0.04, ES = 0.28), <italic>Myf‐6</italic> (3.9 ± 0.5‐fold change, 95% CI = 3.1–4.7 vs. 1.1–2.8, <italic>P</italic> &lt; 0.0001, ES = 0.92), <italic>MEOX‐2</italic> (2.1 ± 0.4‐fold change, 95% CI = 1.3–2.8 vs. 0.7–2.2, <italic>P=</italic>0.01, ES = 0.19), <italic>C‐met</italic> (1.7 ± 0.1‐fold change, 95% CI = 1.4–1.9 vs. 0.8–1.4, <italic>P=</italic>0.003, ES = 0.89) but not <italic>PAX‐7</italic> (<italic>P</italic> &gt; 0.05) as a marker of satellite cell proliferation (<italic>Figure</italic>
<xref rid="jcsm12472-fig-0009" ref-type="fig">9</xref>I–N).</p>
                <fig fig-type="Figure" xml:lang="en" id="jcsm12472-fig-0009" orientation="portrait" position="float">
                  <label>Figure 9</label>
                  <caption>
                    <p>Muscle gene expression. Changes in testosterone and placebo in (A–D) testosterone metabolism gene expression, (E, F) anabolism, (G, H) fibre type, and (I–N) myogenic from baseline to Week 6. Values are means ± standard error of the mean. <sup>a</sup>Significantly different from baseline, <italic>P</italic> &lt; 0.05; <sup>b</sup>significantly different between two groups, <italic>P</italic> &lt; 0.05.</p>
                  </caption>
                  <graphic id="nlm-graphic-17" xlink:href="JCSM-10-1276-g009"/>
                </fig>
              </sec>
              <sec id="jcsm12472-sec-0030">
                <title>Mitochondrial oxidative phosphorylation capacity</title>
                <p>Testosterone augmented mitochondrial transcription factor A (<italic>Tfam</italic>) expression at 6 weeks (1.4 ± 0.2‐fold change, 95% CI = 1.1–1.7 vs. 0.2–0.9, <italic>P=</italic>0.0002, ES = 0.91), whereas expression of peroxisome proliferator‐activated receptor‐γ co‐activator 1‐α (PGC1‐α) was increased only after the first bout of exercise (1.2 ± 0.2‐fold change, 95% CI = 1.1–1.8 vs. 0.3–1.1, <italic>P=</italic>0.037, ES = 0.7, <italic>Figure</italic>
<xref rid="jcsm12472-fig-0010" ref-type="fig">10</xref>A and <xref rid="jcsm12472-fig-0010" ref-type="fig">10</xref>B). In addition to increased mitochondrial density (assessed by relative change of CS activity) in the T group (1.22 ± 0.07‐fold change, 95% CI = 0.9–1.4 vs. 0.7–1.1, <italic>P=</italic>0.03, ES = 0.29, <italic>Figure</italic>
<xref rid="jcsm12472-fig-0010" ref-type="fig">10</xref>D), only the T group showed enhanced protein levels of OxPhos complex (C)‐IV (95% CI = 1.2–2.6 vs. 0.3–1.7, <italic>P=</italic>0.02, ES = 0.41) and V (95% CI = 0.9–2.2 vs. 0.1–1.3, <italic>P=</italic>0.04, ES = 0.23), while there was a trend in C‐II (<italic>P=</italic>0.08) but not in C‐I (<italic>P=</italic>0.24) or C‐III (<italic>P=</italic>0.3) (<italic>Figure</italic>
<xref rid="jcsm12472-fig-0010" ref-type="fig">10</xref>F–J). There was no impact of RET or T therapy upon mtDNA copy number (<italic>P</italic> &gt; 0.05, <italic>Figure</italic>
<xref rid="jcsm12472-fig-0010" ref-type="fig">10</xref>E).</p>
                <fig fig-type="Figure" xml:lang="en" id="jcsm12472-fig-0010" orientation="portrait" position="float">
                  <label>Figure 10</label>
                  <caption>
                    <p>Mitochondrial oxidative phosphorylation capacity markers. Values are means ± standard error of the mean. <sup>a</sup>Significantly different from baseline, <italic>P</italic> &lt; 0.05; <sup>b</sup>significantly different between two groups, <italic>P</italic> &lt; 0.05.</p>
                  </caption>
                  <graphic id="nlm-graphic-19" xlink:href="JCSM-10-1276-g010"/>
                </fig>
              </sec>
            </sec>
            <sec id="jcsm12472-sec-0031">
              <title>Discussion</title>
              <p>There is a great deal of interest in identifying interventions that will combat muscle wasting in older age. Herein, we elucidated that just 6 week whole‐body RET coupled with the exogenous provision of T had significant positive effects on FFM, and muscular performance via inducing net protein accretion through anabolic pathways, thus offsetting age‐related deficits in adaptive responses to RET.<xref rid="jcsm12472-bib-0020" ref-type="ref">20</xref>
</p>
              <p>The role of T in regulating muscle gains when coupled with RET remains somewhat contentious. For instance, Ahtiainen <italic>et al</italic>.<xref rid="jcsm12472-bib-0044" ref-type="ref">44</xref> reported that 12 month RET increased FFM without altering endogenous T levels, concluding that changes in endogenous T levels did not impact RET‐induced muscular adaptations.<xref rid="jcsm12472-bib-0044" ref-type="ref">44</xref> However, in another study, suppression of endogenous T using Zoladex blunted muscle adaptations to 8 week RET in younger men<xref rid="jcsm12472-bib-0045" ref-type="ref">45</xref>, suggesting that endogenous T levels are, at very least, permissive in regulating hypertrophic adaptations to RET. Therefore, given established links between ageing and muscle loss, declines in T responses to acute RE,<xref rid="jcsm12472-bib-0020" ref-type="ref">20</xref> and age‐related anabolic resistance to RET,<xref rid="jcsm12472-bib-0020" ref-type="ref">20</xref> we postulated that short‐term T adjuvant to RET would be of benefit. Consistent with this thesis, it was previously reported that exogenous T therapy adjuvant to RET for longer periods (10–12 weeks) led to greater muscle mass gains<xref rid="jcsm12472-bib-0046" ref-type="ref">46</xref>, <xref rid="jcsm12472-bib-0047" ref-type="ref">47</xref> than with RET alone. Our present albeit shorter‐term data also showed that RET adjuvant to T led to significant increases in whole‐body and appendicular FFM. Moreover, RET‐induced gains in MT, Lf, PA, and CSA in VL and quadriceps illustrate that T therapy augmented local thigh muscle remodelling, mainly by increasing Lf (number of sarcomeres in series<xref rid="jcsm12472-bib-0048" ref-type="ref">48</xref>) rather than increases in PA; remodelling also associated with T‐specific hypertrophy of type IIX fibres. Previous studies in younger adults have shown that the hypertrophic response to T occurs in both slow and fast muscle fibres<xref rid="jcsm12472-bib-0049" ref-type="ref">49</xref>, <xref rid="jcsm12472-bib-0050" ref-type="ref">50</xref>, <xref rid="jcsm12472-bib-0051" ref-type="ref">51</xref> (although these studies were over longer periods). Considering previously described preferential loss of fast fibres during ageing,<xref rid="jcsm12472-bib-0052" ref-type="ref">52</xref>, <xref rid="jcsm12472-bib-0053" ref-type="ref">53</xref> our data suggest that exogenous provision of T to healthy non‐hypogonadal older men can be considered as a therapy preventing atrophy—and perhaps loss—of these muscle fibres.</p>
              <p>Because muscular performance is the culmination of neural and muscle structural elements and is the most important attribute to maintaining mobility, we determined the role of exogenous T in relation to aspects of muscle function. In doing so, we established that the T group developed greater static (MVC) and sum dynamic (1‐RM) strength gains (in line with greater muscle mass gains that strongly correlated with strength improvement). Interestingly, previous work has shown that there may be a neural component to the effects of T, for example, influencing neurotransmitter synthesis,<xref rid="jcsm12472-bib-0054" ref-type="ref">54</xref> leading to reduced force fluctuations<xref rid="jcsm12472-bib-0055" ref-type="ref">55</xref> and inducing recruitment of larger/faster motor units (fast twitch fibres).<xref rid="jcsm12472-bib-0056" ref-type="ref">56</xref> Nonetheless, our MVC per LM ‘specific force' data illustrate that muscle mass gains were associated with strength‐related improvements; given the strong correlation between FFM gains and strength improvement in T group, we can thus conclude that RET‐induced FFM gains were a major component of improved muscle performance in both groups. Physiological endogenous T levels are correlated with RET‐induced gain of FFM and strength,<xref rid="jcsm12472-bib-0057" ref-type="ref">57</xref> perhaps explaining blunted adaptation to RET in older vs. younger men.<xref rid="jcsm12472-bib-0020" ref-type="ref">20</xref>, <xref rid="jcsm12472-bib-0058" ref-type="ref">58</xref> Dose–response studies reported that higher doses (supra‐physiological doses; i.e. 600 mg weekly) of T result in graded increments in FFM and strength than lower doses (physiological doses) in men, indicating that efficiency of the T therapy is associated with the higher T doses.<xref rid="jcsm12472-bib-0022" ref-type="ref">22</xref>, <xref rid="jcsm12472-bib-0059" ref-type="ref">59</xref>, <xref rid="jcsm12472-bib-0060" ref-type="ref">60</xref> Thus, the ‘moderately' supra‐physiological T levels<xref rid="jcsm12472-bib-0061" ref-type="ref">61</xref> in our study reveals that short‐term T supplementation was able to ‘overcome' previously observed anabolic resistance to RET<xref rid="jcsm12472-bib-0020" ref-type="ref">20</xref> in relation to muscle growth. However, further studies are needed to fully address the physiological vs. supra‐physiological prerequisites to efficacy.</p>
              <p>In order to assess the mechanisms underlying the ergogenic effects of T therapy adjuvant to RET in older men, we for the first time quantified cumulative rates of myofibrillar protein synthesis over the 6 weeks of RET. In doing so, we demonstrated that T augmented MPS during RET while concomitantly increasing (estimated) FBR<xref rid="jcsm12472-bib-0062" ref-type="ref">62</xref> (which is supported by the 3MH data) and crucially with net balance calculations illustrating MPS &gt; MPB. MPB is an important metabolic component of muscle remodelling and protein turnover increase with RET but to a lesser extent than MPS.<xref rid="jcsm12472-bib-0063" ref-type="ref">63</xref> The logical extrapolation of a sustained increase in net muscle protein deposition after RET is an increase in FFM and strength,<xref rid="jcsm12472-bib-0005" ref-type="ref">5</xref> entirely in line with our mass and strength gain data. Links between T and MPS have been previously established. For instance, decreased muscle mass with castration‐induced androgen withdrawal suppressed myofibrillar protein synthesis in mice.<xref rid="jcsm12472-bib-0064" ref-type="ref">64</xref> In addition, 6 months<xref rid="jcsm12472-bib-0011" ref-type="ref">11</xref> and 4 weeks<xref rid="jcsm12472-bib-0065" ref-type="ref">65</xref> of T administration increased MPS measured acutely in older men. Further, T administration led to increases in MPS without concomitant increases in inward amino acid transport,<xref rid="jcsm12472-bib-0066" ref-type="ref">66</xref> indicating increased efficiency of reutilization of amino acids from MPB with T.<xref rid="jcsm12472-bib-0066" ref-type="ref">66</xref> Interestingly, it was suggested that T administration may improve net protein balance via decreasing MPB, rather than an increasing MPS.<xref rid="jcsm12472-bib-0067" ref-type="ref">67</xref> However, we show that T coupled to RET increased net protein accretion despite elevation of both MPS and MPB, because increases in MPS &gt; MPB.</p>
              <p>In order to explore the mechanisms underpinning increases in MPS, we investigated aspects regulating the translational ‘efficiency' of ribosomes<xref rid="jcsm12472-bib-0068" ref-type="ref">68</xref> corresponding to the translational rate per ribosome.<xref rid="jcsm12472-bib-0069" ref-type="ref">69</xref> To evaluate this, we determined acute RE‐induced phosphorylation within MAPKAPK‐2 (target of MAPK pathway), MEK1/2 (upstream components in ERK1/2 cascade),<xref rid="jcsm12472-bib-0070" ref-type="ref">70</xref> and mTORC1<xref rid="jcsm12472-bib-0020" ref-type="ref">20</xref> pathways, across the duration of the 6 week RET. It is noteworthy from past work that activation of many of these pathways is blunted in older age<xref rid="jcsm12472-bib-0020" ref-type="ref">20</xref>, <xref rid="jcsm12472-bib-0070" ref-type="ref">70</xref>, <xref rid="jcsm12472-bib-0071" ref-type="ref">71</xref> and that in the present study, T administration could reverse these impairments. Consistently, there is a general blunted activation of mTORc1,<xref rid="jcsm12472-bib-0071" ref-type="ref">71</xref> ERK1/2,<xref rid="jcsm12472-bib-0070" ref-type="ref">70</xref> and MAPKs<xref rid="jcsm12472-bib-0070" ref-type="ref">70</xref> presumably due to lesser bioavailability of T.<xref rid="jcsm12472-bib-0064" ref-type="ref">64</xref>, <xref rid="jcsm12472-bib-0072" ref-type="ref">72</xref> In support of this, T therapy augmented IGF‐1/Akt/mTOR signalling activity (which regulates MPS<xref rid="jcsm12472-bib-0064" ref-type="ref">64</xref>), presumably explaining enhanced mass and functional gains and suggesting that T levels, at least permissively, regulate muscle adaptations. In addition to increases in translational efficiency, another facet that is blunted with age<xref rid="jcsm12472-bib-0020" ref-type="ref">20</xref> and potentially impacts ‘capacity' for increasing protein synthesis and net protein balance and is critical for anabolic potential and hypertrophy is ribosomal RNA content.<xref rid="jcsm12472-bib-0073" ref-type="ref">73</xref> In the present study, exogenous T therapy coupled with RET increased total RNA content per ‘cellular unit' (RNA:DNA ratio), an indicator of ribosomal abundance,<xref rid="jcsm12472-bib-0074" ref-type="ref">74</xref> and total RNA:ASP ratio, as an index of synthetic capacity, thereby offsetting age‐related deficits.<xref rid="jcsm12472-bib-0075" ref-type="ref">75</xref> Although we observed only subtle (non‐significant) increases in ASP:DNA ratio, an indicator of myonuclear domain size,<xref rid="jcsm12472-bib-0074" ref-type="ref">74</xref> despite there being robust increases in muscle mass (DXA, ultrasound, and histology), this is to be expected because of the maintenance of the myonuclear domain size beyond which additional hypertrophy can only be realized by addition of myonuclei.<xref rid="jcsm12472-bib-0068" ref-type="ref">68</xref>
</p>
              <p>No study has previously examined the effect of RET adjuvant to T in relation to muscle steroid‐metabolism handling in older human muscle. In our study, T therapy augmented AR mRNA and steroidogenic enzyme expression perhaps resulting in higher muscle T processing capacity, presumably due to infiltration of T from the circulation<xref rid="jcsm12472-bib-0076" ref-type="ref">76</xref> and processing by 5‐α reductase. Furthermore, the AR<xref rid="jcsm12472-bib-0077" ref-type="ref">77</xref> not only alters mRNA expression of thousands of target genes <xref rid="jcsm12472-bib-0078" ref-type="ref">78</xref> but also is associated with fibre‐type CSA increases,<xref rid="jcsm12472-bib-0079" ref-type="ref">79</xref> as well as triggering anabolic kinase signalling, that is, ERK, PI3K, and Akt,<xref rid="jcsm12472-bib-0072" ref-type="ref">72</xref> suggesting transcriptional links to augmented MPS, FFM, and strength in the T group in the present study and others.<xref rid="jcsm12472-bib-0026" ref-type="ref">26</xref>, <xref rid="jcsm12472-bib-0079" ref-type="ref">79</xref>, <xref rid="jcsm12472-bib-0080" ref-type="ref">80</xref>, <xref rid="jcsm12472-bib-0081" ref-type="ref">81</xref> In addition to increases in T metabolism‐related mRNA expression, we demonstrated that myogenic and growth factor‐related gene expression was enhanced with T. Specifically, <italic>IGF‐1Ec</italic> up‐regulation is purported to correlate with transcriptional activity<xref rid="jcsm12472-bib-0082" ref-type="ref">82</xref> and initiation of satellite cell proliferation,<xref rid="jcsm12472-bib-0083" ref-type="ref">83</xref> while <italic>IGF1‐Ea</italic> expression is correlated with increased translation<xref rid="jcsm12472-bib-0082" ref-type="ref">82</xref> and promotion of myogenic differentiation.<xref rid="jcsm12472-bib-0083" ref-type="ref">83</xref> Both intramuscular IGF‐1 and T independently stimulate AR and thereafter expression of other anabolic genes<xref rid="jcsm12472-bib-0072" ref-type="ref">72</xref>, <xref rid="jcsm12472-bib-0077" ref-type="ref">77</xref>, <xref rid="jcsm12472-bib-0078" ref-type="ref">78</xref>; therefore, it is highly likely that an IGF‐1 signalling axis played a role in the efficacy of T therapy. Here, we also show augmented expression of myogenic regulatory factors (MRFs) and fast fibre‐type‐specific mRNA expression (i.e. <italic>MHCIIa</italic> expression<xref rid="jcsm12472-bib-0083" ref-type="ref">83</xref>) in line with fast fibre, lower body, and whole‐body hypertrophy with T. This supports previous work<xref rid="jcsm12472-bib-0077" ref-type="ref">77</xref>, <xref rid="jcsm12472-bib-0084" ref-type="ref">84</xref> demonstrating a pro‐myogenic role for T; for example, T increased the transformation of pluripotent precursor cells down the myogenic lineage. It has been shown that single bouts of RE or short‐term RET are sufficient to increase the abundance of MRFs mRNA species in young participants.<xref rid="jcsm12472-bib-0073" ref-type="ref">73</xref>, <xref rid="jcsm12472-bib-0076" ref-type="ref">76</xref> However, in the present study, in line with past work in older age,<xref rid="jcsm12472-bib-0083" ref-type="ref">83</xref>, <xref rid="jcsm12472-bib-0085" ref-type="ref">85</xref> in the P group, these regulatory genes did not change either after an acute bout of RE or after 6 week RET with the exception of <italic>C‐myc</italic> (which controls cell growth and ribosomal biogenesis<xref rid="jcsm12472-bib-0020" ref-type="ref">20</xref>). We speculate this contributed to blunted adaptations to RET in P<xref rid="jcsm12472-bib-0020" ref-type="ref">20</xref> while helping explain greater muscle mass accretion with T therapy.</p>
              <p>In addition to declines in muscle mass and function with age, muscle mitochondria are also subject to age‐related remodelling. For instance, it was reported that ageing is associated with decreases in PGC1‐α mRNA (a main regulator of mitochondrial biogenesis and oxidative capacity<xref rid="jcsm12472-bib-0086" ref-type="ref">86</xref>), OxPhos capacity, mitochondria enzyme activity (e.g. CS), mtDNA content, and increases in oxidative stress, which all result in an impaired mitochondrial function<xref rid="jcsm12472-bib-0087" ref-type="ref">87</xref>. Crucially, exercise, including RET, is known to induce mitochondrial adaptations. For instance, 12 week RET augmented mitochondrial content,<xref rid="jcsm12472-bib-0088" ref-type="ref">88</xref> volume,<xref rid="jcsm12472-bib-0089" ref-type="ref">89</xref> and respiratory capacity,<xref rid="jcsm12472-bib-0090" ref-type="ref">90</xref> in younger participants. Further, 6 month RET increased mitochondrial mass in older women<xref rid="jcsm12472-bib-0091" ref-type="ref">91</xref> and mitochondrial function/transcriptome activity in older men.<xref rid="jcsm12472-bib-0092" ref-type="ref">92</xref> As we showed in our P study group, short‐term RET did not augment mitochondrial CS activity in older men; but similar to short‐term (i.e. 7–9 weeks) endurance training adjuvant to T therapy in mice,<xref rid="jcsm12472-bib-0093" ref-type="ref">93</xref>, <xref rid="jcsm12472-bib-0094" ref-type="ref">94</xref> we showed RET coupled to T therapy augmented PGC1‐α/Tfam mRNA, mitochondrial CS activity,<xref rid="jcsm12472-bib-0002" ref-type="ref">2</xref> and protein levels of complex IV (cytochrome <italic>c</italic> oxidase subunit<xref rid="jcsm12472-bib-0085" ref-type="ref">85</xref>) and V (ATP synthase subunit)<xref rid="jcsm12472-bib-0085" ref-type="ref">85</xref> (not mtDNA copy number). Possible mechanisms include heightened activation of IGF‐1/MAPK pathways<xref rid="jcsm12472-bib-0087" ref-type="ref">87</xref>, <xref rid="jcsm12472-bib-0095" ref-type="ref">95</xref> and augmented MRFs mRNA (e.g. <italic>Myogenin</italic>)<xref rid="jcsm12472-bib-0096" ref-type="ref">96</xref> during RET, as observed in the T study group, which consequently mediate mitochondrial gene expression.<xref rid="jcsm12472-bib-0087" ref-type="ref">87</xref>, <xref rid="jcsm12472-bib-0096" ref-type="ref">96</xref> Furthermore, because mitochondrial gene expression (i.e. PGC1‐α) is regulated by Akt/mTOR signalling,<xref rid="jcsm12472-bib-0097" ref-type="ref">97</xref>, <xref rid="jcsm12472-bib-0098" ref-type="ref">98</xref> which were all up‐regulated with T, this may also explain our observations of greater CS activity with adjuvant T therapy. Moreover, sustained muscle growth and MPS during RET in the T group likely required greater increases in mitochondrial function or volume due to the increased energy demands of intracellular protein accretion.<xref rid="jcsm12472-bib-0089" ref-type="ref">89</xref> Previous work has also shown that the AR<xref rid="jcsm12472-bib-0098" ref-type="ref">98</xref> and systemic levels of T were positively associated with cytochrome <italic>c</italic> oxidase,<xref rid="jcsm12472-bib-0098" ref-type="ref">98</xref>, <xref rid="jcsm12472-bib-0099" ref-type="ref">99</xref> CS<xref rid="jcsm12472-bib-0100" ref-type="ref">100</xref> activity, and mitochondrial protein synthesis, in addition to Tfam and PGC1‐α expression,<xref rid="jcsm12472-bib-0098" ref-type="ref">98</xref> culminating in enhanced mitochondrial biogenesis and respiratory capacity and function.<xref rid="jcsm12472-bib-0099" ref-type="ref">99</xref> Conversely, AR and T deficiency has been associated with lower levels of PGC1‐α expression<xref rid="jcsm12472-bib-0101" ref-type="ref">101</xref> resulting in decreases in OxPhos capacity.<xref rid="jcsm12472-bib-0102" ref-type="ref">102</xref> In summary, greater MPS, myofibrillar protein accretion, and consequent muscle hypertrophy alongside greater mitochondrial adaptations<xref rid="jcsm12472-bib-0002" ref-type="ref">2</xref> in the T therapy group demonstrate the efficacy of adjuvant T in yielding positive hypertrophic and energetic adaptations.</p>
              <p>We conclude that administration of T coupled to RET is an effective short‐term (6 weeks) intervention to overcome age‐related deficits in the responsiveness of older muscle to RET. Short‐term RET adjuvant to T was also well tolerated and could be useful as both pre‐habilitation and rehabilitation interventions in elective surgery and other clinical procedures in older populations. Nevertheless, it is important to be cognizant of potential adverse effects. T therapy has been associated by (non‐significant) increases in some disorders, for example, cardiovascular risk<xref rid="jcsm12472-bib-0103" ref-type="ref">103</xref> and/or prostate hypertrophy.<xref rid="jcsm12472-bib-0104" ref-type="ref">104</xref> While randomized controlled trials have been insufficiently powered to detect differences in the rates of adverse events,<xref rid="jcsm12472-bib-0105" ref-type="ref">105</xref> some have reported an increased risk of stroke and/or myocardial infarction,<xref rid="jcsm12472-bib-0106" ref-type="ref">106</xref> whereas others have reported to be uncertain of such effects.<xref rid="jcsm12472-bib-0105" ref-type="ref">105</xref>, <xref rid="jcsm12472-bib-0107" ref-type="ref">107</xref>, <xref rid="jcsm12472-bib-0108" ref-type="ref">108</xref>, <xref rid="jcsm12472-bib-0109" ref-type="ref">109</xref> No adverse events were noted during or after completion of the present study in older men and a major benefit of our approach is the short‐term efficacy of therapy. Finally, we reveal the likely mechanisms underlying the effect of T therapy in relation to ‘overcoming' aspects of age‐related anabolic resistance, vis‐à‐vis, elevating protein turnover (with greater increases in MPS), enhancing translational efficiency and capacity, and inducing pro‐myogenic and T handling gene regulation. Given links between declining T and muscle ageing in women,<xref rid="jcsm12472-bib-0110" ref-type="ref">110</xref> similar studies in women are likely to deliver similar benefits. Short‐term T administration may have a role in the treatment of frailty in older men without inducing any adverse side effects; however, older men receiving T therapy should be carefully monitored because of its potential risks.</p>
            </sec>
            <sec sec-type="COI-statement" id="jcsm12472-sec-0034">
              <title>Conflict of interest</title>
              <p>None declared.</p>
            </sec>
            <sec id="jcsm12472-sec-0033">
              <title>Funding</title>
              <p>This work was supported by the Medical Research Council (grant numbers MR/R502364/1 and MR/P021220/1) as part of the MRC‐ARUK Centre for Musculoskeletal Ageing Research awarded to the Universities of Nottingham and Birmingham, and the National Institute for Health Research, Nottingham Biomedical Research Centre.</p>
            </sec>
          </body>
          <back>
            <ack id="jcsm12472-sec-0032">
              <title>Acknowledgements</title>
              <p>The authors are grateful for the clinical and technical support of Amanda Gates, as well as the administrative support of Tanya Fletcher. The authors of this manuscript certify that they comply with the ethical guidelines for authorship and publishing in the <italic>Journal of Cachexia, Sarcopenia and Muscle</italic>.<xref rid="jcsm12472-bib-0111" ref-type="ref">111</xref>
</p>
            </ack>
            <ref-list id="jcsm12472-bibl-0001" content-type="cited-references">
              <title>References</title>
              <ref id="jcsm12472-bib-0001">
                <label>1</label>
                <mixed-citation publication-type="journal" id="jcsm12472-cit-0002"><string-name><surname>Mitchell</surname><given-names>WK</given-names></string-name>, <string-name><surname>Williams</surname><given-names>J</given-names></string-name>, <string-name><surname>Atherton</surname><given-names>P</given-names></string-name>, <string-name><surname>Larvin</surname><given-names>M</given-names></string-name>, <string-name><surname>Lund</surname><given-names>J</given-names></string-name>, <string-name><surname>Narici</surname><given-names>M</given-names></string-name>. <article-title>Sarcopenia, dynapenia, and the impact of advancing age on human skeletal muscle size and strength; a quantitative review</article-title>. <source xml:lang="en">Front Physiol</source><year>2012</year>;<volume>3</volume>:<fpage>1</fpage>–<lpage>18</lpage>.<pub-id pub-id-type="pmid">22275902</pub-id></mixed-citation>
              </ref>
              <ref id="jcsm12472-bib-0002">
                <label>2</label>
                <mixed-citation publication-type="journal" id="jcsm12472-cit-0003"><string-name><surname>Groennebaek</surname><given-names>T</given-names></string-name>, <string-name><surname>Vissing</surname><given-names>K</given-names></string-name>. <article-title>Impact of resistance training on skeletal muscle mitochondrial biogenesis, content, and function</article-title>. <source xml:lang="en">Front Physiol</source><year>2017</year>;<volume>8</volume>:<fpage>1</fpage>–<lpage>7</lpage>.<pub-id pub-id-type="pmid">28154536</pub-id></mixed-citation>
              </ref>
              <ref id="jcsm12472-bib-0003">
                <label>3</label>
                <mixed-citation publication-type="journal" id="jcsm12472-cit-0004"><string-name><surname>Stanworth</surname><given-names>RD</given-names></string-name>, <string-name><surname>Jones</surname><given-names>TH</given-names></string-name>. <article-title>Testosterone for the aging male; current evidence and recommended practice</article-title>. <source xml:lang="en">Clin Interv Aging</source><year>2008</year>;<volume>3</volume>:<fpage>25</fpage>–<lpage>44</lpage>.<pub-id pub-id-type="pmid">18488876</pub-id></mixed-citation>
              </ref>
              <ref id="jcsm12472-bib-0004">
                <label>4</label>
                <mixed-citation publication-type="journal" id="jcsm12472-cit-0005"><string-name><surname>Borst</surname><given-names>SE</given-names></string-name>, <string-name><surname>Yarrow</surname><given-names>JF</given-names></string-name>. <article-title>Injection of testosterone may be safer and more effective than transdermal administration for combating loss of muscle and bone in older men</article-title>. <source xml:lang="en">Am J Physiol Endocrinol Metab</source><year>2015</year>;<volume>308</volume>:<fpage>1035</fpage>–<lpage>1042</lpage>.</mixed-citation>
              </ref>
              <ref id="jcsm12472-bib-0005">
                <label>5</label>
                <mixed-citation publication-type="journal" id="jcsm12472-cit-0006"><string-name><surname>Ferrando</surname><given-names>AA</given-names></string-name>, <string-name><surname>Sheffield‐Moore</surname><given-names>M</given-names></string-name>, <string-name><surname>Yeckel</surname><given-names>CW</given-names></string-name>, <string-name><surname>Gilkison</surname><given-names>C</given-names></string-name>, <string-name><surname>Jiang</surname><given-names>J</given-names></string-name>, <string-name><surname>Achacosa</surname><given-names>A</given-names></string-name>, et al. <article-title>Testosterone administration to older men improves muscle function: molecular and physiological mechanisms</article-title>. <source xml:lang="en">Am J Physiol Endocrinol Metab</source><year>2002</year>;<volume>282</volume>:<fpage>601</fpage>–<lpage>607</lpage>.</mixed-citation>
              </ref>
              <ref id="jcsm12472-bib-0006">
                <label>6</label>
                <mixed-citation publication-type="journal" id="jcsm12472-cit-0007"><string-name><surname>Hackett</surname><given-names>G</given-names></string-name>. <article-title>Testosterone replacement therapy and mortality in older men</article-title>. <source xml:lang="en">Drug Saf</source><year>2016</year>;<volume>39</volume>:<fpage>117</fpage>–<lpage>130</lpage>.<pub-id pub-id-type="pmid">26482385</pub-id></mixed-citation>
              </ref>
              <ref id="jcsm12472-bib-0007">
                <label>7</label>
                <mixed-citation publication-type="journal" id="jcsm12472-cit-0008"><string-name><surname>Gruenewald</surname><given-names>DA</given-names></string-name>, <string-name><surname>Matsumoto</surname><given-names>AM</given-names></string-name>. <article-title>Testosterone supplementation therapy for older men: potential benefits and risks</article-title>. <source xml:lang="en">J Am Geriatr Soc</source><year>2003</year>;<volume>51</volume>:<fpage>101</fpage>–<lpage>115</lpage>.<pub-id pub-id-type="pmid">12534854</pub-id></mixed-citation>
              </ref>
              <ref id="jcsm12472-bib-0008">
                <label>8</label>
                <mixed-citation publication-type="journal" id="jcsm12472-cit-0009"><string-name><surname>Svartberg</surname><given-names>J</given-names></string-name>, <string-name><surname>Agledahl</surname><given-names>I</given-names></string-name>, <string-name><surname>Figenschau</surname><given-names>Y</given-names></string-name>, <string-name><surname>Sildnes</surname><given-names>T</given-names></string-name>, <string-name><surname>Waterloo</surname><given-names>K</given-names></string-name>, <string-name><surname>Jorde</surname><given-names>R</given-names></string-name>. <article-title>Testosterone treatment in elderly men with subnormal testosterone levels improves body composition and BMD in the hip</article-title>. <source xml:lang="en">Int J Impot Res</source><year>2008</year>;<volume>20</volume>:<fpage>378</fpage>–<lpage>387</lpage>.<pub-id pub-id-type="pmid">18480825</pub-id></mixed-citation>
              </ref>
              <ref id="jcsm12472-bib-0009">
                <label>9</label>
                <mixed-citation publication-type="journal" id="jcsm12472-cit-0010"><string-name><surname>Usui</surname><given-names>T</given-names></string-name>, <string-name><surname>Kajita</surname><given-names>K</given-names></string-name>, <string-name><surname>Kajita</surname><given-names>T</given-names></string-name>, <string-name><surname>Mori</surname><given-names>I</given-names></string-name>, <string-name><surname>Hanamoto</surname><given-names>T</given-names></string-name>, <string-name><surname>Ikeda</surname><given-names>T</given-names></string-name>, et al. <article-title>Elevated mitochondrial biogenesis in skeletal muscle is associated with testosterone‐induced body weight loss in male mice</article-title>. <source xml:lang="en">FEBS Lett</source><year>2014</year>;<volume>588</volume>:<fpage>1935</fpage>–<lpage>1941</lpage>.<pub-id pub-id-type="pmid">24726723</pub-id></mixed-citation>
              </ref>
              <ref id="jcsm12472-bib-0010">
                <label>10</label>
                <mixed-citation publication-type="journal" id="jcsm12472-cit-0011"><string-name><surname>Sinha‐Hikim</surname><given-names>I</given-names></string-name>, <string-name><surname>Cornford</surname><given-names>M</given-names></string-name>, <string-name><surname>Gaytan</surname><given-names>H</given-names></string-name>, <string-name><surname>Lee</surname><given-names>ML</given-names></string-name>, <string-name><surname>Bhasin</surname><given-names>S</given-names></string-name>. <article-title>Effects of testosterone supplementation on skeletal muscle fiber hypertrophy and satellite cells in community‐dwelling older men</article-title>. <source xml:lang="en">J Clin Endocrinol Metabol</source><year>2006</year>;<volume>91</volume>:<fpage>3024</fpage>–<lpage>3033</lpage>.</mixed-citation>
              </ref>
              <ref id="jcsm12472-bib-0011">
                <label>11</label>
                <mixed-citation publication-type="journal" id="jcsm12472-cit-0012"><string-name><surname>Brodsky</surname><given-names>IG</given-names></string-name>, <string-name><surname>Balagopal</surname><given-names>P</given-names></string-name>, <string-name><surname>Nair</surname><given-names>KS</given-names></string-name>. <article-title>Effects of testosterone replacement on muscle mass and muscle protein synthesis in hypogonadal men—a clinical research center study</article-title>. <source xml:lang="en">J Clin Endocrinol Metabol</source><year>1996</year>;<volume>81</volume>:<fpage>3469</fpage>–<lpage>3475</lpage>.</mixed-citation>
              </ref>
              <ref id="jcsm12472-bib-0012">
                <label>12</label>
                <mixed-citation publication-type="journal" id="jcsm12472-cit-0013"><string-name><surname>Lobley</surname><given-names>G</given-names></string-name>, <string-name><surname>Connell</surname><given-names>A</given-names></string-name>, <string-name><surname>Milne</surname><given-names>E</given-names></string-name>, <string-name><surname>Buchan</surname><given-names>V</given-names></string-name>, <string-name><surname>Calder</surname><given-names>AG</given-names></string-name>, <string-name><surname>Anderson</surname><given-names>SE</given-names></string-name>, et al. <article-title>Muscle protein synthesis in response to testosterone administration in wether lambs</article-title>. <source xml:lang="en">Br J Nutr</source><year>1990</year>;<volume>64</volume>:<fpage>691</fpage>–<lpage>704</lpage>.<pub-id pub-id-type="pmid">1702317</pub-id></mixed-citation>
              </ref>
              <ref id="jcsm12472-bib-0013">
                <label>13</label>
                <mixed-citation publication-type="journal" id="jcsm12472-cit-0014"><string-name><surname>Ragnarsson</surname><given-names>O</given-names></string-name>, <string-name><surname>Burt</surname><given-names>MG</given-names></string-name>, <string-name><surname>Ho</surname><given-names>KK</given-names></string-name>, <string-name><surname>Johannsson</surname><given-names>G</given-names></string-name>. <article-title>Effect of short‐term GH and testosterone administration on body composition and glucose homoeostasis in men receiving chronic glucocorticoid therapy</article-title>. <source xml:lang="en">Eur J Endocrinol</source><year>2013</year>;<volume>168</volume>:<fpage>243</fpage>–<lpage>251</lpage>.<pub-id pub-id-type="pmid">23169695</pub-id></mixed-citation>
              </ref>
              <ref id="jcsm12472-bib-0014">
                <label>14</label>
                <mixed-citation publication-type="journal" id="jcsm12472-cit-0015"><string-name><surname>Liu</surname><given-names>PY</given-names></string-name>, <string-name><surname>Swerdloff</surname><given-names>RS</given-names></string-name>, <string-name><surname>Veldhuis</surname><given-names>JD</given-names></string-name>. <article-title>The rationale, efficacy and safety of androgen therapy in older men: future research and current practice recommendations</article-title>. <source xml:lang="en">J Clin Endocrinol Metabol</source><year>2004</year>;<volume>89</volume>:<fpage>4789</fpage>–<lpage>4796</lpage>.</mixed-citation>
              </ref>
              <ref id="jcsm12472-bib-0015">
                <label>15</label>
                <mixed-citation publication-type="journal" id="jcsm12472-cit-0016"><string-name><surname>Clague</surname><given-names>JE</given-names></string-name>, <string-name><surname>Wu</surname><given-names>FC</given-names></string-name>, <string-name><surname>Horan</surname><given-names>MA</given-names></string-name>. <article-title>Difficulties in measuring the effect of testosterone replacement therapy on muscle function in older men</article-title>. <source xml:lang="en">Int J Androl</source><year>1999</year>;<volume>22</volume>:<fpage>261</fpage>–<lpage>265</lpage>.<pub-id pub-id-type="pmid">10442299</pub-id></mixed-citation>
              </ref>
              <ref id="jcsm12472-bib-0016">
                <label>16</label>
                <mixed-citation publication-type="journal" id="jcsm12472-cit-0017"><string-name><surname>Hawkins</surname><given-names>VN</given-names></string-name>, <string-name><surname>Foster‐Schubert</surname><given-names>K</given-names></string-name>, <string-name><surname>Chubak</surname><given-names>J</given-names></string-name>, <string-name><surname>Sorensen</surname><given-names>B</given-names></string-name>, <string-name><surname>Ulrich</surname><given-names>CM</given-names></string-name>, <string-name><surname>Stancyzk</surname><given-names>FZ</given-names></string-name>, et al. <article-title>Effect of exercise on serum sex hormones in men: a 12‐month randomized clinical trial</article-title>. <source xml:lang="en">Med Sci Sports Exerc</source><year>2008</year>;<volume>40</volume>:<fpage>223</fpage>–<lpage>233</lpage>.<pub-id pub-id-type="pmid">18202581</pub-id></mixed-citation>
              </ref>
              <ref id="jcsm12472-bib-0017">
                <label>17</label>
                <mixed-citation publication-type="journal" id="jcsm12472-cit-0018"><string-name><surname>Ribeiro</surname><given-names>MBT</given-names></string-name>, <string-name><surname>Guzzoni</surname><given-names>V</given-names></string-name>, <string-name><surname>Hord</surname><given-names>JM</given-names></string-name>, <string-name><surname>Lopes</surname><given-names>GN</given-names></string-name>, <string-name><surname>de Cássia Marqueti</surname><given-names>R</given-names></string-name>, <string-name><surname>Andrade</surname><given-names>RV</given-names></string-name>, et al. <article-title>Resistance training regulates gene expression of molecules associated with intramyocellular lipids, glucose signaling and fiber size in old rats</article-title>. <source xml:lang="en">Sci Rep</source><year>2017</year>;<volume>7</volume>:<fpage>1</fpage>–<lpage>13</lpage>.<pub-id pub-id-type="pmid">28127051</pub-id></mixed-citation>
              </ref>
              <ref id="jcsm12472-bib-0018">
                <label>18</label>
                <mixed-citation publication-type="journal" id="jcsm12472-cit-0019"><string-name><surname>Phillips</surname><given-names>BE</given-names></string-name>, <string-name><surname>Williams</surname><given-names>JP</given-names></string-name>, <string-name><surname>Greenhaff</surname><given-names>PL</given-names></string-name>, <string-name><surname>Smith</surname><given-names>K</given-names></string-name>, <string-name><surname>Atherton</surname><given-names>PJ</given-names></string-name>. <article-title>Physiological adaptations to resistance exercise as a function of age</article-title>. <source xml:lang="en">JCI Insight</source><year>2017</year>;<volume>2</volume>:<fpage>1</fpage>–<lpage>16</lpage>.</mixed-citation>
              </ref>
              <ref id="jcsm12472-bib-0019">
                <label>19</label>
                <mixed-citation publication-type="journal" id="jcsm12472-cit-0020"><string-name><surname>Rønnestad</surname><given-names>BR</given-names></string-name>, <string-name><surname>Nygaard</surname><given-names>H</given-names></string-name>, <string-name><surname>Raastad</surname><given-names>T</given-names></string-name>. <article-title>Physiological elevation of endogenous hormones results in superior strength training adaptation</article-title>. <source xml:lang="en">Eur J Appl Physiol</source><year>2011</year>;<volume>111</volume>:<fpage>2249</fpage>–<lpage>2259</lpage>.<pub-id pub-id-type="pmid">21327794</pub-id></mixed-citation>
              </ref>
              <ref id="jcsm12472-bib-0020">
                <label>20</label>
                <mixed-citation publication-type="journal" id="jcsm12472-cit-0021"><string-name><surname>Brook</surname><given-names>MS</given-names></string-name>, <string-name><surname>Wilkinson</surname><given-names>DJ</given-names></string-name>, <string-name><surname>Mitchell</surname><given-names>WK</given-names></string-name>, <string-name><surname>Lund</surname><given-names>JN</given-names></string-name>, <string-name><surname>Phillips</surname><given-names>BE</given-names></string-name>, <string-name><surname>Szewczyk</surname><given-names>NJ</given-names></string-name>, et al. <article-title>Synchronous deficits in cumulative muscle protein synthesis and ribosomal biogenesis underlie age‐related anabolic resistance to exercise in humans</article-title>. <source xml:lang="en">J Physiol</source><year>2016</year>;<volume>594</volume>:<fpage>7399</fpage>–<lpage>7417</lpage>.<pub-id pub-id-type="pmid">27654940</pub-id></mixed-citation>
              </ref>
              <ref id="jcsm12472-bib-0021">
                <label>21</label>
                <mixed-citation publication-type="journal" id="jcsm12472-cit-0022"><string-name><surname>Glintborg</surname><given-names>D</given-names></string-name>, <string-name><surname>Christensen</surname><given-names>L</given-names></string-name>, <string-name><surname>Kvorning</surname><given-names>T</given-names></string-name>, <string-name><surname>Larsen</surname><given-names>R</given-names></string-name>, <string-name><surname>Brixen</surname><given-names>K</given-names></string-name>, <string-name><surname>Hougaard</surname><given-names>D</given-names></string-name>, et al. <article-title>Strength training and testosterone treatment have opposing effects on migration inhibitor factor levels in ageing men</article-title>. <source xml:lang="en">Mediators Inflamm</source><year>2013</year>;<volume>2013</volume>:<fpage>1</fpage>–<lpage>7</lpage>.</mixed-citation>
              </ref>
              <ref id="jcsm12472-bib-0022">
                <label>22</label>
                <mixed-citation publication-type="journal" id="jcsm12472-cit-0023"><string-name><surname>Bhasin</surname><given-names>S</given-names></string-name>, <string-name><surname>Storer</surname><given-names>TW</given-names></string-name>, <string-name><surname>Berman</surname><given-names>N</given-names></string-name>, <string-name><surname>Callegari</surname><given-names>C</given-names></string-name>, <string-name><surname>Clevenger</surname><given-names>B</given-names></string-name>, <string-name><surname>Phillips</surname><given-names>J</given-names></string-name>, et al. <article-title>The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men</article-title>. <source xml:lang="en">N Engl J Med</source><year>1996</year>;<volume>335</volume>:<fpage>1</fpage>–<lpage>7</lpage>.<pub-id pub-id-type="pmid">8637535</pub-id></mixed-citation>
              </ref>
              <ref id="jcsm12472-bib-0023">
                <label>23</label>
                <mixed-citation publication-type="journal" id="jcsm12472-cit-0024"><string-name><surname>Wentzensen</surname><given-names>N</given-names></string-name>, <string-name><surname>Trabert</surname><given-names>B</given-names></string-name>. <article-title>Hormone therapy: short‐term relief, long‐term consequences</article-title>. <source xml:lang="en">The Lancet</source><year>2015</year>;<volume>385</volume>:<fpage>1806</fpage>–<lpage>1808</lpage>.</mixed-citation>
              </ref>
              <ref id="jcsm12472-bib-0024">
                <label>24</label>
                <mixed-citation publication-type="journal" id="jcsm12472-cit-0025"><string-name><surname>Rolf</surname><given-names>C</given-names></string-name>, <string-name><surname>Nieschlag</surname><given-names>E</given-names></string-name>. <article-title>Potential adverse effects of long‐term testosterone therapy</article-title>. <source xml:lang="en">Baillieres Clin Endocrinol Metab</source><year>1998</year>;<volume>12</volume>:<fpage>521</fpage>–<lpage>534</lpage>.<pub-id pub-id-type="pmid">10332571</pub-id></mixed-citation>
              </ref>
              <ref id="jcsm12472-bib-0025">
                <label>25</label>
                <mixed-citation publication-type="journal" id="jcsm12472-cit-0026"><string-name><surname>Brook</surname><given-names>MS</given-names></string-name>, <string-name><surname>Wilkinson</surname><given-names>DJ</given-names></string-name>, <string-name><surname>Mitchell</surname><given-names>WK</given-names></string-name>, <string-name><surname>Lund</surname><given-names>JN</given-names></string-name>, <string-name><surname>Szewczyk</surname><given-names>NJ</given-names></string-name>, <string-name><surname>Greenhaff</surname><given-names>PL</given-names></string-name>, et al. <article-title>Skeletal muscle hypertrophy adaptations predominate in the early stages of resistance exercise training, matching deuterium oxide‐derived measures of muscle protein synthesis and mechanistic target of rapamycin complex 1 signaling</article-title>. <source xml:lang="en">FASEB J</source><year>2015</year>;<volume>29</volume>:<fpage>4485</fpage>–<lpage>4496</lpage>.<pub-id pub-id-type="pmid">26169934</pub-id></mixed-citation>
              </ref>
              <ref id="jcsm12472-bib-0026">
                <label>26</label>
                <mixed-citation publication-type="journal" id="jcsm12472-cit-0027"><string-name><surname>Brook</surname><given-names>MS</given-names></string-name>, <string-name><surname>Wilkinson</surname><given-names>DJ</given-names></string-name>, <string-name><surname>Smith</surname><given-names>K</given-names></string-name>, <string-name><surname>Atherton</surname><given-names>PJ</given-names></string-name>. <article-title>The metabolic and temporal basis of muscle hypertrophy in response to resistance exercise</article-title>. <source xml:lang="en">Eur J Sport Sci</source><year>2016</year>;<volume>16</volume>:<fpage>633</fpage>–<lpage>644</lpage>.<pub-id pub-id-type="pmid">26289597</pub-id></mixed-citation>
              </ref>
              <ref id="jcsm12472-bib-0027">
                <label>27</label>
                <mixed-citation publication-type="journal" id="jcsm12472-cit-0028"><string-name><surname>Trost</surname><given-names>LW</given-names></string-name>, <string-name><surname>Mulhall</surname><given-names>JP</given-names></string-name>. <article-title>Challenges in testosterone measurement, data interpretation, and methodological appraisal of interventional trials</article-title>. <source xml:lang="en">J Sex Med</source><year>2016</year>;<volume>13</volume>:<fpage>1029</fpage>–<lpage>1046</lpage>.<pub-id pub-id-type="pmid">27209182</pub-id></mixed-citation>
              </ref>
              <ref id="jcsm12472-bib-0028">
                <label>28</label>
                <mixed-citation publication-type="journal" id="jcsm12472-cit-0029"><string-name><surname>Yassin</surname><given-names>AA</given-names></string-name>, <string-name><surname>Haffejee</surname><given-names>M</given-names></string-name>. <article-title>Testosterone depot injection in male hypogonadism: a critical appraisal</article-title>. <source xml:lang="en">Clin Interv Aging</source><year>2007</year>;<volume>2</volume>:<fpage>577</fpage>–<lpage>590</lpage>.<pub-id pub-id-type="pmid">18225458</pub-id></mixed-citation>
              </ref>
              <ref id="jcsm12472-bib-0029">
                <label>29</label>
                <mixed-citation publication-type="journal" id="jcsm12472-cit-0030"><string-name><surname>Nieschlag</surname><given-names>E</given-names></string-name>, <string-name><surname>Behre</surname><given-names>HM</given-names></string-name>. <article-title>Clinical uses of testosterone in hypogonadism and other conditions</article-title>. <source xml:lang="en">Testosterone: Action, Defic, Substit</source><year>2004</year>;<volume>14</volume>:<fpage>292</fpage>–<lpage>308</lpage>.</mixed-citation>
              </ref>
              <ref id="jcsm12472-bib-0030">
                <label>30</label>
                <mixed-citation publication-type="journal" id="jcsm12472-cit-0031"><string-name><surname>Dietrichson</surname><given-names>P</given-names></string-name>, <string-name><surname>Coakley</surname><given-names>J</given-names></string-name>, <string-name><surname>Smith</surname><given-names>P</given-names></string-name>, <string-name><surname>Griffiths</surname><given-names>R</given-names></string-name>, <string-name><surname>Helliwell</surname><given-names>T</given-names></string-name>, <string-name><surname>Edwards</surname><given-names>R</given-names></string-name>. <article-title>Conchotome and needle percutaneous biopsy of skeletal muscle</article-title>. <source xml:lang="en">J Neurol Neurosurg Psychiatry</source><year>1987</year>;<volume>50</volume>:<fpage>1461</fpage>–<lpage>1467</lpage>.<pub-id pub-id-type="pmid">3694206</pub-id></mixed-citation>
              </ref>
              <ref id="jcsm12472-bib-0031">
                <label>31</label>
                <mixed-citation publication-type="journal" id="jcsm12472-cit-0032"><string-name><surname>Sundell</surname><given-names>J</given-names></string-name>. <article-title>Resistance training is an effective tool against metabolic and frailty syndromes</article-title>. <source xml:lang="en">Adv Prev Med</source><year>2011</year>;<volume>2011</volume>:<fpage>1</fpage>–<lpage>7</lpage>.</mixed-citation>
              </ref>
              <ref id="jcsm12472-bib-0032">
                <label>32</label>
                <mixed-citation publication-type="journal" id="jcsm12472-cit-0033"><string-name><surname>Dohoney</surname><given-names>P</given-names></string-name>, <string-name><surname>Chromiak</surname><given-names>JA</given-names></string-name>, <string-name><surname>Lemire</surname><given-names>D</given-names></string-name>, <string-name><surname>Abadie</surname><given-names>BR</given-names></string-name>, <string-name><surname>Kovacs</surname><given-names>C</given-names></string-name>. <article-title>Prediction of one repetition maximum (1‐RM) strength from a 4–6 RM and a 7–10 RM submaximal strength test in healthy young adult males</article-title>. <source xml:lang="en">J Exerc Physiol</source><year>2002</year>;<volume>5</volume>:<fpage>54</fpage>–<lpage>59</lpage>.</mixed-citation>
              </ref>
              <ref id="jcsm12472-bib-0033">
                <label>33</label>
                <mixed-citation publication-type="journal" id="jcsm12472-cit-0034"><string-name><surname>Quinlan</surname><given-names>JI</given-names></string-name>, <string-name><surname>Maganaris</surname><given-names>CN</given-names></string-name>, <string-name><surname>Franchi</surname><given-names>MV</given-names></string-name>, <string-name><surname>Smith</surname><given-names>K</given-names></string-name>, <string-name><surname>Atherton</surname><given-names>PJ</given-names></string-name>, <string-name><surname>Szewczyk</surname><given-names>NJ</given-names></string-name>, et al. <article-title>Muscle and tendon contributions to reduced rate of torque development in healthy older males</article-title>. <source xml:lang="en">J Gerontol</source><year>2017</year>;<fpage>539</fpage>–<lpage>545</lpage>.</mixed-citation>
              </ref>
              <ref id="jcsm12472-bib-0034">
                <label>34</label>
                <mixed-citation publication-type="journal" id="jcsm12472-cit-0035"><string-name><surname>Franchi</surname><given-names>MV</given-names></string-name>, <string-name><surname>Wilkinson</surname><given-names>DJ</given-names></string-name>, <string-name><surname>Quinlan</surname><given-names>JI</given-names></string-name>, <string-name><surname>Mitchell</surname><given-names>WK</given-names></string-name>, <string-name><surname>Lund</surname><given-names>JN</given-names></string-name>, <string-name><surname>Williams</surname><given-names>JP</given-names></string-name>, et al. <article-title>Early structural remodeling and deuterium oxide‐derived protein metabolic responses to eccentric and concentric loading in human skeletal muscle</article-title>. <source xml:lang="en">Physiol Rep</source><year>2015</year>;<volume>3</volume>:<fpage>1</fpage>–<lpage>11</lpage>.</mixed-citation>
              </ref>
              <ref id="jcsm12472-bib-0035">
                <label>35</label>
                <mixed-citation publication-type="journal" id="jcsm12472-cit-0036"><string-name><surname>Noorkoiv</surname><given-names>M</given-names></string-name>, <string-name><surname>Nosaka</surname><given-names>K</given-names></string-name>, <string-name><surname>Blazevich</surname><given-names>AJ</given-names></string-name>. <article-title>Assessment of quadriceps muscle cross‐sectional area by ultrasound extended‐field‐of‐view imaging</article-title>. <source xml:lang="en">Eur J Appl Physiol</source><year>2010</year>;<volume>109</volume>:<fpage>631</fpage>–<lpage>639</lpage>.<pub-id pub-id-type="pmid">20191287</pub-id></mixed-citation>
              </ref>
              <ref id="jcsm12472-bib-0036">
                <label>36</label>
                <mixed-citation publication-type="journal" id="jcsm12472-cit-0037"><string-name><surname>Kadi</surname><given-names>F</given-names></string-name>, <string-name><surname>Hägg</surname><given-names>G</given-names></string-name>, <string-name><surname>Håkansson</surname><given-names>R</given-names></string-name>, <string-name><surname>Holmner</surname><given-names>S</given-names></string-name>, <string-name><surname>Butler‐Browne</surname><given-names>GS</given-names></string-name>, <string-name><surname>Thornell</surname><given-names>L‐E</given-names></string-name>. <article-title>Structural changes in male trapezius muscle with work‐related myalgia</article-title>. <source xml:lang="en">Acta Neuropathol</source><year>1998</year>;<volume>95</volume>:<fpage>352</fpage>–<lpage>360</lpage>.<pub-id pub-id-type="pmid">9560012</pub-id></mixed-citation>
              </ref>
              <ref id="jcsm12472-bib-0037">
                <label>37</label>
                <mixed-citation publication-type="journal" id="jcsm12472-cit-0038"><string-name><surname>Wilkinson</surname><given-names>DJ</given-names></string-name>, <string-name><surname>Franchi</surname><given-names>MV</given-names></string-name>, <string-name><surname>Brook</surname><given-names>MS</given-names></string-name>, <string-name><surname>Narici</surname><given-names>MV</given-names></string-name>, <string-name><surname>Williams</surname><given-names>JP</given-names></string-name>, <string-name><surname>Mitchell</surname><given-names>WK</given-names></string-name>, et al. <article-title>A validation of the application of D<sub>2</sub>O stable isotope tracer techniques for monitoring day‐to‐day changes in muscle protein subfraction synthesis in humans</article-title>. <source xml:lang="en">Am J Physiol Endocrinol Metab</source><year>2014</year>;<volume>306</volume>:<fpage>571</fpage>–<lpage>579</lpage>.</mixed-citation>
              </ref>
              <ref id="jcsm12472-bib-0038">
                <label>38</label>
                <mixed-citation publication-type="journal" id="jcsm12472-cit-0039"><string-name><surname>MacDonald</surname><given-names>A</given-names></string-name>, <string-name><surname>Small</surname><given-names>A</given-names></string-name>, <string-name><surname>Greig</surname><given-names>C</given-names></string-name>, <string-name><surname>Husi</surname><given-names>H</given-names></string-name>, <string-name><surname>Ross</surname><given-names>J</given-names></string-name>, <string-name><surname>Stephens</surname><given-names>N</given-names></string-name>, et al. <article-title>A novel oral tracer procedure for measurement of habitual myofibrillar protein synthesis</article-title>. <source xml:lang="en">Rapid Commun Mass Spectrom</source><year>2013</year>;<volume>27</volume>:<fpage>1769</fpage>–<lpage>1777</lpage>.<pub-id pub-id-type="pmid">23821570</pub-id></mixed-citation>
              </ref>
              <ref id="jcsm12472-bib-0039">
                <label>39</label>
                <mixed-citation publication-type="journal" id="jcsm12472-cit-0040"><string-name><surname>Sheffield‐Moore</surname><given-names>M</given-names></string-name>, <string-name><surname>Dillon</surname><given-names>E</given-names></string-name>, <string-name><surname>Randolph</surname><given-names>K</given-names></string-name>, <string-name><surname>Casperson</surname><given-names>S</given-names></string-name>, <string-name><surname>White</surname><given-names>G</given-names></string-name>, <string-name><surname>Jennings</surname><given-names>K</given-names></string-name>, et al. <article-title>Isotopic decay of urinary or plasma 3‐methylhistidine as a potential biomarker of pathologic skeletal muscle loss</article-title>. <source xml:lang="en">J Cachexia Sarcopenia Muscle</source><year>2014</year>;<volume>5</volume>:<fpage>19</fpage>–<lpage>25</lpage>.<pub-id pub-id-type="pmid">24009031</pub-id></mixed-citation>
              </ref>
              <ref id="jcsm12472-bib-0040">
                <label>40</label>
                <mixed-citation publication-type="journal" id="jcsm12472-cit-0041"><string-name><surname>Bass</surname><given-names>JJ</given-names></string-name>, <string-name><surname>Wilkinson</surname><given-names>DJ</given-names></string-name>, <string-name><surname>Rankin</surname><given-names>D</given-names></string-name>, <string-name><surname>Phillips</surname><given-names>BE</given-names></string-name>, <string-name><surname>Szewczyk</surname><given-names>NJ</given-names></string-name>, <string-name><surname>Smith</surname><given-names>K</given-names></string-name>, et al. <article-title>An overview of technical considerations for Western blotting applications to physiological research</article-title>. <source xml:lang="en">Scand J Med Sci Sports</source><year>2017</year>;<volume>27</volume>:<fpage>4</fpage>–<lpage>25</lpage>.<pub-id pub-id-type="pmid">27263489</pub-id></mixed-citation>
              </ref>
              <ref id="jcsm12472-bib-0041">
                <label>41</label>
                <mixed-citation publication-type="journal" id="jcsm12472-cit-0042"><string-name><surname>Schmittgen</surname><given-names>TD</given-names></string-name>, <string-name><surname>Livak</surname><given-names>KJ</given-names></string-name>. <article-title>Analyzing real‐time PCR data by the comparative C<sub>T</sub> method</article-title>. <source xml:lang="en">Nat Protoc</source><year>2008</year>;<volume>3</volume>:<fpage>1101</fpage>–<lpage>1108</lpage>.<pub-id pub-id-type="pmid">18546601</pub-id></mixed-citation>
              </ref>
              <ref id="jcsm12472-bib-0042">
                <label>42</label>
                <mixed-citation publication-type="book" id="jcsm12472-cit-0043"><string-name><surname>Trounce</surname><given-names>IA</given-names></string-name>, <string-name><surname>Kim</surname><given-names>YL</given-names></string-name>, <string-name><surname>Jun</surname><given-names>AS</given-names></string-name>, <string-name><surname>Wallace</surname><given-names>DC</given-names></string-name>. <chapter-title>Assessment of mitochondrial oxidative phosphorylation in patient muscle biopsies, lymphoblasts, and transmitochondrial cell lines</chapter-title> In <person-group person-group-type="editor"><name name-style="western"><surname>Attardi</surname><given-names>G</given-names></name></person-group>, <person-group person-group-type="editor"><name name-style="western"><surname>Chomyn</surname><given-names>A</given-names></name></person-group>, eds. <source xml:lang="en">Mitochondrial Biogenesis and Genetics: Part B.</source>
<publisher-name>Academic Press: Elsevier</publisher-name>; <year>1996</year> pp. <fpage>484</fpage>–<lpage>509</lpage>.</mixed-citation>
              </ref>
              <ref id="jcsm12472-bib-0043">
                <label>43</label>
                <mixed-citation publication-type="journal" id="jcsm12472-cit-0044"><string-name><surname>Lakens</surname><given-names>D</given-names></string-name>. <article-title>Calculating and reporting effect sizes to facilitate cumulative science: a practical primer for <italic>t</italic>‐tests and ANOVAs</article-title>. <source xml:lang="en">Front Psychol</source><year>2013</year>;<volume>4</volume>:<fpage>1</fpage>–<lpage>12</lpage>.<pub-id pub-id-type="pmid">23382719</pub-id></mixed-citation>
              </ref>
              <ref id="jcsm12472-bib-0044">
                <label>44</label>
                <mixed-citation publication-type="journal" id="jcsm12472-cit-0045"><string-name><surname>Ahtiainen</surname><given-names>JP</given-names></string-name>, <string-name><surname>Nyman</surname><given-names>K</given-names></string-name>, <string-name><surname>Huhtaniemi</surname><given-names>I</given-names></string-name>, <string-name><surname>Parviainen</surname><given-names>T</given-names></string-name>, <string-name><surname>Helste</surname><given-names>M</given-names></string-name>, <string-name><surname>Rannikko</surname><given-names>A</given-names></string-name>, et al. <article-title>Effects of resistance training on testosterone metabolism in younger and older men</article-title>. <source xml:lang="en">Exp Gerontol</source><year>2015</year>;<volume>69</volume>:<fpage>148</fpage>–<lpage>158</lpage>.<pub-id pub-id-type="pmid">26079649</pub-id></mixed-citation>
              </ref>
              <ref id="jcsm12472-bib-0045">
                <label>45</label>
                <mixed-citation publication-type="journal" id="jcsm12472-cit-0046"><string-name><surname>Kvorning</surname><given-names>T</given-names></string-name>, <string-name><surname>Andersen</surname><given-names>M</given-names></string-name>, <string-name><surname>Brixen</surname><given-names>K</given-names></string-name>, <string-name><surname>Madsen</surname><given-names>K</given-names></string-name>. <article-title>Suppression of endogenous testosterone production attenuates the response to strength training: a randomized, placebo‐controlled, and blinded intervention study</article-title>. <source xml:lang="en">Am J Physiol Endocrinol Metab</source><year>2006</year>;<volume>291</volume>:<fpage>1325</fpage>–<lpage>1332</lpage>.</mixed-citation>
              </ref>
              <ref id="jcsm12472-bib-0046">
                <label>46</label>
                <mixed-citation publication-type="journal" id="jcsm12472-cit-0047"><string-name><surname>Sullivan</surname><given-names>DH</given-names></string-name>, <string-name><surname>Roberson</surname><given-names>PK</given-names></string-name>, <string-name><surname>Johnson</surname><given-names>LE</given-names></string-name>, <string-name><surname>Bishara</surname><given-names>O</given-names></string-name>, <string-name><surname>Evans</surname><given-names>WJ</given-names></string-name>, <string-name><surname>Smith</surname><given-names>ES</given-names></string-name>, et al. <article-title>Effects of muscle strength training and testosterone in frail elderly males</article-title>. <source xml:lang="en">Med Sci Sports Exerc</source><year>2005</year>;<volume>37</volume>:<fpage>1664</fpage>–<lpage>1672</lpage>.<pub-id pub-id-type="pmid">16260965</pub-id></mixed-citation>
              </ref>
              <ref id="jcsm12472-bib-0047">
                <label>47</label>
                <mixed-citation publication-type="journal" id="jcsm12472-cit-0048"><string-name><surname>Casaburi</surname><given-names>R</given-names></string-name>, <string-name><surname>Bhasin</surname><given-names>S</given-names></string-name>, <string-name><surname>Cosentino</surname><given-names>L</given-names></string-name>, <string-name><surname>Porszasz</surname><given-names>J</given-names></string-name>, <string-name><surname>Somfay</surname><given-names>A</given-names></string-name>, <string-name><surname>Lewis</surname><given-names>MI</given-names></string-name>, et al. <article-title>Effects of testosterone and resistance training in men with chronic obstructive pulmonary disease</article-title>. <source xml:lang="en">Am J Respir Crit Care Med</source><year>2004</year>;<volume>170</volume>:<fpage>870</fpage>–<lpage>878</lpage>.<pub-id pub-id-type="pmid">15271690</pub-id></mixed-citation>
              </ref>
              <ref id="jcsm12472-bib-0048">
                <label>48</label>
                <mixed-citation publication-type="journal" id="jcsm12472-cit-0049"><string-name><surname>Atkinson</surname><given-names>RA</given-names></string-name>, <string-name><surname>Srinivas‐Shankar</surname><given-names>U</given-names></string-name>, <string-name><surname>Roberts</surname><given-names>SA</given-names></string-name>, <string-name><surname>Connolly</surname><given-names>MJ</given-names></string-name>, <string-name><surname>Adams</surname><given-names>JE</given-names></string-name>, <string-name><surname>Oldham</surname><given-names>JA</given-names></string-name>, et al. <article-title>Effects of testosterone on skeletal muscle architecture in intermediate‐frail and frail elderly men</article-title>. <source xml:lang="en">J Gerontol A Biol Sci Med Sci</source><year>2010</year>;<volume>65</volume>:<fpage>1215</fpage>–<lpage>1219</lpage>.<pub-id pub-id-type="pmid">20601412</pub-id></mixed-citation>
              </ref>
              <ref id="jcsm12472-bib-0049">
                <label>49</label>
                <mixed-citation publication-type="journal" id="jcsm12472-cit-0050"><string-name><surname>Kadi</surname><given-names>F</given-names></string-name>, <string-name><surname>Eriksson</surname><given-names>A</given-names></string-name>, <string-name><surname>Holmner</surname><given-names>S</given-names></string-name>, <string-name><surname>Thornell</surname><given-names>LE</given-names></string-name>. <article-title>Effects of anabolic steroids on the muscle cells of strength‐trained athletes</article-title>. <source xml:lang="en">Med Sci Sports Exerc</source><year>1999</year>;<volume>31</volume>:<fpage>1528</fpage>–<lpage>1534</lpage>.<pub-id pub-id-type="pmid">10589853</pub-id></mixed-citation>
              </ref>
              <ref id="jcsm12472-bib-0050">
                <label>50</label>
                <mixed-citation publication-type="journal" id="jcsm12472-cit-0051"><string-name><surname>Kadi</surname><given-names>F</given-names></string-name>. <article-title>Cellular and molecular mechanisms responsible for the action of testosterone on human skeletal muscle. A basis for illegal performance enhancement</article-title>. <source xml:lang="en">Br J Pharmacol</source><year>2008</year>;<volume>154</volume>:<fpage>522</fpage>–<lpage>528</lpage>.<pub-id pub-id-type="pmid">18414389</pub-id></mixed-citation>
              </ref>
              <ref id="jcsm12472-bib-0051">
                <label>51</label>
                <mixed-citation publication-type="journal" id="jcsm12472-cit-0052"><string-name><surname>Sinha‐Hikim</surname><given-names>I</given-names></string-name>, <string-name><surname>Artaza</surname><given-names>J</given-names></string-name>, <string-name><surname>Woodhouse</surname><given-names>L</given-names></string-name>, <string-name><surname>Gonzalez‐Cadavid</surname><given-names>N</given-names></string-name>, <string-name><surname>Singh</surname><given-names>AB</given-names></string-name>, <string-name><surname>Lee</surname><given-names>MI</given-names></string-name>, et al. <article-title>Testosterone‐induced increase in muscle size in healthy young men is associated with muscle fiber hypertrophy</article-title>. <source xml:lang="en">Am J Physiol Endocrinol Metab</source><year>2002</year>;<volume>283</volume>:<fpage>154</fpage>–<lpage>164</lpage>.</mixed-citation>
              </ref>
              <ref id="jcsm12472-bib-0052">
                <label>52</label>
                <mixed-citation publication-type="journal" id="jcsm12472-cit-0053"><string-name><surname>Kovacheva</surname><given-names>EL</given-names></string-name>, <string-name><surname>Hikim</surname><given-names>AP</given-names></string-name>, <string-name><surname>Shen</surname><given-names>R</given-names></string-name>, <string-name><surname>Sinha</surname><given-names>I</given-names></string-name>, <string-name><surname>Sinha‐Hikim</surname><given-names>I</given-names></string-name>. <article-title>Testosterone supplementation reverses sarcopenia in aging through regulation of myostatin, c‐Jun NH<sub>2</sub>‐terminal kinase, Notch, and Akt signaling pathways</article-title>. <source xml:lang="en">Endocrinology</source><year>2010</year>;<volume>151</volume>:<fpage>628</fpage>–<lpage>638</lpage>.<pub-id pub-id-type="pmid">20022929</pub-id></mixed-citation>
              </ref>
              <ref id="jcsm12472-bib-0053">
                <label>53</label>
                <mixed-citation publication-type="journal" id="jcsm12472-cit-0054"><string-name><surname>Deschenes</surname><given-names>MR</given-names></string-name>. <article-title>Effects of aging on muscle fibre type and size</article-title>. <source xml:lang="en">Sports Med</source><year>2004</year>;<volume>34</volume>:<fpage>809</fpage>–<lpage>824</lpage>.<pub-id pub-id-type="pmid">15462613</pub-id></mixed-citation>
              </ref>
              <ref id="jcsm12472-bib-0054">
                <label>54</label>
                <mixed-citation publication-type="journal" id="jcsm12472-cit-0055"><string-name><surname>Hakkinen</surname><given-names>K</given-names></string-name>, <string-name><surname>Pakarinen</surname><given-names>A</given-names></string-name>, <string-name><surname>Kraemer</surname><given-names>WJ</given-names></string-name>, <string-name><surname>Newton</surname><given-names>RU</given-names></string-name>, <string-name><surname>Alen</surname><given-names>M</given-names></string-name>. <article-title>Basal concentrations and acute responses of serum hormones and strength development during heavy resistance training in middle‐aged and elderly men and women</article-title>. <source xml:lang="en">J Gerontol Biol Sci Med Sci</source><year>2000</year>;<volume>55</volume>:<fpage>95</fpage>–<lpage>105</lpage>.</mixed-citation>
              </ref>
              <ref id="jcsm12472-bib-0055">
                <label>55</label>
                <mixed-citation publication-type="journal" id="jcsm12472-cit-0056"><string-name><surname>Tracy</surname><given-names>BL</given-names></string-name>, <string-name><surname>Byrnes</surname><given-names>WC</given-names></string-name>, <string-name><surname>Enoka</surname><given-names>RM</given-names></string-name>. <article-title>Strength training reduces force fluctuations during anisometric contractions of the quadriceps femoris muscles in old adults</article-title>. <source xml:lang="en">J Appl Physiol</source><year>2004</year>;<volume>96</volume>:<fpage>1530</fpage>–<lpage>1540</lpage>.<pub-id pub-id-type="pmid">14565966</pub-id></mixed-citation>
              </ref>
              <ref id="jcsm12472-bib-0056">
                <label>56</label>
                <mixed-citation publication-type="journal" id="jcsm12472-cit-0057"><string-name><surname>Bellew</surname><given-names>J</given-names></string-name>. <article-title>The effect of strength training on control of force in older men and women</article-title>. <source xml:lang="en">Aging Clin Exp Res</source><year>2002</year>;<volume>14</volume>:<fpage>35</fpage>–<lpage>41</lpage>.<pub-id pub-id-type="pmid">12027150</pub-id></mixed-citation>
              </ref>
              <ref id="jcsm12472-bib-0057">
                <label>57</label>
                <mixed-citation publication-type="journal" id="jcsm12472-cit-0058"><string-name><surname>Häkkinen</surname><given-names>K</given-names></string-name>, <string-name><surname>Pakarinen</surname><given-names>A</given-names></string-name>. <article-title>Serum hormones and strength development during strength training in middle‐aged and elderly males and females</article-title>. <source xml:lang="en">Acta Physiol Scand</source><year>1994</year>;<volume>150</volume>:<fpage>211</fpage>–<lpage>219</lpage>.<pub-id pub-id-type="pmid">8191900</pub-id></mixed-citation>
              </ref>
              <ref id="jcsm12472-bib-0058">
                <label>58</label>
                <mixed-citation publication-type="journal" id="jcsm12472-cit-0059"><string-name><surname>Vingren</surname><given-names>JL</given-names></string-name>, <string-name><surname>Kraemer</surname><given-names>WJ</given-names></string-name>, <string-name><surname>Ratamess</surname><given-names>NA</given-names></string-name>, <string-name><surname>Anderson</surname><given-names>JM</given-names></string-name>, <string-name><surname>Volek</surname><given-names>JS</given-names></string-name>, <string-name><surname>Maresh</surname><given-names>CM</given-names></string-name>. <article-title>Testosterone physiology in resistance exercise and training: the up‐stream regulatory elements</article-title>. <source xml:lang="en">Sports Med</source><year>2010</year>;<volume>40</volume>:<fpage>1037</fpage>–<lpage>1053</lpage>.<pub-id pub-id-type="pmid">21058750</pub-id></mixed-citation>
              </ref>
              <ref id="jcsm12472-bib-0059">
                <label>59</label>
                <mixed-citation publication-type="journal" id="jcsm12472-cit-0060"><string-name><surname>Bhasin</surname><given-names>S</given-names></string-name>, <string-name><surname>Woodhouse</surname><given-names>L</given-names></string-name>, <string-name><surname>Casaburi</surname><given-names>R</given-names></string-name>, <string-name><surname>Singh</surname><given-names>AB</given-names></string-name>, <string-name><surname>Bhasin</surname><given-names>D</given-names></string-name>, <string-name><surname>Berman</surname><given-names>N</given-names></string-name>, et al. <article-title>Testosterone dose–response relationships in healthy young men</article-title>. <source xml:lang="en">Am J Physiol Endocrinol Metab</source><year>2001</year>;<volume>281</volume>:<fpage>1172</fpage>–<lpage>1181</lpage>.</mixed-citation>
              </ref>
              <ref id="jcsm12472-bib-0060">
                <label>60</label>
                <mixed-citation publication-type="journal" id="jcsm12472-cit-0061"><string-name><surname>Storer</surname><given-names>TW</given-names></string-name>, <string-name><surname>Magliano</surname><given-names>L</given-names></string-name>, <string-name><surname>Woodhouse</surname><given-names>L</given-names></string-name>, <string-name><surname>Lee</surname><given-names>ML</given-names></string-name>, <string-name><surname>Dzekov</surname><given-names>C</given-names></string-name>, <string-name><surname>Dzekov</surname><given-names>J</given-names></string-name>, et al. <article-title>Testosterone dose‐dependently increases maximal voluntary strength and leg power, but does not affect fatigability or specific tension</article-title>. <source xml:lang="en">J Clin Endocrinol Metabol</source><year>2003</year>;<volume>88</volume>:<fpage>1478</fpage>–<lpage>1485</lpage>.</mixed-citation>
              </ref>
              <ref id="jcsm12472-bib-0061">
                <label>61</label>
                <mixed-citation publication-type="journal" id="jcsm12472-cit-0062"><string-name><surname>Travison</surname><given-names>TG</given-names></string-name>, <string-name><surname>Vesper</surname><given-names>HW</given-names></string-name>, <string-name><surname>Orwoll</surname><given-names>E</given-names></string-name>, <string-name><surname>Wu</surname><given-names>F</given-names></string-name>, <string-name><surname>Kaufman</surname><given-names>JM</given-names></string-name>, <string-name><surname>Wang</surname><given-names>Y</given-names></string-name>, et al. <article-title>Harmonized reference ranges for circulating testosterone levels in men of four cohort studies in the United States and Europe</article-title>. <source xml:lang="en">J Clin Endocrinol Metabol</source><year>2017</year>;<volume>102</volume>:<fpage>1161</fpage>–<lpage>1173</lpage>.</mixed-citation>
              </ref>
              <ref id="jcsm12472-bib-0062">
                <label>62</label>
                <mixed-citation publication-type="journal" id="jcsm12472-cit-0063"><string-name><surname>Pivarnik</surname><given-names>JM</given-names></string-name>, <string-name><surname>Hickson</surname><given-names>JF</given-names><suffix>Jr</suffix></string-name>, <string-name><surname>Wolinsky</surname><given-names>I</given-names></string-name>. <article-title>Urinary 3‐methylhistidine excretion increases with repeated weight training exercise</article-title>. <source xml:lang="en">Med Sci Sports Exerc</source><year>1989</year>;<volume>21</volume>:<fpage>283</fpage>–<lpage>287</lpage>.<pub-id pub-id-type="pmid">2733577</pub-id></mixed-citation>
              </ref>
              <ref id="jcsm12472-bib-0063">
                <label>63</label>
                <mixed-citation publication-type="journal" id="jcsm12472-cit-0064"><string-name><surname>Tipton</surname><given-names>KD</given-names></string-name>, <string-name><surname>Hamilton</surname><given-names>DL</given-names></string-name>, <string-name><surname>Gallagher</surname><given-names>IJ</given-names></string-name>. <article-title>Assessing the role of muscle protein breakdown in response to nutrition and exercise in humans</article-title>. <source xml:lang="en">Sports Med (Auckland, NZ)</source><year>2018</year>;<volume>48</volume>:<fpage>53</fpage>–<lpage>64</lpage>.</mixed-citation>
              </ref>
              <ref id="jcsm12472-bib-0064">
                <label>64</label>
                <mixed-citation publication-type="journal" id="jcsm12472-cit-0065"><string-name><surname>White</surname><given-names>JP</given-names></string-name>, <string-name><surname>Gao</surname><given-names>S</given-names></string-name>, <string-name><surname>Puppa</surname><given-names>MJ</given-names></string-name>, <string-name><surname>Sato</surname><given-names>S</given-names></string-name>, <string-name><surname>Welle</surname><given-names>SL</given-names></string-name>, <string-name><surname>Carson</surname><given-names>JA</given-names></string-name>. <article-title>Testosterone regulation of Akt/mTORC1/FoxO3a signaling in skeletal muscle</article-title>. <source xml:lang="en">Mol Cell Endocrinol</source><year>2013</year>;<volume>365</volume>:<fpage>174</fpage>–<lpage>186</lpage>.<pub-id pub-id-type="pmid">23116773</pub-id></mixed-citation>
              </ref>
              <ref id="jcsm12472-bib-0065">
                <label>65</label>
                <mixed-citation publication-type="journal" id="jcsm12472-cit-0066"><string-name><surname>Urban</surname><given-names>RJ</given-names></string-name>, <string-name><surname>Bodenburg</surname><given-names>YH</given-names></string-name>, <string-name><surname>Gilkison</surname><given-names>C</given-names></string-name>, <string-name><surname>Foxworth</surname><given-names>J</given-names></string-name>, <string-name><surname>Coggan</surname><given-names>AR</given-names></string-name>, <string-name><surname>Wolfe</surname><given-names>RR</given-names></string-name>, et al. <article-title>Testosterone administration to elderly men increases skeletal muscle strength and protein synthesis</article-title>. <source xml:lang="en">Am J Physiol Endocrinol Metab</source><year>1995</year>;<volume>269</volume>:<fpage>820</fpage>–<lpage>826</lpage>.</mixed-citation>
              </ref>
              <ref id="jcsm12472-bib-0066">
                <label>66</label>
                <mixed-citation publication-type="journal" id="jcsm12472-cit-0067"><string-name><surname>Ferrando</surname><given-names>AA</given-names></string-name>, <string-name><surname>Tipton</surname><given-names>KD</given-names></string-name>, <string-name><surname>Doyle</surname><given-names>D</given-names></string-name>, <string-name><surname>Phillips</surname><given-names>SM</given-names></string-name>, <string-name><surname>Cortiella</surname><given-names>J</given-names></string-name>, <string-name><surname>Wolfe</surname><given-names>RR</given-names></string-name>. <article-title>Testosterone injection stimulates net protein synthesis but not tissue amino acid transport</article-title>. <source xml:lang="en">Am J Physiol Endocrinol Metab</source><year>1998</year>;<volume>275</volume>:<fpage>864</fpage>–<lpage>871</lpage>.</mixed-citation>
              </ref>
              <ref id="jcsm12472-bib-0067">
                <label>67</label>
                <mixed-citation publication-type="journal" id="jcsm12472-cit-0068"><string-name><surname>Nader</surname><given-names>GA</given-names></string-name>, <string-name><surname>von Walden</surname><given-names>F</given-names></string-name>, <string-name><surname>Liu</surname><given-names>C</given-names></string-name>, <string-name><surname>Lindvall</surname><given-names>J</given-names></string-name>, <string-name><surname>Gutmann</surname><given-names>L</given-names></string-name>, <string-name><surname>Pistilli</surname><given-names>EE</given-names></string-name>, et al. <article-title>Resistance exercise training modulates acute gene expression during human skeletal muscle hypertrophy</article-title>. <source xml:lang="en">J Appl Physiol</source><year>2014</year>;<volume>116</volume>:<fpage>693</fpage>–<lpage>702</lpage>.<pub-id pub-id-type="pmid">24458751</pub-id></mixed-citation>
              </ref>
              <ref id="jcsm12472-bib-0068">
                <label>68</label>
                <mixed-citation publication-type="journal" id="jcsm12472-cit-0069"><string-name><surname>Van der Meer</surname><given-names>S</given-names></string-name>, <string-name><surname>Jaspers</surname><given-names>R</given-names></string-name>, <string-name><surname>Degens</surname><given-names>H</given-names></string-name>. <article-title>Is the myonuclear domain size fixed?</article-title><source xml:lang="en">J Musculoskelet Neuronal Interact</source><year>2011</year>;<volume>11</volume>:<fpage>286</fpage>–<lpage>297</lpage>.<pub-id pub-id-type="pmid">22130137</pub-id></mixed-citation>
              </ref>
              <ref id="jcsm12472-bib-0069">
                <label>69</label>
                <mixed-citation publication-type="journal" id="jcsm12472-cit-0070"><string-name><surname>Chaillou</surname><given-names>T</given-names></string-name>. <article-title>Impaired ribosome biogenesis could contribute to anabolic resistance to strength exercise in the elderly</article-title>. <source xml:lang="en">J Physiol</source><year>2017</year>;<volume>595</volume>:<fpage>1447</fpage>–<lpage>1448</lpage>.<pub-id pub-id-type="pmid">28105708</pub-id></mixed-citation>
              </ref>
              <ref id="jcsm12472-bib-0070">
                <label>70</label>
                <mixed-citation publication-type="journal" id="jcsm12472-cit-0071"><string-name><surname>Williamson</surname><given-names>D</given-names></string-name>, <string-name><surname>Gallagher</surname><given-names>P</given-names></string-name>, <string-name><surname>Harber</surname><given-names>M</given-names></string-name>, <string-name><surname>Hollon</surname><given-names>C</given-names></string-name>, <string-name><surname>Trappe</surname><given-names>S</given-names></string-name>. <article-title>Mitogen‐activated protein kinase (MAPK) pathway activation: effects of age and acute exercise on human skeletal muscle</article-title>. <source xml:lang="en">J Physiol</source><year>2003</year>;<volume>547</volume>:<fpage>977</fpage>–<lpage>987</lpage>.<pub-id pub-id-type="pmid">12562918</pub-id></mixed-citation>
              </ref>
              <ref id="jcsm12472-bib-0071">
                <label>71</label>
                <mixed-citation publication-type="journal" id="jcsm12472-cit-0072"><string-name><surname>Parkington</surname><given-names>JD</given-names></string-name>, <string-name><surname>LeBrasseur</surname><given-names>NK</given-names></string-name>, <string-name><surname>Siebert</surname><given-names>AP</given-names></string-name>, <string-name><surname>Fielding</surname><given-names>RA</given-names></string-name>. <article-title>Contraction‐mediated mTOR, p70S6k, and ERK1/2 phosphorylation in aged skeletal muscle</article-title>. <source xml:lang="en">J Appl Physiol</source><year>2004</year>;<volume>97</volume>:<fpage>243</fpage>–<lpage>248</lpage>.<pub-id pub-id-type="pmid">15033970</pub-id></mixed-citation>
              </ref>
              <ref id="jcsm12472-bib-0072">
                <label>72</label>
                <mixed-citation publication-type="journal" id="jcsm12472-cit-0073"><string-name><surname>Bennett</surname><given-names>NC</given-names></string-name>, <string-name><surname>Gardiner</surname><given-names>RA</given-names></string-name>, <string-name><surname>Hooper</surname><given-names>JD</given-names></string-name>, <string-name><surname>Johnson</surname><given-names>DW</given-names></string-name>, <string-name><surname>Gobe</surname><given-names>GC</given-names></string-name>. <article-title>Molecular cell biology of androgen receptor signalling</article-title>. <source xml:lang="en">Int J Biochem Cell Biol</source><year>2010</year>;<volume>42</volume>:<fpage>813</fpage>–<lpage>827</lpage>.<pub-id pub-id-type="pmid">19931639</pub-id></mixed-citation>
              </ref>
              <ref id="jcsm12472-bib-0073">
                <label>73</label>
                <mixed-citation publication-type="journal" id="jcsm12472-cit-0074"><string-name><surname>Wilborn</surname><given-names>CD</given-names></string-name>, <string-name><surname>Taylor</surname><given-names>LW</given-names></string-name>, <string-name><surname>Greenwood</surname><given-names>M</given-names></string-name>, <string-name><surname>Kreider</surname><given-names>RB</given-names></string-name>, <string-name><surname>Willoughby</surname><given-names>DS</given-names></string-name>. <article-title>Effects of different intensities of resistance exercise on regulators of myogenesis</article-title>. <source xml:lang="en">J Strength Cond Res</source><year>2009</year>;<volume>23</volume>:<fpage>2179</fpage>–<lpage>2187</lpage>.<pub-id pub-id-type="pmid">19826309</pub-id></mixed-citation>
              </ref>
              <ref id="jcsm12472-bib-0074">
                <label>74</label>
                <mixed-citation publication-type="journal" id="jcsm12472-cit-0075"><string-name><surname>Kemp</surname><given-names>C</given-names></string-name>, <string-name><surname>Oliver</surname><given-names>W</given-names></string-name>, <string-name><surname>Wheeler</surname><given-names>T</given-names></string-name>, <string-name><surname>Chishti</surname><given-names>A</given-names></string-name>, <string-name><surname>Koohmaraie</surname><given-names>M</given-names></string-name>. <article-title>The effects of <italic>Capn1</italic> gene inactivation on skeletal muscle growth, development, and atrophy, and the compensatory role of other proteolytic systems</article-title>. <source xml:lang="en">J Anim Sci</source><year>2013</year>;<volume>91</volume>:<fpage>3155</fpage>–<lpage>3167</lpage>.<pub-id pub-id-type="pmid">23798514</pub-id></mixed-citation>
              </ref>
              <ref id="jcsm12472-bib-0075">
                <label>75</label>
                <mixed-citation publication-type="journal" id="jcsm12472-cit-0076"><string-name><surname>Saunders</surname><given-names>HL</given-names></string-name>, <string-name><surname>Steciw</surname><given-names>B</given-names></string-name>, <string-name><surname>Kline</surname><given-names>A</given-names></string-name>. <article-title>Effect of testosterone and insulin on rat skeletal muscle RNA</article-title>. <source xml:lang="en">Endocrinology</source><year>1962</year>;<volume>71</volume>:<fpage>314</fpage>–<lpage>320</lpage>.<pub-id pub-id-type="pmid">14497529</pub-id></mixed-citation>
              </ref>
              <ref id="jcsm12472-bib-0076">
                <label>76</label>
                <mixed-citation publication-type="journal" id="jcsm12472-cit-0077"><string-name><surname>Vingren</surname><given-names>JL</given-names></string-name>, <string-name><surname>Kraemer</surname><given-names>WJ</given-names></string-name>, <string-name><surname>Hatfield</surname><given-names>DL</given-names></string-name>, <string-name><surname>Anderson</surname><given-names>JM</given-names></string-name>, <string-name><surname>Volek</surname><given-names>JS</given-names></string-name>, <string-name><surname>Ratamess</surname><given-names>NA</given-names></string-name>, et al. <article-title>Effect of resistance exercise on muscle steroidogenesis</article-title>. <source xml:lang="en">J Appl Physiol</source><year>2008</year>;<volume>105</volume>:<fpage>1754</fpage>–<lpage>1760</lpage>.<pub-id pub-id-type="pmid">18832756</pub-id></mixed-citation>
              </ref>
              <ref id="jcsm12472-bib-0077">
                <label>77</label>
                <mixed-citation publication-type="journal" id="jcsm12472-cit-0078"><string-name><surname>Bhasin</surname><given-names>S</given-names></string-name>, <string-name><surname>Taylor</surname><given-names>WE</given-names></string-name>, <string-name><surname>Singh</surname><given-names>R</given-names></string-name>, <string-name><surname>Artaza</surname><given-names>J</given-names></string-name>, <string-name><surname>Sinha‐Hikim</surname><given-names>I</given-names></string-name>, <string-name><surname>Jasuja</surname><given-names>R</given-names></string-name>, et al. <article-title>The mechanisms of androgen effects on body composition: mesenchymal pluripotent cell as the target of androgen action</article-title>. <source xml:lang="en">J Gerontol A Biol Sci Med Sci</source><year>2003</year>;<volume>58</volume>:<fpage>1103</fpage>–<lpage>1110</lpage>.</mixed-citation>
              </ref>
              <ref id="jcsm12472-bib-0078">
                <label>78</label>
                <mixed-citation publication-type="journal" id="jcsm12472-cit-0079"><string-name><surname>Jiang</surname><given-names>M</given-names></string-name>, <string-name><surname>Ma</surname><given-names>Y</given-names></string-name>, <string-name><surname>Chen</surname><given-names>C</given-names></string-name>, <string-name><surname>Fu</surname><given-names>X</given-names></string-name>, <string-name><surname>Yang</surname><given-names>S</given-names></string-name>, <string-name><surname>Li</surname><given-names>X</given-names></string-name>, et al. <article-title>Androgen‐responsive gene database: integrated knowledge on androgen‐responsive genes</article-title>. <source xml:lang="en">Mol Endocrinol</source><year>2009</year>;<volume>23</volume>:<fpage>1927</fpage>–<lpage>1933</lpage>.<pub-id pub-id-type="pmid">19762544</pub-id></mixed-citation>
              </ref>
              <ref id="jcsm12472-bib-0079">
                <label>79</label>
                <mixed-citation publication-type="journal" id="jcsm12472-cit-0080"><string-name><surname>Roberts</surname><given-names>MD</given-names></string-name>, <string-name><surname>Haun</surname><given-names>CT</given-names></string-name>, <string-name><surname>Mobley</surname><given-names>CB</given-names></string-name>, <string-name><surname>Mumford</surname><given-names>PW</given-names></string-name>, <string-name><surname>Romero</surname><given-names>MA</given-names></string-name>, <string-name><surname>Roberson</surname><given-names>PA</given-names></string-name>, et al. <article-title>Physiological differences between low versus high skeletal muscle hypertrophic responders to resistance exercise training: current perspectives and future research directions</article-title>. <source xml:lang="en">Front Physiol</source><year>2018</year>;<volume>9</volume>:<fpage>1</fpage>–<lpage>17</lpage>.<pub-id pub-id-type="pmid">29377031</pub-id></mixed-citation>
              </ref>
              <ref id="jcsm12472-bib-0080">
                <label>80</label>
                <mixed-citation publication-type="journal" id="jcsm12472-cit-0081"><string-name><surname>Sato</surname><given-names>K</given-names></string-name>, <string-name><surname>Iemitsu</surname><given-names>M</given-names></string-name>, <string-name><surname>Matsutani</surname><given-names>K</given-names></string-name>, <string-name><surname>Kurihara</surname><given-names>T</given-names></string-name>, <string-name><surname>Hamaoka</surname><given-names>T</given-names></string-name>, <string-name><surname>Fujita</surname><given-names>S</given-names></string-name>. <article-title>Resistance training restores muscle sex steroid hormone steroidogenesis in older men</article-title>. <source xml:lang="en">FASEB J</source><year>2014</year>;<volume>28</volume>:<fpage>1891</fpage>–<lpage>1897</lpage>.<pub-id pub-id-type="pmid">24443372</pub-id></mixed-citation>
              </ref>
              <ref id="jcsm12472-bib-0081">
                <label>81</label>
                <mixed-citation publication-type="journal" id="jcsm12472-cit-0082"><string-name><surname>Willoughby</surname><given-names>DS</given-names></string-name>, <string-name><surname>Taylor</surname><given-names>L</given-names></string-name>. <article-title>Effects of sequential bouts of resistance exercise on androgen receptor expression</article-title>. <source xml:lang="en">Med Sci Sports Exerc</source><year>2004</year>;<volume>36</volume>:<fpage>1499</fpage>–<lpage>1506</lpage>.<pub-id pub-id-type="pmid">15354030</pub-id></mixed-citation>
              </ref>
              <ref id="jcsm12472-bib-0082">
                <label>82</label>
                <mixed-citation publication-type="journal" id="jcsm12472-cit-0083"><string-name><surname>Philippou</surname><given-names>A</given-names></string-name>, <string-name><surname>Papageorgiou</surname><given-names>E</given-names></string-name>, <string-name><surname>Bogdanis</surname><given-names>G</given-names></string-name>, <string-name><surname>Halapas</surname><given-names>A</given-names></string-name>, <string-name><surname>Sourla</surname><given-names>A</given-names></string-name>, <string-name><surname>Maridaki</surname><given-names>M</given-names></string-name>, et al. <article-title>Expression of IGF‐1 isoforms after exercise‐induced muscle damage in humans: characterization of the MGF E peptide actions in vitro</article-title>. <source xml:lang="en">In Vivo</source><year>2009</year>;<volume>23</volume>:<fpage>567</fpage>–<lpage>575</lpage>.<pub-id pub-id-type="pmid">19567392</pub-id></mixed-citation>
              </ref>
              <ref id="jcsm12472-bib-0083">
                <label>83</label>
                <mixed-citation publication-type="journal" id="jcsm12472-cit-0084"><string-name><surname>Hameed</surname><given-names>M</given-names></string-name>, <string-name><surname>Orrell</surname><given-names>R</given-names></string-name>, <string-name><surname>Cobbold</surname><given-names>M</given-names></string-name>, <string-name><surname>Goldspink</surname><given-names>G</given-names></string-name>, <string-name><surname>Harridge</surname><given-names>S</given-names></string-name>. <article-title>Expression of IGF‐I splice variants in young and old human skeletal muscle after high resistance exercise</article-title>. <source xml:lang="en">J Physiol</source><year>2003</year>;<volume>547</volume>:<fpage>247</fpage>–<lpage>254</lpage>.<pub-id pub-id-type="pmid">12562960</pub-id></mixed-citation>
              </ref>
              <ref id="jcsm12472-bib-0084">
                <label>84</label>
                <mixed-citation publication-type="journal" id="jcsm12472-cit-0085"><string-name><surname>Singh</surname><given-names>R</given-names></string-name>, <string-name><surname>Artaza</surname><given-names>JN</given-names></string-name>, <string-name><surname>Taylor</surname><given-names>WE</given-names></string-name>, <string-name><surname>Gonzalez‐Cadavid</surname><given-names>NF</given-names></string-name>, <string-name><surname>Bhasin</surname><given-names>S</given-names></string-name>. <article-title>Androgens stimulate myogenic differentiation and inhibit adipogenesis in C3H 10T1/2 pluripotent cells through an androgen receptor‐mediated pathway</article-title>. <source xml:lang="en">Endocrinology</source><year>2003</year>;<volume>144</volume>:<fpage>5081</fpage>–<lpage>5088</lpage>.<pub-id pub-id-type="pmid">12960001</pub-id></mixed-citation>
              </ref>
              <ref id="jcsm12472-bib-0085">
                <label>85</label>
                <mixed-citation publication-type="journal" id="jcsm12472-cit-0086"><string-name><surname>Kvorning</surname><given-names>T</given-names></string-name>, <string-name><surname>Andersen</surname><given-names>M</given-names></string-name>, <string-name><surname>Brixen</surname><given-names>K</given-names></string-name>, <string-name><surname>Schjerling</surname><given-names>P</given-names></string-name>, <string-name><surname>Suetta</surname><given-names>C</given-names></string-name>, <string-name><surname>Madsen</surname><given-names>K</given-names></string-name>. <article-title>Suppression of testosterone does not blunt mRNA expression of myoD, myogenin, IGF, myostatin or androgen receptor post strength training in humans</article-title>. <source xml:lang="en">J Physiol</source><year>2007</year>;<volume>578</volume>:<fpage>579</fpage>–<lpage>593</lpage>.<pub-id pub-id-type="pmid">17095559</pub-id></mixed-citation>
              </ref>
              <ref id="jcsm12472-bib-0086">
                <label>86</label>
                <mixed-citation publication-type="journal" id="jcsm12472-cit-0087"><string-name><surname>Wilkinson</surname><given-names>SB</given-names></string-name>, <string-name><surname>Phillips</surname><given-names>SM</given-names></string-name>, <string-name><surname>Atherton</surname><given-names>PJ</given-names></string-name>, <string-name><surname>Patel</surname><given-names>R</given-names></string-name>, <string-name><surname>Yarasheski</surname><given-names>KE</given-names></string-name>, <string-name><surname>Tarnopolsky</surname><given-names>MA</given-names></string-name>, et al. <article-title>Differential effects of resistance and endurance exercise in the fed state on signalling molecule phosphorylation and protein synthesis in human muscle</article-title>. <source xml:lang="en">J Physiol</source><year>2008</year>;<volume>586</volume>:<fpage>3701</fpage>–<lpage>3717</lpage>.<pub-id pub-id-type="pmid">18556367</pub-id></mixed-citation>
              </ref>
              <ref id="jcsm12472-bib-0087">
                <label>87</label>
                <mixed-citation publication-type="journal" id="jcsm12472-cit-0088"><string-name><surname>Mosaferi Ziaaldini</surname><given-names>M</given-names></string-name>, <string-name><surname>Attarzadeh Hosseini</surname><given-names>SR</given-names></string-name>, <string-name><surname>Fathei</surname><given-names>M</given-names></string-name>. <article-title>Mitochondrial adaptations in aged skeletal muscle: effect of exercise training</article-title>. <source xml:lang="en">Physiol Res</source><year>2017</year>;<volume>66</volume>:<fpage>1</fpage>–<lpage>14</lpage>.<pub-id pub-id-type="pmid">27982690</pub-id></mixed-citation>
              </ref>
              <ref id="jcsm12472-bib-0088">
                <label>88</label>
                <mixed-citation publication-type="journal" id="jcsm12472-cit-0089"><string-name><surname>Balakrishnan</surname><given-names>VS</given-names></string-name>, <string-name><surname>Rao</surname><given-names>M</given-names></string-name>, <string-name><surname>Menon</surname><given-names>V</given-names></string-name>, <string-name><surname>Gordon</surname><given-names>PL</given-names></string-name>, <string-name><surname>Pilichowska</surname><given-names>M</given-names></string-name>, <string-name><surname>Castaneda</surname><given-names>F</given-names></string-name>, et al. <article-title>Resistance training increases muscle mitochondrial biogenesis in patients with chronic kidney disease</article-title>. <source xml:lang="en">Clin J Am Soc Nephrol</source><year>2010</year>;<volume>5</volume>:<fpage>996</fpage>–<lpage>1002</lpage>.<pub-id pub-id-type="pmid">20498251</pub-id></mixed-citation>
              </ref>
              <ref id="jcsm12472-bib-0089">
                <label>89</label>
                <mixed-citation publication-type="journal" id="jcsm12472-cit-0090"><string-name><surname>Roberts</surname><given-names>MD</given-names></string-name>, <string-name><surname>Romero</surname><given-names>MA</given-names></string-name>, <string-name><surname>Mobley</surname><given-names>CB</given-names></string-name>, <string-name><surname>Mumford</surname><given-names>PW</given-names></string-name>, <string-name><surname>Roberson</surname><given-names>PA</given-names></string-name>, <string-name><surname>Haun</surname><given-names>CT</given-names></string-name>, et al. <article-title>Skeletal muscle mitochondrial volume and myozenin‐1 protein differences exist between high versus low anabolic responders to resistance training</article-title>. <source xml:lang="en">PeerJ</source><year>2018</year>;<volume>6</volume>:<fpage>1</fpage>–<lpage>25</lpage>.</mixed-citation>
              </ref>
              <ref id="jcsm12472-bib-0090">
                <label>90</label>
                <mixed-citation publication-type="journal" id="jcsm12472-cit-0091"><string-name><surname>Porter</surname><given-names>C</given-names></string-name>, <string-name><surname>Reidy</surname><given-names>PT</given-names></string-name>, <string-name><surname>Bhattarai</surname><given-names>N</given-names></string-name>, <string-name><surname>Sidossis</surname><given-names>LS</given-names></string-name>, <string-name><surname>Rasmussen</surname><given-names>BB</given-names></string-name>. <article-title>Resistance exercise training alters mitochondrial function in human skeletal muscle</article-title>. <source xml:lang="en">Med Sci Sports Exerc</source><year>2015</year>;<volume>47</volume>:<fpage>1922</fpage>–<lpage>1931</lpage>.<pub-id pub-id-type="pmid">25539479</pub-id></mixed-citation>
              </ref>
              <ref id="jcsm12472-bib-0091">
                <label>91</label>
                <mixed-citation publication-type="journal" id="jcsm12472-cit-0092"><string-name><surname>Manfredi</surname><given-names>TG</given-names></string-name>, <string-name><surname>Monteiro</surname><given-names>M</given-names></string-name>, <string-name><surname>Lamont</surname><given-names>LS</given-names></string-name>, <string-name><surname>Singh</surname><given-names>MF</given-names></string-name>, <string-name><surname>Foldvari</surname><given-names>M</given-names></string-name>, <string-name><surname>White</surname><given-names>S</given-names></string-name>, et al. <article-title>Post‐menopausal effects of resistance training on muscle damage and mitochondria</article-title>. <source xml:lang="en">J Strength Cond Res/Natl Strength Cond Assoc</source><year>2013</year>;<volume>27</volume>:<fpage>1</fpage>–<lpage>13</lpage>.</mixed-citation>
              </ref>
              <ref id="jcsm12472-bib-0092">
                <label>92</label>
                <mixed-citation publication-type="journal" id="jcsm12472-cit-0093"><string-name><surname>Melov</surname><given-names>S</given-names></string-name>, <string-name><surname>Tarnopolsky</surname><given-names>MA</given-names></string-name>, <string-name><surname>Beckman</surname><given-names>K</given-names></string-name>, <string-name><surname>Felkey</surname><given-names>K</given-names></string-name>, <string-name><surname>Hubbard</surname><given-names>A</given-names></string-name>. <article-title>Resistance exercise reverses aging in human skeletal muscle</article-title>. <source xml:lang="en">PloS One</source><year>2007</year>;<volume>2</volume>:<fpage>1</fpage>–<lpage>9</lpage>.</mixed-citation>
              </ref>
              <ref id="jcsm12472-bib-0093">
                <label>93</label>
                <mixed-citation publication-type="journal" id="jcsm12472-cit-0094"><string-name><surname>van Breda</surname><given-names>E</given-names></string-name>, <string-name><surname>Keizer</surname><given-names>HA</given-names></string-name>, <string-name><surname>Vork</surname><given-names>MM</given-names></string-name>, <string-name><surname>Surtel</surname><given-names>DA</given-names></string-name>, <string-name><surname>de Jong</surname><given-names>YF</given-names></string-name>, <string-name><surname>van der Vusse</surname><given-names>GJ</given-names></string-name>, et al. <article-title>Modulation of fatty‐acid‐binding protein content of rat heart and skeletal muscle by endurance training and testosterone treatment</article-title>. <source xml:lang="en">Pflugers Arch</source><year>1992</year>;<volume>421</volume>:<fpage>274</fpage>–<lpage>279</lpage>.<pub-id pub-id-type="pmid">1326749</pub-id></mixed-citation>
              </ref>
              <ref id="jcsm12472-bib-0094">
                <label>94</label>
                <mixed-citation publication-type="journal" id="jcsm12472-cit-0095"><string-name><surname>Guo</surname><given-names>W</given-names></string-name>, <string-name><surname>Wong</surname><given-names>S</given-names></string-name>, <string-name><surname>Li</surname><given-names>M</given-names></string-name>, <string-name><surname>Liang</surname><given-names>W</given-names></string-name>, <string-name><surname>Liesa</surname><given-names>M</given-names></string-name>, <string-name><surname>Serra</surname><given-names>C</given-names></string-name>, et al. <article-title>Testosterone plus low‐intensity physical training in late life improves functional performance, skeletal muscle mitochondrial biogenesis, and mitochondrial quality control in male mice</article-title>. <source xml:lang="en">PLoS One</source><year>2012</year>;<volume>7</volume>:<fpage>1</fpage>–<lpage>12</lpage>.</mixed-citation>
              </ref>
              <ref id="jcsm12472-bib-0095">
                <label>95</label>
                <mixed-citation publication-type="journal" id="jcsm12472-cit-0096"><string-name><surname>Petersson</surname><given-names>SJ</given-names></string-name>, <string-name><surname>Christensen</surname><given-names>LL</given-names></string-name>, <string-name><surname>Kristensen</surname><given-names>JM</given-names></string-name>, <string-name><surname>Kruse</surname><given-names>R</given-names></string-name>, <string-name><surname>Andersen</surname><given-names>M</given-names></string-name>, <string-name><surname>Højlund</surname><given-names>K</given-names></string-name>. <article-title>Effect of testosterone on markers of mitochondrial oxidative phosphorylation and lipid metabolism in muscle of aging men with subnormal bioavailable testosterone</article-title>. <source xml:lang="en">Eur J Endocrinol</source><year>2014</year>;<volume>171</volume>:<fpage>77</fpage>–<lpage>88</lpage>.<pub-id pub-id-type="pmid">24760536</pub-id></mixed-citation>
              </ref>
              <ref id="jcsm12472-bib-0096">
                <label>96</label>
                <mixed-citation publication-type="journal" id="jcsm12472-cit-0097"><string-name><surname>Chang</surname><given-names>JH</given-names></string-name>, <string-name><surname>Lin</surname><given-names>KH</given-names></string-name>, <string-name><surname>Shih</surname><given-names>CH</given-names></string-name>, <string-name><surname>Chang</surname><given-names>YJ</given-names></string-name>, <string-name><surname>Chi</surname><given-names>HC</given-names></string-name>, <string-name><surname>Chen</surname><given-names>SL</given-names></string-name>. <article-title>Myogenic basic helix–loop–helix proteins regulate the expression of peroxisomal proliferator activated receptor‐γ coactivator‐1α</article-title>. <source xml:lang="en">Endocrinology</source><year>2006</year>;<volume>147</volume>:<fpage>3093</fpage>–<lpage>3106</lpage>.<pub-id pub-id-type="pmid">16527841</pub-id></mixed-citation>
              </ref>
              <ref id="jcsm12472-bib-0097">
                <label>97</label>
                <mixed-citation publication-type="journal" id="jcsm12472-cit-0098"><string-name><surname>Cunningham</surname><given-names>JT</given-names></string-name>, <string-name><surname>Rodgers</surname><given-names>JT</given-names></string-name>, <string-name><surname>Arlow</surname><given-names>DH</given-names></string-name>, <string-name><surname>Vazquez</surname><given-names>F</given-names></string-name>, <string-name><surname>Mootha</surname><given-names>VK</given-names></string-name>, <string-name><surname>Puigserver</surname><given-names>P</given-names></string-name>. <article-title>mTOR controls mitochondrial oxidative function through a YY1–PGC‐1α transcriptional complex</article-title>. <source xml:lang="en">Nature</source><year>2007</year>;<volume>450</volume>:<fpage>736</fpage>–<lpage>740</lpage>.<pub-id pub-id-type="pmid">18046414</pub-id></mixed-citation>
              </ref>
              <ref id="jcsm12472-bib-0098">
                <label>98</label>
                <mixed-citation publication-type="journal" id="jcsm12472-cit-0099"><string-name><surname>Traish</surname><given-names>AM</given-names></string-name>, <string-name><surname>Abdallah</surname><given-names>B</given-names></string-name>, <string-name><surname>Yu</surname><given-names>G</given-names></string-name>. <article-title>Androgen deficiency and mitochondrial dysfunction: implications for fatigue, muscle dysfunction, insulin resistance, diabetes, and cardiovascular disease</article-title>. <source xml:lang="en">Horm Mol Biol Clin Invest</source><year>2011</year>;<volume>8</volume>:<fpage>431</fpage>–<lpage>444</lpage>.</mixed-citation>
              </ref>
              <ref id="jcsm12472-bib-0099">
                <label>99</label>
                <mixed-citation publication-type="journal" id="jcsm12472-cit-0100"><string-name><surname>Koenig</surname><given-names>H</given-names></string-name>, <string-name><surname>Goldstone</surname><given-names>A</given-names></string-name>, <string-name><surname>Lu</surname><given-names>C</given-names></string-name>. <article-title>Androgens regulate mitochondrial cytochrome <italic>c</italic> oxidase and lysosomal hydrolases in mouse skeletal muscle</article-title>. <source xml:lang="en">Biochem J</source><year>1980</year>;<volume>192</volume>:<fpage>349</fpage>–<lpage>353</lpage>.<pub-id pub-id-type="pmid">6272701</pub-id></mixed-citation>
              </ref>
              <ref id="jcsm12472-bib-0100">
                <label>100</label>
                <mixed-citation publication-type="journal" id="jcsm12472-cit-0101"><string-name><surname>Costello</surname><given-names>L</given-names></string-name>, <string-name><surname>Franklin</surname><given-names>RB</given-names></string-name>. <article-title>Testosterone regulates pyruvate dehydrogenase activity of prostate mitochondria</article-title>. <source xml:lang="en">Horm Metab Res</source><year>1993</year>;<volume>25</volume>:<fpage>268</fpage>–<lpage>270</lpage>.<pub-id pub-id-type="pmid">8330862</pub-id></mixed-citation>
              </ref>
              <ref id="jcsm12472-bib-0101">
                <label>101</label>
                <mixed-citation publication-type="journal" id="jcsm12472-cit-0102"><string-name><surname>Fan</surname><given-names>W</given-names></string-name>, <string-name><surname>Yanase</surname><given-names>T</given-names></string-name>, <string-name><surname>Nomura</surname><given-names>M</given-names></string-name>, <string-name><surname>Okabe</surname><given-names>T</given-names></string-name>, <string-name><surname>Goto</surname><given-names>K</given-names></string-name>, <string-name><surname>Sato</surname><given-names>T</given-names></string-name>, et al. <article-title>Androgen receptor null male mice develop late‐onset obesity caused by decreased energy expenditure and lipolytic activity but show normal insulin sensitivity with high adiponectin secretion</article-title>. <source xml:lang="en">Diabetes</source><year>2005</year>;<volume>54</volume>:<fpage>1000</fpage>–<lpage>1008</lpage>.<pub-id pub-id-type="pmid">15793238</pub-id></mixed-citation>
              </ref>
              <ref id="jcsm12472-bib-0102">
                <label>102</label>
                <mixed-citation publication-type="journal" id="jcsm12472-cit-0103"><string-name><surname>Pitteloud</surname><given-names>N</given-names></string-name>, <string-name><surname>Mootha</surname><given-names>VK</given-names></string-name>, <string-name><surname>Dwyer</surname><given-names>AA</given-names></string-name>, <string-name><surname>Hardin</surname><given-names>M</given-names></string-name>, <string-name><surname>Lee</surname><given-names>H</given-names></string-name>, <string-name><surname>Eriksson</surname><given-names>K‐F</given-names></string-name>, et al. <article-title>Relationship between testosterone levels, insulin sensitivity, and mitochondrial function in men</article-title>. <source xml:lang="en">Diabetes Care</source><year>2005</year>;<volume>28</volume>:<fpage>1636</fpage>–<lpage>1642</lpage>.<pub-id pub-id-type="pmid">15983313</pub-id></mixed-citation>
              </ref>
              <ref id="jcsm12472-bib-0103">
                <label>103</label>
                <mixed-citation publication-type="journal" id="jcsm12472-cit-0104"><string-name><surname>Fernández‐Balsells</surname><given-names>MM</given-names></string-name>, <string-name><surname>Murad</surname><given-names>MH</given-names></string-name>, <string-name><surname>Lane</surname><given-names>M</given-names></string-name>, <string-name><surname>Lampropulos</surname><given-names>JF</given-names></string-name>, <string-name><surname>Albuquerque</surname><given-names>F</given-names></string-name>, <string-name><surname>Mullan</surname><given-names>RJ</given-names></string-name>, et al. <article-title>Adverse effects of testosterone therapy in adult men: a systematic review and meta‐analysis</article-title>. <source xml:lang="en">J Clin Endocrinol Metabol</source><year>2010</year>;<volume>95</volume>:<fpage>2560</fpage>–<lpage>2575</lpage>.</mixed-citation>
              </ref>
              <ref id="jcsm12472-bib-0104">
                <label>104</label>
                <mixed-citation publication-type="journal" id="jcsm12472-cit-0105"><string-name><surname>Osterberg</surname><given-names>EC</given-names></string-name>, <string-name><surname>Bernie</surname><given-names>AM</given-names></string-name>, <string-name><surname>Ramasamy</surname><given-names>R</given-names></string-name>. <article-title>Risks of testosterone replacement therapy in men</article-title>. <source xml:lang="en">Indian J Urol: IJU</source><year>2014</year>;<volume>30</volume>:<fpage>2</fpage>–<lpage>7</lpage>.<pub-id pub-id-type="pmid">24497673</pub-id></mixed-citation>
              </ref>
              <ref id="jcsm12472-bib-0105">
                <label>105</label>
                <mixed-citation publication-type="journal" id="jcsm12472-cit-0106"><string-name><surname>Loo</surname><given-names>SY</given-names></string-name>, <string-name><surname>Azoulay</surname><given-names>L</given-names></string-name>, <string-name><surname>Nie</surname><given-names>R</given-names></string-name>, <string-name><surname>Dell'Aniello</surname><given-names>S</given-names></string-name>, <string-name><surname>Yu</surname><given-names>OHY</given-names></string-name>, <string-name><surname>Renoux</surname><given-names>C</given-names></string-name>. <article-title>Cardiovascular and cerebrovascular safety of testosterone replacement therapy among aging men with low testosterone levels: a cohort study</article-title>. <source xml:lang="en">Am J Med</source><year>2019</year>;<volume>19</volume>:<fpage>30281</fpage>–<lpage>30285</lpage>.</mixed-citation>
              </ref>
              <ref id="jcsm12472-bib-0106">
                <label>106</label>
                <mixed-citation publication-type="journal" id="jcsm12472-cit-0107"><string-name><surname>Vigen</surname><given-names>R</given-names></string-name>, <string-name><surname>O'Donnell</surname><given-names>CI</given-names></string-name>, <string-name><surname>Barón</surname><given-names>AE</given-names></string-name>, <string-name><surname>Grunwald</surname><given-names>GK</given-names></string-name>, <string-name><surname>Maddox</surname><given-names>TM</given-names></string-name>, <string-name><surname>Bradley</surname><given-names>SM</given-names></string-name>, et al. <article-title>Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels</article-title>. <source xml:lang="en">JAMA</source><year>2013</year>;<volume>310</volume>:<fpage>1829</fpage>–<lpage>1836</lpage>.<pub-id pub-id-type="pmid">24193080</pub-id></mixed-citation>
              </ref>
              <ref id="jcsm12472-bib-0107">
                <label>107</label>
                <mixed-citation publication-type="journal" id="jcsm12472-cit-0108"><string-name><surname>Sih</surname><given-names>R</given-names></string-name>, <string-name><surname>Morley</surname><given-names>JE</given-names></string-name>, <string-name><surname>Kaiser</surname><given-names>FE</given-names></string-name>, <string-name><surname>Perry</surname><given-names>HM</given-names><suffix>III</suffix></string-name>, <string-name><surname>Patrick</surname><given-names>P</given-names></string-name>, <string-name><surname>Ross</surname><given-names>C</given-names></string-name>. <article-title>Testosterone replacement in older hypogonadal men: a 12‐month randomized controlled trial</article-title>. <source xml:lang="en">J Clin Endocrinol Metabol</source><year>1997</year>;<volume>82</volume>:<fpage>1661</fpage>–<lpage>1667</lpage>.</mixed-citation>
              </ref>
              <ref id="jcsm12472-bib-0108">
                <label>108</label>
                <mixed-citation publication-type="journal" id="jcsm12472-cit-0109"><string-name><surname>Kenny</surname><given-names>AM</given-names></string-name>, <string-name><surname>Kleppinger</surname><given-names>A</given-names></string-name>, <string-name><surname>Annis</surname><given-names>K</given-names></string-name>, <string-name><surname>Rathier</surname><given-names>M</given-names></string-name>, <string-name><surname>Browner</surname><given-names>B</given-names></string-name>, <string-name><surname>Judge</surname><given-names>JO</given-names></string-name>, et al. <article-title>Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels, low bone mass, and physical frailty</article-title>. <source xml:lang="en">J Am Geriatr Soc</source><year>2010</year>;<volume>58</volume>:<fpage>1134</fpage>–<lpage>1143</lpage>.<pub-id pub-id-type="pmid">20722847</pub-id></mixed-citation>
              </ref>
              <ref id="jcsm12472-bib-0109">
                <label>109</label>
                <mixed-citation publication-type="journal" id="jcsm12472-cit-0110"><string-name><surname>Rhoden</surname><given-names>EL</given-names></string-name>, <string-name><surname>Morgentaler</surname><given-names>A</given-names></string-name>. <article-title>Risks of testosterone‐replacement therapy and recommendations for monitoring</article-title>. <source xml:lang="en">N Engl J Med</source><year>2004</year>;<volume>350</volume>:<fpage>482</fpage>–<lpage>492</lpage>.<pub-id pub-id-type="pmid">14749457</pub-id></mixed-citation>
              </ref>
              <ref id="jcsm12472-bib-0110">
                <label>110</label>
                <mixed-citation publication-type="journal" id="jcsm12472-cit-0111"><string-name><surname>Häkkinen</surname><given-names>K</given-names></string-name>, <string-name><surname>Pakarinen</surname><given-names>A</given-names></string-name>. <article-title>Muscle strength and serum testosterone, cortisol and SHBG concentrations in middle‐aged and elderly men and women</article-title>. <source xml:lang="en">Acta Physiol Scand</source><year>1993</year>;<volume>148</volume>:<fpage>199</fpage>–<lpage>207</lpage>.<pub-id pub-id-type="pmid">8352031</pub-id></mixed-citation>
              </ref>
              <ref id="jcsm12472-bib-0111">
                <label>111</label>
                <mixed-citation publication-type="journal" id="jcsm12472-cit-0112"><string-name><surname>von Haehling</surname><given-names>S</given-names></string-name>, <string-name><surname>Morley</surname><given-names>JE</given-names></string-name>, <string-name><surname>Coats</surname><given-names>AJ</given-names></string-name>, <string-name><surname>Anker</surname><given-names>SD</given-names></string-name>. <article-title>Ethical guidelines for publishing in the <italic>Journal of Cachexia, Sarcopenia and Muscle</italic>: update 2017</article-title>. <source xml:lang="en">J Cachexia Sarcopenia Muscle</source><year>2017</year>;<volume>8</volume>:<fpage>1081</fpage>–<lpage>1083</lpage>.<pub-id pub-id-type="pmid">29098794</pub-id></mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
